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What is pain?
Normal pain anatomy and physiology
Pain is a useful and even necessary warning system to protect the body from fur-
ther harm. In the normal situation, a painful stimulus, either by tissue damage or 
inflammatory, is detected by nociceptors in the skin or other tissues. From there, 
mainly C- and A-delta-fibers transport the signal to the spinal cord which carries it 
towards the brain.
In the brain, the sensory cortex localizes the pain and the limbic system is re-
sponsible for the emotional processing. Descending inhibitory tracts can facilitate, 
modulate and suppress the incoming pain signal. (Figure 1)
Figure 1. Diagram of pain pathways. Painful stimuli travel from 
the pain source up to the sensory cortex in the brain. Descend-
ing inhibitory tracts, originating from the limbic system, modu-
late the stimulus on the spinal level. By dr. David Nelson, adapt-
ed with permission.
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Classifi cation of pain
Pain can be classifi ed based on the neurophysiology into nociceptive and non-
nociceptive pain (Figure 2).
Nociceptive pain is caused by activation or sensitization of free nerve endings 
(nociceptors) and is usually caused by (the risk of) tissue damage. It can be sub-
divided into somatic pain (originating from bone, soft tissue, joints and muscles) 
and visceral pain (originating from organs). Joint pain (most often caused by 
osteoarthritis in an elderly population) and back pain are examples of nociceptive 
pain conditions.
Non-nociceptive pain can be neuropathic pain, in which there is a lesion or ill-
ness of the nervous system, or idiopathic, in which there is no apparent cause of 
the experienced pain. Fibromyalgia and irritable bowel syndrome are examples of 
chronic non-nociceptive pain.
In some pain conditions, such as migraine and in some cases of chronic back 
pain, it is thought that both nociceptive and non-nociceptive mechanisms play a 
role.
Pain
Nociceptive
Somatic
Visceral
Non-nociceptive
Neuropathic
Idiopathic
Combined 
Nociceptive/non-
nocipective
Figure 2. Classifi cation of pain by neurophysiological mechanism with in colors some examples on 
where in the body the pain can arise.
Pathophysiology of chronic pain
In chronic pain, the normal pain processing is altered by central sensitization. The 
nervous system is able to change its structure and physiology when exposed to 
repeated stimuli, which is called plasticity. Under a continuous stimulating con-
dition, peripheral nerves can become more sensitive to noxious stimuli and the 
pain processing in the central nervous system is altered, causing the descending 
inhibitory systems to function improperly and making it more susceptible for the 
development of chronic pain elsewhere in the body.
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Definition of chronic pain
Pain is defined as an unpleasant sensory and emotional experience associated with 
actual or potential tissue damage, or described in terms of such damage[1].
Chronic pain is pain that persists past the normal time of healing, which some-
times may be less than a month and in other cases more than six months[2]. In most 
research however, pain persisting after three months is considered chronic. Since 
different causes of pain may have different durations of normal healing, a general-
ized definition of pain lasting for more than three months may not be sufficient to 
properly identify individuals with chronic pain. With the inclusion of more objective 
measures, the definition of chronic pain may be more robust.
Chronic musculoskeletal pain in the general population
Chronic musculoskeletal pain is a common disabling condition with a great impact 
on daily functioning [3, 4]. In the Netherlands, 19% of all individuals aged 21 years 
and older experience chronic pain and in elderly this is more than half. This means 
that more than 2 million Dutch people experience pain on a daily basis, which is 
a higher incidence than most common diseases like diabetes and coronary heart 
disease[5].
The quality of life of chronic pain patients is decreased and psychological prob-
lems occur often, even more than in cancer patients [6-8]. Although 85% of the 
chronic pain syndromes have an underlying cause, such as osteoarthritis, there are 
many individuals in which the chronic pain they experience remains unexplained. 
The lower quality of life is among others caused by a lack of social participation, 
consequences for work and sleep disturbances. Especially the unexplained part of 
chronic pain in combination with limited understanding from the society is likely to 
underlie the lower quality of life in these subjects.
Chronic pain accounts for an annual socioeconomic burden of 20 billion euros in 
the Netherlands alone, mainly due to sickness absence and social security funds 
[9]. Therefore, it is not surprising that the European Federation of ‘International 
Association for the Study of Pain (IASP)’ chapters considers chronic pain as a major 
health care problem and advises to see chronic pain not only as a symptom but as 
a disease in its own right [10].
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Causes and consequences of chronic pain and central sensitization
Chronic pain is a complex trait with a multifactorial etiology. In the remaining of 
this chapter, the topics studied in this thesis will be introduced. First, the genetic 
and hormonal influences on the development of chronic pain are discussed. From 
there, we look further into the structural changes of the brain in chronic pain and 
functional changes in the nervous system, represented by an altered heat pain sen-
sitivity. At the end, the consequences of chronic pain and osteoarthritis, as one of 
the major causes of chronic pain in the elderly, on gait and mobility are described.
Genetics of pain sensitivity
Evidence from birth-cohort and twin studies suggest that chronic pain and the 
sensitivity to painful stimuli and pain tolerability have a rather large heritability up 
to 60% [11-13]. This suggests a genetic vulnerability. However, the exact genes 
involved are unknown until now.
It is unlikely, that there is a single unique pain gene since it is generally accepted 
that susceptibility to chronic pain is very similar in its genetic architecture to other 
complex traits. Therefore, multiple genes might be involved and each individual 
DNA variant probably only contributes a little to the overall variability. For other 
complex traits, such as diabetes or osteoporosis, large-scale association studies 
have been able to identify consistent associations and new candidate genes [14, 
15]. Therefore, performing genome-wide association studies (GWAS) on pain 
phenotypes such as experimental heat pain sensitivity might be helpful to further 
elucidate the genetics of pain sensitivity. Experimental pain sensitivity can also 
serve as an endophenotype for the susceptibility for developing chronic pain. 
Therefore, studying the genetics behind this endophenotype may also help in the 
search for pain genes.
Until now, there are no successful large genetic studies on (heat) pain sensitivity. 
Most research focused on a number of candidate genes in relation to pain and pain 
perception. One of the most studied genes is the catechol-O-methyltranferase 
(COMT) gene which influences pain perception through enzymatic breakdown of 
neurotransmitters. Despite the large number of studies on the relation between 
amino acid variations in this gene and various pain outcomes, results are still in-
consistent [16-18].
Hormonal influences on chronic pain
The prevalence of chronic pain is higher in women and it is known that pain experi-
ence and coping strategies differ between men and women [19-21]. Hormonal in-
fluences have been considered to underlie a least part of the differences in chronic 
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pain between men and women. There is some limited evidence that estrogens 
play a role in the apparent gender specificity in pain experience[22]. Estrogen and 
testosterone are the two most studied sex hormones in relation to pain.
Testosterone is thought to be important during the development of the nervous 
system and is hypothesized to create a set point for pain sensitivity. [23]
Estrogen is thought to be more of influence later in life. More or longer estrogen 
exposure during life, for example measured by the number of menstrual cycles, has 
been found to be associated with more migraine later in life [24], whereas lower 
current estrogen levels, like in postmenopausal women, is associated with a higher 
prevalence of chronic musculoskeletal pain[22, 25].
Imaging the brain in chronic pain
Since plasticity of the nervous system underlies part of the pathophysiology of 
chronic pain, structural changes are likely to occur in the brain. Studying these 
changes can help us understand the pathophysiology of chronic pain better which 
might help in developing treatment strategies.
Previous studies that examined structural brain alterations in chronic pain, fo-
cused on a variety of pain phenotypes, such as migraine, back pain, osteoarthritis 
and fibromyalgia [26-35]. Regions that are part of the limbic system (Figure 3) and 
the signaling pathway were among the identified pain-associated brain areas. 
Despite the possible identification of structural brain alterations in these selected 
Figure 3. Visualization of the major parts of the anatomy of the limbic system in the brain, among 
others the hippocampus, hypothalamus, amygdala and thalamus.
By OpenStax College [CC BY 3.0 (http://creativecommons.org/licenses/by/3.0)]
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clinical cases, it remains unclear which brain regions are morphologically altered in 
chronic pain and experimental pain in the general population.
Besides structural MRI research, diffusion tensor imaging (DTI) can provide ad-
ditional information on the microstructural organization of the white matter in the 
brain. Previous studies investigating chronic pain and white matter microstructural 
organization have focused on specific chronic pain disorders, such as irritable bowel 
syndrome, fibromyalgia, migraine and chronic pancreatitis [36-40], but the results 
have been inconsistent and lacked power to determine the common and specific 
white matter tracts involved in chronic pain.
Quantitative sensory testing
In daily clinical practice, quantitative sensory testing (QST) is often used as a tool 
to diagnose central and peripheral sensitization in chronic pain patients. However, 
it can also be used to monitor effectiveness of pain treatment [41-45]. QST quanti-
fies the sensitivity for experimental stimuli and there are many different modalities 
which can be used. Commonly used stimuli are mechanical (pin-prick), pressure 
and thermal stimuli.
In previous articles, specific pain phenotypes, originating from clinical study case 
groups, have been studied, such as neuropathic pain, fibromyalgia and osteoar-
thritis related pain, and changes in QST measurements were observed [41, 43, 45, 
46]. Efforts were made to define reference thresholds for clinical use, but there is 
still limited information on QST normal values measurements in aging individuals 
and whether there are additional determinants influencing this measurement [47].
Osteoarthritis and mobility
Chronic pain in the lower body is often a cause for a decreased mobility and a 
lower quality of life. Especially in older individuals, this decreased mobility is also 
related to a higher mortality [48-52].
Gait is an accurate health indicator and poor gait is strongly associated with a 
higher risk of falls and mortality [50, 53-57]. Gait is a complex concept that can be 
assessed using many parameters. It has been shown that these parameters can 
be summarized into seven gait domains (Figure 4), comprehensively capturing the 
gait pattern: (1) Rhythm, reflecting cadence and single support time; (2) Variability, 
reflecting variability in step length and time; (3) Phases, reflecting double support 
time and single support time as a percentage of the total stride time; (4) Pace, 
reflecting step length and velocity; (5) Tandem, reflecting errors in tandem walking; 
(6) Turning, reflecting the number of steps and time needed to turn; and (7) Base of 
Support, reflecting stride width and stride width variability [58, 59]
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Previous studies on the association between pain and gait parameters mainly 
focused on osteoarthritis (OA), the most common cause of pain in the lower body 
of elderly people[60-66]. The experienced pain does not always reflect the joint 
damage. Therefore, studying the association between gait and chronic pain in 
the lower body independent of the presence of OA will inform more about the 
independent effect of lower body pain on gait.
Better understanding of the relationship between lower body pain, OA and gait 
may allow for new interventions to decrease pain and gait problems, and hence 
related morbidity and mortality.
The Rotterdam Study
The studies presented in this thesis are performed within the large population based 
prospective cohort study, the Rotterdam Study (RS). In the Netherlands and among 
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Figure 4. Illustration of the 7 gait domains. A: Normal walk (Rhythm, Variability, Phases, Pace and 
Base of support), B: Turn, C: Tandem walk
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the participants, it is also known as ‘Erasmus Rotterdam Gezondheid Onderzoek’ 
(ERGO). This ongoing study started in 1990 and examines determinants of chronic 
disabling disease in the elderly[67]. Up to know, more than 15,000 participants of 
45 years and older are included in the three sub-populations, RS-I, RS-II (initiated 
in 1999) and RS-III (initiated in 2006).
All participants were examined extensively at baseline with a home interview and 
an extensive set of approximately 1,500 examinations at the research center. For 
example, blood and urine was collected and x-rays were taken of the major joints. 
Many of these examinations were repeated every 3-5 years in the last 25 years. 
Therefore, 5 follow-up visits are available for RS-I. In figure 5, the visits from all 3 
cohorts up to 2013 are shown.
Figure 5. Diagram of the examination cycles of the Rotterdam Study (RS). RS-I-1 refers to the base-
line examination of the original cohort (pilot phase 07/1989–12/1989; cohort recruitment 01/1990–
09/1993). RS-I- 2, RS-I-3, RS-I-4, and RS-I-5 refer to re-examination of the original cohort members. 
RS-II-1 refers to the extension of the cohort with persons in the study district that became 55 years 
since the start of the study or those of 55 years or over that migrated into the study district. RS-II-2 
refers to re-examination of the extension cohort. RS-III-1 refers to the baseline examination of all 
persons aged 45 years and over living in the study district that had not been examined (i.e., mainly 
comprising those aged 45–60 years). RS-II-3 and RS-III-2 refer to ongoing and future re-examinations. 
Examination RS-I-4 and RS-II-2 were conducted as one project and feature an identical research pro-
gram. Similarly, examinations RS-I-5, RS-II-3, and RS-III-2 will share the same program items. Adapted 
from: Albert Hofman, et al. The Rotterdam Study: 2016 objectives and design update. Eur J Epide-
miol. 2015;30:661-708.
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Aim of this thesis
The overall objective of this thesis is the identification and characterization of causal 
and consequential determinants of chronic musculoskeletal pain in the general 
population. In chapter 2, the genetic determinants influencing heat pain sensitivity 
thresholds are studied. Next, the influence of hormones during development and 
during the course of life is studied in chapter 3. In chapter 4, quantitative and 
qualitative determinants of brain structure in chronic pain are presented. Epide-
miological considerations are raised in chapter 5 regarding thermal quantitative 
sensory testing, a widely used tool for measuring pain sensitivity and sensitization 
in chronic pain. The influence of osteoarthritis and chronic pain on gait is studied 
in chapter 6.
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Abstract
Introduction: Chronic pain and pain sensitivity are complex traits with a variety of 
potential determinants. Although not yet fully elucidated, pain sensitivity and the 
risk for chronic pain are thought to be partly genetic. In our study, we attempt to 
further elucidate the genetic predisposition of pain sensitivity.
Methods: In a total number of 3,795 participants from the Rotterdam study (a large 
prospective population based cohort) heat pain thresholds (HPT) were determined. 
We estimated the total additive genetic influence on HPT measurements due to 
common genetic variation using GCTA, and we performed a genome wide as-
sociation study (GWAS) to identify new loci associated with HPT in the general 
population. Finally, we reviewed the literature for previously reported DNA variants 
associated with experimental pain thresholds and tried to replicate these findings 
in our dataset.
Results: The overall heritability estimate of HPT was 19%. In individuals without 
chronic pain, this estimate was 32% compared to 9% in individuals with chronic 
pain. In addition, the heritability was higher in women compared to men. Our 
GWAS revealed one genome-wide significant signal (1:176688345:D) which is 
located in the twelfth intron of the PAPPA2 gene (p= 2.48*10-8). Additionally, we 
found six suggestive signals (P<1.0*10-6). Genetic variants previously associated 
with pain sensitivity were not replicated in our study.
Conclusion: A significant proportion of the variability of HPT is explained by genet-
ics. The extent to which HPT is genetically determined is higher when individuals 
do not experience chronic pain. Future genetic studies on pain sensitivity should 
take the presence of chronic pain into account since it influences the phenotype 
substantially. This largest genetic screen for pain sensitivity up to date provides 
new potential genetic loci for further research.
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Introduction
Chronic pain and pain sensitivity are complex traits with a variety of potential 
determinants. The development of chronic pain and an increased sensitivity by 
sensitization of the nervous system are unintended consequences after tissue dam-
age. In this scenario, the pain is prolonged or more severe compared to what might 
be expected during a normal healing process [1].
A wide variety of risk factors have been described for the development of chronic 
pain. One of them is an intrinsic high pain sensitivity, which can be assessed by 
experimental pain sensitivity measurements [2]. In theory, experimental pain 
sensitivity is less sensitive to bias due to disease or tissue damage, compared to 
more subjective pain phenotypes such as pain severity scores [3]. There are many 
different measurements to determine pain sensitivity, such as pain thresholds 
and tolerance for different stimuli. The heat pain threshold (HPT) is one of the 
most studied measurements for pain sensitivity: the HPT is noninvasive and can 
be used for measuring pain sensitivity and pain thresholds. Measurements can be 
done over multiple body points, and the temperature and the duration of the pain 
stimulus can be highly controlled [3]. Finally, there is good reproducibility between 
two sessions [4].
The proportion of genetic influence on pain has been under debate. In previous 
studies, the heritability of pain sensitivity and chronic pain has been estimated 
in classical twin studies. A review by Nielsen et al. [5] showed that the heritability 
estimates of specific pain phenotypes differ: for example, back and neck pain have 
heritability estimates ranging from 0% to 68% [6-13], osteoarthritis has heritability 
estimates ranging from 0% to 53% [14,15], and irritable bowel syndrome has heri-
tability estimates ranging from 0% to 48% [16-20]. The heritability of experimental 
pain sensitivity has been studied scarcely, with only three previous study reports. 
All three reports had a twins design and used various experimental designs, such 
as cold pressor tests and heat pain thresholds [21-23], and relatively small sample 
sizes were used. Consequently, heritability estimates ranged between 0% and 60%. 
Other studies investigating the genetic background of pain sensitivity focused on 
candidate genes previously described to play a role in pain, or studied the genetic 
variants in modestly sized pain patient populations [24-36].
In a previous study by our group, we investigated the genetic background of 
chronic widespread pain [37]. Although we identified a DNA variant to be asso-
ciated with CWP, we also identified significant heterogeneity among phenotype 
definitions among the cohorts. As for other complex traits, it would be helpful to 
dissect the pain phenotype into quantitative underlying endophenotypes, such as 
intrinsic pain sensitivity, which can be measured by experimental pain thresholds. 
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The present study therefore focuses on experimental HPT as an endophenotype 
underlying the development of chronic pain.
The aim of the current study was to further elucidate the genetic predisposition 
of pain sensitivity, defined as the HPT. In the Rotterdam Study, a large prospective 
population based cohort, we estimated the heritability of the HPT and the influ-
ence of gender and the presence of chronic pain on the heritability of the trait. 
We performed a genome wide association study (GWAS) to search for potential 
new genetic markers associated with HPT in a general population. And finally, we 
reviewed the literature for significantly pain sensitivity associated variants and we 
tried to replicate those findings in our population.
Methods
Study population
This study is performed within the Rotterdam Study (RS), a large prospective 
population-based cohort study of men and women aged 45 years and over. The 
study design and rationale are described elsewhere in detail [38]. In summary, de-
terminants, incidence and progression of chronic disabling diseases in the elderly 
are studied. The first cohort (RS-I) within the Rotterdam study started in 1990 and 
included 7,983 individuals ages 55 years and older. In 1999, an additional 3,011 
subjects were included in Rotterdam study II (RS-II). The third cohort (RS-III) was 
invited in 2005, adding 3,932 individuals aged 45 years and over. All participants 
were examined in detail at baseline and at subsequent follow up visits, which took 
place approximately every six years. In summary, a home interview and extensive 
set of examinations at the research center was performed. For the present study, 
we used data from 3,795 participants for whom data on experimental pain sensitiv-
ity, data on the presence of chronic pain and genetic information were available. 
The Rotterdam Study has been approved by the Medical Ethics Committee of the 
Erasmus MC and by the Ministry of Health, Welfare and Sport of the Netherlands, 
implementing the “Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rot-
terdam Study)”. All participants provided written informed consent to participate 
in the study and to obtain information from their treating physicians.
Genotyping
Genotyping was done using Illumina Infinium HumanHap550 Beadchips (RS-II), or 
the Illumina Infinium HumanHap610 Beadchips (RS-III). Details about genotyping 
and Quality Control have been described previously [37]. In short, a total of 2,612 
subjects were genotyped in RS-II (Illumina 550 duo) and a total of 3,523 subjects in 
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RS-III (Illumina 610 quad). Exclusion criteria were a call rate <98%, Hardy-Weinberg 
p-value <10-6 and minor allele frequency < 0.01%, autosomal heterozygosity, sex 
mismatch and outlying identity-by-state clustering estimates. A total of 2,157 for 
RS-II and 3,048 for RS-III passed genotyping quality control. Data was imputed 
with the 1000-Genomes reference panel (phase 1, version 3) using MACH version 
1.0.15/1.0.16 [39]. A total number of 30,072,738 SNPs were available for association 
analysis.
Experimental pain sensitivity assessment: Heat pain threshold measurement
In the 3,795 participants of the Rotterdam study included in this study, quantitative 
sensory testing was conducted. We used a commercially available thermo-sensory 
analyzer, the TSA II (Medoc Advanced Medical Systems, Durham, NC). The mea-
surement probe had a surface of 30x30mm, and was placed on the inner site of the 
non-dominant forearm.
During the HPT measurement, the starting temperature of the probe was 32 
degrees Celsius. Then, the probe would increase in temperature with 1.5 degrees 
per second until the participant ended the test or the maximum temperature of 50 
degrees Celsius was reached. The participant was asked to push a large red ‘quiz 
button’ and therewith end the measurement at the moment the stimulus started to 
feel unpleasant or painful. After each measurement, the temperature returned to 
32 degrees Celsius before the next measurement started. The HPT measurement 
was repeated five times in a row. For the analysis, the average temperature of the 
last three measurements was used.
Heritability estimation
To quantify the proportion of HPT variance explained by genetic variants, we used 
the restricted maximum likelihood (REML) method. This method is able to quantify 
heritability estimates attributable to all genetic variants and is implemented in 
the Genome-wide Complex Trait Analysis (GCTA) package. [40] We created one 
genetic relationship matrix (GRM) file for the unrelated participants in our RS-II 
and RS-III populations, and included all genotyped SNPs. This resulted in a GRM 
file of 495,775 SNPs for 3,795 samples. No pairs of individuals exceeded the GCTA 
standard cutoff coefficient of 0.025 for genetic relatedness. A p-value<0.05 was 
considered to be statistically significant in this analysis.
The mean HPT (as described before) was used as phenotype and adjustments 
were made for age and gender.
Additional analyses were performed in which we stratified both for gender and 
the presence of chronic musculoskeletal pain.
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Genome Wide Association Study (GWAS) and meta-analysis
We performed two GWAS for HPT: one in RS-II and one in RS-III. We used 
MACH2QTL via GRIMP [41], which uses the genotype dosage values (0-2 as a con-
tinuous variables) as the predictor in a linear regression framework. HPT was used 
as the outcome measurement and adjustments were made for age, gender and 
the presence of chronic pain. In addition, the GWAS was repeated in participants 
without chronic pain.
Quality control was done with EasyQC [42]. The effective allele count was calcu-
lated for all SNPs by 2*minor allele frequency*R2(correlatedness of the data)*sample 
size. SNPs with an effective allele count >5 were included in the meta-analysis. An 
effective allele count of >5 represents minor alleles appearing at least 5 times in 
the study population.
The summary statistics of the results of the GWAS in RS-II and RS-III were meta-
analyzed using METAL (www.sph.umich.edu/csg/abecasis/metal) after genomic 
control correction to the standard errors and p-values. METAL applies an inverse-
variance methodology assuming fixed effects with Cochran’s Q and I2 metrics to 
quantify between-study heterogeneity.
For the GWAS, the statistical significant threshold was set on 5.0*10-8. SNPs with 
a p-value < 1.0*10-6 were called suggestive signals.
Systemic review of genetic variants previously described
We systematically searched the literature for previous associations with experimen-
tal pain thresholds. We used the Human Genome Epidemiology (HuGe) Navigator 
Phenopedia database for this. [43] This database provides a comprehensive archive 
of studies assessing the associations between phenotypes and genetic variants 
and this database is continuously updated.
The phenopedia tool provides a list of genes previously associated with your 
phenotype of interest, and includes links to the articles in which these associa-
tions were published. We used the search term ‘pain threshold’ on 16 September 
2014. All publications were manually screened for the phenotype studied and the 
SNPs identified. We only included the studies which investigated the association of 
genetic variants with measures of quantitative sensory testing. The SNPs selected 
for the analysis were those described to be significantly associated with the pain 
threshold phenotype. Additionally, an rs-id needed to be available.
For all reported SNPs, we examined their association with HPT in our GWAS 
meta-analysis results. The significance threshold was set at p-value<0.05.
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Results
Population characteristics
For this study, 1,326 individuals from the third follow up visit of RS-II and 2,469 
individuals from the second follow up visit of RS-III were included in whom HPT 
measurements and genotype information was available. Characteristics are shown 
in Table 1. The participants from RS-II were significantly older and had a lower per-
centage of women. The prevalence of chronic pain was significantly higher in RS-II 
and mean HPT measures were slightly lower in RS-II compared to those in RS-III.
Table 1. Study population characteristics
Total RS-II RS-III
N= 3,795 1,326 2,469
Age, mean (SD) 65.9 (7.5) 72.6 (5.2) 62.3 (6.0)
Women, % (n) 56% (2,125) 54% (716) 57% (1,407)
Chronic pain present, % (n) 44% (1,670) 47% (623) 42% (1,037)
Heat pain threshold, mean (SD) in degrees Celsius 47.5 (3.0) 47.3 (3.2) 47.7 (2.8)
RS-II = Rotterdam Study II; RS-III is Rotterdam Study III; SD = standard deviation; n = sample size.
Heritability estimation
In the complete population, the GCTA estimate of genetic influence due to the ad-
ditive effect of common SNPs was 19% (SE 0.09; p-value=0.02). Since gender is one 
of the major factors determining HPT, we subsequently stratified the population 
according to gender. We oberved the heritability estimate in women to be 35% (SE 
0.20; p-value 0.04), while it was 9% in men (SE 0.28; p-value 0.38). Chronic pain is 
known to influence HPTs significantly through central sensitization. Therefore, we 
studied the heritability of HPT separately in individuals with and without chronic 
pain. For individuals with chronic pain, the heritability was estimated to be 8% 
(SE 0.20; p-value=0.35). For individuals without chronic pain, this was higher and 
statistically significant with 32% (SE 0.17; p-value=0.03).
GWAS meta-analysis
A total of 30,072,738 markers were tested for the association with HPT in our popu-
lation of in total 3,795 individuals. Genomic control inflation factors for the p-values 
in RS-II and RS-III were low (λ=1.01 and 1.001 respectively). The Quantile-Quantile 
plot indicated no substantial population stratification due to cryptic relatedness, 
population substructure or other biases (Figure 1). The results of the GWAS meta-
analysis are summarized in a Manhattan Plot of the p-values (Figure 2).
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We identified one SNP on chromosome 1 to be genome-wide significant (p-value 
<5.0* *10-8). This SNP represents a deletion located on position 176,688,345 on 
chromosome 1 (p-value=2.48 *10-8). It is a relatively rare deletion (minor allele 
frequency = 0.02), and it is located in the twelfth intron of the PAPPA2 gene. The 
PAPPA2 gene encodes for a protein which is thought to be a local regulator of 
insulin-like growth factor (IGF) bioavailability. IGF is implicated in nociceptive (pain) 
Figure 1. Quantile-quantile plot (Q-Q plot) for the GWAS meta-analysis with HPT.
This plot compares additive model statistics to those expected under the null distribution using 
fixed-effects for all analyzed 1000G imputed SNPs passing the quality control. Analysis adjusted for 
the presence of chronic pain.
Figure 2. Manhattan plot of the P-values of the GWAS meta-analysis of HPT in RS-II and RS-III. Analy-
sis adjusted for the presence of chronic pain. The red line represents the line for genome wide sig-
nificance (p-value 5.0*10−8), the blue line represents the line for suggestive signals (p-value 1.0*10−6).
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sensitivity of primary afferent neurons [44]. Additionally, the deletion is located 
140kb downstream of the ASTN1 gene. ASTN1 (or astrotactin 1) is a neuronal adhe-
sion molecule required for migration of young postmitotic neuroblasts in cortical 
regions of developing brain, including cerebrum, hippocampus, cerebellum, and 
olfactory bulb [45].
 Next to the genome-wide significant hit, we found six other suggestive signals 
with a p-value <1.0*10-6 (Table 2). Five of six top SNPs have relative low allele fre-
quencies (MAF<0.05).
We found one locus to be suggestive in both the analyses: in the original GWAS 
(adjusting for chronic pain), the intronic SNP rs187924640 (MAF=0.015) was a 
suggestive hit (p=2.56*10-7), and in the sensitivity analysis (excluding chronic pain 
cases) this SNP was also close to significance (p-value=8.23*10-7). The PRKC1 gene 
encodes for the protein kinase C iota type, which is implicated in the regulation of 
neuronal growth and specification [46-48].
Systematic review of genetic variants previously described
In the HuGe navigator, the search term ‘Pain threshold’ provided a total of 60 
publications describing 44 different genes. After selection for pain threshold 
phenotypes and SNPs having an rs-id, we were left with fifteen publications. In 
these articles, nine SNPs in six different genes (COMT, DRD3, OPRK, OPRM1, 
SLA6A4 and HTR1A) were previously reported to be significantly associated with 
pain threshold phenotypes. The selected SNPs, the direction of the effect in the 
previous articles and the results in our GWAS study are shown in Table 3. None of 
the nine SNPs were significantly associated with HPT in our GWAS meta-analysis 
results.
Table 2. Genome Wide Association Analysis ‘Heat Pain Threshold’ adjusted for presence of chronic 
pain, tophits signals p-value < 1.0*10−6
Marker Chr Pos Coded
allele
Other
allele
AF Beta StdErr P-value
(all partici-
pants)
P-value
(no pain
cases)
Position Gene
1:176688345:D 1 176688345 D I 0.02 −2.09 0.38 2.48*10-8 1.11*10-5 intron 12 PAPPA2
rs13049646 21 43651846 T G 0.98 1.52 0.29 1.84*10-7 1.24*10-5 intron 2 ABCG1
rs187924640 3 169948817 T G 0.02 −1.57 0.31 2.56*10-7 8.23*10-7 intron 1 PRKCI
rs512766 10 97228338 C G 0.10 0.60 0.12 5.41*10-7 2.96*10-4 intron 1 SORBS1
rs74371079 12 1084044 A G 0.06 −0.81 0.16 5.98*10-7 2.00*10-4 intron 1 RAD52
rs141493091 1 84375770 A C 0.04 −1.09 0.22 6.81*10-7 7.60*10-4 intron 15 TTLL7
rs7239184 18 67129023 T G 0.96 0.91 0.19 9.94*10-7 3.52*10-3 intron 1 DOK6
Chr = chromosome; Pos = position; Coded allele = effect allele; AF = allele frequency of coded al-
lele; Beta = effect size of effect allele; StdErr = standard error of the effect.
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Discussion
In this population based study, we aimed to identify the genetic background of 
an experimental measure of pain sensitivity, the heat pain threshold (HPT). We 
observed an overall heritability estimate of 19% which was dependent on gender 
and the presence of chronic pain. We performed a genome wide association study 
(GWAS) to search for potential new loci and found seven interesting new loci. In a 
candidate SNP approach, we were not able to replicate the earlier associated SNPs 
with the HPT in our study.
Although not yet fully elucidated, a significant proportion of the variability of HPT 
is explained by genetics. The method we used to measure heritability is different 
from twin and pedigree analysis. Our method uses only common DNA variants in 
linkage with the genotyped SNPs (on the Illumina SNP arrays) to estimate herita-
bility, while family-based studies use all genetic variants, including rare variants 
[40,49]. Since there are less SNPs included in our analysis, the heritability of the trait 
will be underestimated. The GCTA method has been applied to other complex 
traits like height, and in this study a heritability of 55% for height was observed [50]. 
This is much lower than the heritability estimates based on twin studies, in which 
Table 3. Associations of HPT with the candidate gene SNPs.
Coded
allele
Other
allele
AF Beta P-value
(all participants)
Effect
direction
in literature*
References
COMT
 rs4680 A G 0.55 −0.09 0.18 −, −, −, −, − [25-27,31,34]
DRD3
 rs6280 T C 0.69 0.02 0.77 − [35]
OPRK
 rs6473799 A G 0.77 0.09 0.27 − [36]
 rs7016778 A T 0.88 0.15 0.17 + [36]
 rs7824175 C G 0.92 −0.01 0.94 − [36]
 rs9479757 A G 0.10 −0.05 0.69 + [30]
OPRM1
 rs1799971 A G 0.89 0.02 0.82 +,+ [24,28]
SLC6A4
 rs25531 T C 0.93 0.025 0.89 +, + [29,33]
HTR1A
 rs6295 C G 0.50 0.04 0.63 + [32]
* A negative direction (−) means a higher sensitivity for QST coinciding with a lower HPT; A positive 
direction (+) means a lower sensitivity for QST coinciding with a higher HPT.
Coded allele = effect allele; AF = allele frequency of coded allele; Beta = effect size of effect allele.
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89-93% of the height variance can be explained by genetics [51]. Therefore, we 
expect the heritability estimate of the HPT to be higher than the 19% we identified. 
The advantage of GCTA is that this method is able to estimate the heritability in 
a large sample of unrelated individuals, which makes it more generalizable to a 
general population [52].
Interestingly, we found an evident difference in the heritability estimate of HPT 
between genders and between individuals with and without chronic pain. In women 
and in individuals without chronic pain, the phenotypic variance is explained ge-
netically for one third. In men and in individuals with chronic pain, the heritability 
estimate was not significant. In our study sample, almost 20% of all men reached 
the maximum threshold of 50 degrees Celsius for the HPT. As a consequence, part 
of the variability of the HPT-measurement is lost, which results in lower power to 
measure heritability in this part of the population. Another explanation could be 
that the HPT in men is influenced by other, not yet identified, factors. Our results 
also showed that heritability of HPT is much higher in individuals without chronic 
pain compared to those that have pain. It is known that experimental pain sensitiv-
ity (like HPT) is influenced by the presence of chronic pain, caused by central sen-
sitization of the nervous system [1]. We hypothesize that the presence of chronic 
pain overrides the subtle genetic effects observed in the general population. This 
may be one of the reasons why former studies were not able to find consistently in-
fluencing genes for pain sensitivity phenotypes. Therefore, the presence of chronic 
pain should be taken into account when performing genetic analysis on HPT and 
potentially for other pain sensitivity thresholds in future studies.
To the best of our knowledge, we here present results from the largest genetic 
study on experimental pain performed up to date. In the GWAS for the HPT ad-
justed for chronic pain, there was one deletion (1:176688345:D) on chromosome 1 
which reached genome wide significance (p= 2.48*10-8). This deletion is located in 
the twelfth intron of the PAPPA2 gene, of which the encoded protein is thought to 
be a local regulator of insulin-like growth factor (IGF) bioavailability. IGF is impli-
cated to play a role in the nociceptive (pain) sensitivity of primary afferent neurons. 
Neurotrophy, neurogenesis and metabolic functions are shown to be influenced by 
IGF in the adult brain [53]. In vitro, upregulation of IGF showed a higher sensitiv-
ity of primary afferent neurons [54,55]. Additionally, the deletion is located 140kb 
downstream of the ASTN1 gene. ASTN1 (or astrotactin 1) is a neuronal adhesion 
molecule required for migration of young postmitotic neuroblasts in cortical regions 
of developing brain, including cerebrum, hippocampus, cerebellum, and olfactory 
bulb [45]. Trafficking of the ASTN1 protein is regulated by the ASTN2 gene [56]. 
Interestingly, an SNP within ASTN2 (rs4836732) was found to be associated with the 
pain-related phenotype total hip replacement in women (p=6.11E-11) [57].
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One suggestive hit, located within the PRKCI gene, was associated with HPT 
in both the overall analysis (including all participants) and the sensitivity analysis 
(without chronic pain cases). The PRKCI gene encodes the protein kinase C iota 
gene, which has been found to regulate neuronal growth in the hippocampus in 
embryonic rats, specification of neurons during development in cerebellar purkinje 
cells in zebrafish and inhibiton of spinal cord precursors, also in zebrafish [46-48]. 
These functional associations indicate that the PRKCI gene might in fact be influ-
encing neuronal functioning.
Although very interesting, our GWAS findings need to be replicated in an 
independent cohort, before definite conclusions can be drawn. Since the power 
to detect SNPs associated with our phenotype was relatively low (n=3,795), there 
might be some false positive hits. Additionally, there might be interesting signals 
among the suggestive SNPs and replication should demonstrate the true signals. 
After replication of our findings, functional testing of candidate genes would help 
to give more insight into the biology of HPT.
In the study of candidate genes previously reported to be associated with pain 
sensitivity measurements, we showed that none of the SNPs was significantly as-
sociated with HPT in our GWAS meta-analysis, although our sample size was at 
least 10 times larger. This can be explained by the fact that many of the previous 
reported loci were investigated in small populations of pain patients. This could 
indicate that the associations found are more associated to the pain syndrome 
than the pain sensitivity itself. The lack of reproducibility of SNPs in candidate 
genes in large GWAS meta-analyses has been shown before for other phenotypes 
such as BMD [58].
In conclusion, our study reports a heritability estimate for HPT of 19%. We identi-
fied significant influences of gender and chronic pain on the heritability estimates 
of HPT. Therefore, future genetic studies on pain sensitivity should be adjusted for 
gender and the presence of chronic pain, or individuals with chronic pain should be 
excluded from the analysis. This will result in a more homogenous pain phenotype 
and this will increase the chances of finding new genetic loci involved. The exact 
genes influencing HPT remain not fully elucidated, but this study provides new 
potential genes for further research.
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Abstract
Objective: Type 3 finger length pattern (longer fourth digit than second digit) is 
influenced by prenatal androgens and has been studied previously as a biomarker 
for sexually dimorphic traits. Because osteoarthritis (OA) and chronic pain are 
known to be sexually dimorphic traits, we evaluated the association between finger 
length pattern and OA and chronic joint pain.
Methods: This study was part of the Rotterdam Study, a prospective population-
based cohort study. We examined 4,784 participants. Associations between type 
3 finger length and radiologic knee, hip, and hand OA and chronic joint pain were 
analyzed using a logistic regression model. Our results for OA were combined with 
previously published data in a meta-analysis.
Results: Participants with type 3 finger length pattern had an odds ratio of 1.64 
for hand OA (P = 1.06*10−7). No associations with radiologic knee or hip OA were 
observed in the Rotterdam Study. The meta-analysis of previously published data 
and our novel data showed a significant association between type 3 finger length 
pattern and clinical symptomatic knee OA, but no association was found with 
radiologic knee OA. In addition, within the Rotterdam Study, we observed an odds 
ratio of 1.41 for individuals having joint pain at multiple sites (P=1.4*10−3).
Conclusion: Type 3 finger length pattern, as an indicator of prenatal androgen ex-
posure, was associated with having symptomatic knee OA, chronic pain, and hand 
OA. Therefore, it may be applicable as an easy measurable biomarker to identify 
susceptible subjects for these traits.
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Introduction
Finger length pattern, or digit ratio, is the ratio between the second digit (2D; index 
finger) and fourth digit (4D; ring finger) and is thought to be influenced by the bal-
ance between androgens and estrogens in a narrow window during embryogenesis 
in the second trimester. During this period, sex hormones play an important role 
in the development of several organ systems, such as the reproductive system and 
the brain. Relatively high androgen levels during this period are associated with 
a longer 4D compared with the 2D, resulting in a lower ratio of 2D to 4D length 
(2D:4D) [1]. This association has been shown in an experimental murine study in 
which elevation of androgen levels during development resulted in a decreased 
2D:4D [2]. This result indicates that a lower 2D:4D is a crude measure for relatively 
high levels of prenatal androgen exposure.
To determine finger length pattern, 2 distinct methods have been described, 
both using hand radiographs [3]. The first method is a simple and fast visual 
classification method in which the soft tissue outline of the 2D and 4D is classified 
into 3 groups: the ring finger is shorter than (type 1), equal to (type 2), or longer 
than (type 3) the index finger. The second method measures the length of the 2D 
and 4D and computes a ratio (2D:4D). A 2D:4D < 1 represents the same phenotype 
as a type 3 finger length pattern, a 2D:4D = 1 is similar to type 2, and a 2D:4D > 1 
corresponds to type 1.
Finger length pattern has been studied in relation to a number of diseases and 
physiologic and psychological traits, and the majority of these traits are associ-
ated with sex or sex hormones. Associations have been described with coronary 
heart disease [4], autism [5], homosexuality [6], fertility [7], and age at menarche 
[8,9]. In these associations, type 3 finger length pattern (relatively higher androgen 
levels during development) has been described as a biomarker for increased risk 
of developing several different sex-related traits. This makes finger length pattern 
an interesting phenotype to study in relation to other sex- or sex hormone–related 
traits, such as osteoarthritis (OA) and chronic joint pain.
OA is known to be a sex-related phenotype, with a higher incidence in women, 
specifically after menopause, indicating a sex hormone component in the etiology 
[10]. Four previous studies have examined the association between finger length 
type and OA risk, but these studies had inconsistent findings. The first study, using 
a case control design, showed that type 3 finger length pattern was positively as-
sociated with having symptomatic knee or hip OA [11]. This finding was confirmed 
in a nested case control study by Ferraro et al. [12] for knee OA; however, Hau-
gen et al. [13] failed to replicate this association with radiographic knee OA in a 
population-based cohort. The final study showed a positive association between 
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type 3 finger length pattern and total knee replacement in the general population 
[14]. The inconsistencies between these studies could be due to a difference in 
the definition of OA. The studies that showed an association compared clinical 
symptomatic OA cases to pain-free controls. The population-based cohort study 
used radiologic OA in the knee as the definition and did not find an association. 
Therefore, we hypothesized that the previously found associations might have 
been driven by pain rather than joint damage.
Like finger length pattern, embryogenic brain development is influenced by 
prenatal androgen exposure, specifically in the development of sex differences 
in the brain [15]. Chronic pain is also sex associated; therefore, prenatal androgen 
exposure, as measured by finger length pattern, might be associated with the risk 
for chronic pain by this shared association with sex and thus androgens.
In this study, we aimed to further elucidate the association of type 3 finger length 
pattern with OA of the knee, hip, or hand. We systematically reviewed the literature 
for previous studies examining the association between finger length pattern and 
OA and meta-analyzed the results, including our own novel data. Subsequently, 
we aimed to evaluate the association between type 3 finger length pattern and 
chronic joint pain.
Patients and methods
Study population
The Rotterdam Study is a large prospective population-based cohort study of men 
and women aged ≥ 45 years. The study design and rationale have been described 
elsewhere in detail [16]. In summary, the objective of the Rotterdam Study was to 
investigate the determinants, incidence, and progression of chronic disabling dis-
eases in the elderly. The first cohort, Rotterdam Study I, consisted of 7,983 people 
aged ≥ 55 years in 1989. This study population was extended in 1999, adding 3,011 
participants in Rotterdam Study II (RS-II) and adding 3,932 subjects ≥ 45 years and 
older in Rotterdam Study III (RS- III) in 2006. All participants were examined at base-
line in detail. A home interview was conducted and subjects had an extensive set 
of examinations at the research center, including radiographs taken from the hip, 
knee, and hand. The Medical and Ethical Review Committee of Erasmus University 
Medical School approved the study and written informed consent was obtained 
from each participant. The data used in this study are the baseline data of a subset 
of the participants in RS-II and RS-III. In these subjects, radiographs of the hands 
were available and finger length pattern was determined.
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Finger length pattern
The radiograph of the right hand at the baseline visit was used to determine finger 
length pattern. Finger length pattern was visually scored as type 1 (ring finger 
shorter than index finger), type 2 (ring finger same as index finger), or type 3 (ring 
finger longer than index finger). Interreader correlation was high (κ = 0.85).
Definition of outcome measures
Knee and hip OA: OA of the hip and the knee was scored by the Kellgren/Lawrence 
(K/L) grading system. The definition of having knee or hip OA was a K/L score of ≥ 
2, as described previously [17]. Total joint replacements (TJRs) due to primary OA 
visible on radiographs were considered as OA. TJRs due to fractures and other 
diseases were excluded.
Hand OA: Radiographs of the hand were scored for radiographic features of OA 
at the following joint levels: distal interphalangeal (DIP) joints, the interphalangeal 
joint of the thumb, proximal interphalangeal (PIP) joints, metacarpophalangeal 
joints, first carpometacarpal joint (CMC1), and trapezioscaphoid (TS) joint. An over-
all grade for OA was scored by the K/L grading system. Hand OA was defined as 
having a K/L score ≥ 2 in 2 of 3 joint groups (DIP, PIP, and CMC1/TS), as previously 
described [17].
Chronic joint pain: All participants completed a pain homunculus to report the 
chronic painful sites in the body. The pain homunculus showed a picture of the front 
and the back of the human body. Participants were asked the following question: 
“Did you have pain anywhere in your body, for at least half of the days, during the 
last 6 weeks?” Circles were drawn around the painful areas by the participant. The 
homunculi were scored using a template assigning 14 different joint pain regions 
(e.g., neck, shoulders, elbows, hands, low back, hips, knees, and feet). Chronic joint 
pain was defined as subjects having ≥ 1 painful sites. Subjects having > 2 painful 
joints were identified as a more severe phenotype.
Symptomatic OA: Symptomatic OA was defined as having both radiologic evi-
dence of OA and chronic pain in the same joint. Subjects with asymptomatic OA 
showed radiologic evidence for OA in the knee but did not experience chronic 
pain in the affected joint. The data from the pain homunculus, as described above, 
were used to assess pain in the affected joint. In the analysis, symptomatic OA was 
compared with asymptomatic OA.
Statistical analysis
Binary logistic regression was used to test the association between type 3 finger 
length pattern and the different outcome measures. All analyses were adjusted for 
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age, sex, and body mass index (BMI). SPSS, version 17.0, was used for the associa-
tion analysis. A P value less than 0.05 was considered statistically significant.
Association analysis of OA: For radiographic knee OA, hip OA, hand OA, and 
symptomatic OA, odds ratios (ORs) were assessed. The subjects derived from the 
RS-II and RS- III were combined for these analyses. Separate analyses of the 2 sub-
cohorts were also performed to detect possible cohort effects.
Association analysis of chronic joint pain: The association between type 3 finger 
length pattern and joint pain at any site was evaluated in the same manner, by bi-
nary logistic regression. Subsequently, we studied the association with chronic joint 
pain at > 2 sites of the body compared to no joint pain. Analyses were performed 
for the 2 different cohorts of the Rotterdam Study separately to detect possible 
cohort effects and combined to increase the power.
Systematic review of the literature: We identified and included all articles describ-
ing the association of finger length pattern and OA by a systematic search using 
the PubMed database on January 31, 2013, with the keywords (“Osteoarthritis” or 
“Arthrosis” or “OA”) and (“Finger length pattern” or “digit ratio”). Subsequently, 
we extended the search by screening the references of the studies included.
Meta-analysis: The results retrieved from previous published studies and our 
novel data from the Rotterdam Study were used for the meta-analysis. We used 
Comprehensive Meta-Analysis software, version 2. If heterogeneity existed (I2 > 
25%), a random-effects model (Dersimonian-Laird) was used instead of a fixed-
effects model (inverse-variance method) for the analysis.
Results
Baseline characteristics
Finger length pattern was determined in 2,205 participants in the RS-II and 2,579 
participants in the RS-III. The baseline characteristics are shown in Table 1. In con-
cordance with previous studies [2,3,18 –20], type 3 finger length pattern was more 
prevalent in men than women (35% versus 18%; P < 0.001). Radiographic OA in 
the knee, hip, or hand was more frequently present in women compared with men 
(36% versus 25%; P < 0.001). This distribution was similar for symptomatic OA (35% 
in women versus 27% in men; P= 0.002). In addition, a higher incidence of chronic 
joint pain was observed in women than in men (50% versus 37%; P < 0.001).
Association analysis of OA in the Rotterdam Study
Table 2 shows the results of the association analysis of type 3 finger length pattern 
and the different types of radiographic OA in the Rotterdam Study. We did not find 
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an association between type 3 finger length pattern and knee or hip OA. However, 
we observed that participants with type 3 finger length pattern had an OR of 1.64 
for hand OA (P= 1.061*10−7). The association was of similar magnitude in both 
sexes (OR 1.61, P= 9.3*10−5 for men versus OR 1.66, P= 3.4*10−4 for women).
Severe OA could lead to shortening of the digits and an overestimation of the 
presence of type 3 finger length pattern. As a sensitivity analysis, we therefore 
excluded participants with severe OA of the 2D. Severe OA was defined as a K/L 
score of ≥ 3 and comprising joint space narrowing. The association between finger 
length pattern and hand OA was attenuated to an OR of 1.43. Nevertheless, the 
association remained highly significant (P= 3.26*10−4).
Additionally, a sensitivity analysis was performed to study the association of type 
3 finger length pattern and the radiographic severity of knee OA, as described by 
the K/L score. No significant association was found (OR 1.05, P= 0.474).
Table 1. Characteristics of the study participants*
RS-II RS-III
Total
(n=2205)
Men
(n=985)
Women
(n=1220)
Total
(n=2579)
Men
(n=1100)
Women
(n=1483)
Age, mean 
± SD years
64.5 ± 7.7 64.1±7.3 64.8 ± 7.9 56.7 ± 6.9 56.6 ± 6.6 56.8 ± 7.0
Body Mass Index, 
mean ± SD kg/m2
27.2 ± 4.2 27.0 ± 3.9 27.4 ± 4.4 27.9 ± 4.8 28.1 ± 4.2 27.7 ± 5.2
Finger length pattern:
Type 1 353 (16) 100 (10) 253 (21) 467 (18) 119 (11) 348 (24)
Type 2 1,221 (55) 515 (52) 706 (58) 1,514 (59) 612 (56) 902 (61)
Type 3 631 (29) 370 (38) 261 (21) 602 (23) 369 (34) 233 (16)
Radiographic osteoarthritis:
Knee 384/2,102 (18) 137/940 (15) 247/1,162 (21) 270/2,562 (11) 106/1,096 (10) 164/1,466 (11)
Hip 161/2,109 (8) 64/946 (7) 97/1,163 (8) 71/2,459 (3) 26/1,047 (3) 45/1,412 (3)
Hand 692/2,149 (32) 194/964 (20) 498/1,185 (42) 275/2,341 (12) 71/996 (7) 204/1,345 (15)
Symptomatic osteoarthritis:
Knee 123/323 (38) 37/115 (32) 86/208 (41) 92/268 (34) 30/106 (28) 62/162 (38)
Hip 73/135 (54) 22/61 (36) 51/74 (69) 14/70 (20) 5/26 (19) 9/44 (21)
Hand 139/570 (24) 24/152 (16) 115/418 (28) 57/275 (11) 9/71 (13) 48/204 (24)
Chronic joint pain 864/1,835 (47) 316/798 (40) 548/1,037 (53) 1,110/2,566 (43) 393/1,095 (36) 717/1,471 (49)
Chronic joint pain
> 2 sites 318/1835 (17) 91/798 (11) 227/1037 (22) 342/2566 (13) 84/1095 (8) 258/1471 (18) 
*Values the number of cases/total number (%), unless stated otherwise. RS-II = Rotterdam Study II; 
RS-III = Rotterdam Study III
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Systematic review of the literature
The literature search in PubMed and reference screening resulted in 4 studies 
that examined the association between type 3 finger length pattern and OA. We 
contacted Haugen et al [13] to calculate the OR for the association between the 
visually classified type 3 finger length pattern, knee OA, and hand OA, because 
these data were not shown in their study. The characteristics of the included stud-
ies are shown in Table 3.
Meta-analysis
In the previous studies, the association with knee OA especially had conflicting re-
sults. Because the phenotype definition was also comparable between the studies, 
knee OA was used in the meta-analysis. In Figure 1, the results of the meta-analysis 
of the association between visually classified type 3 finger length pattern and the 
risk of having knee OA are shown. In the fixed-effects model, large heterogene-
ity was found between the studies (I2 = 77%). Therefore, a random-effects model 
was used that showed an overall borderline significant association between type 3 
finger length pattern and knee OA (P= 0.035). We subsequently stratified the meta-
analyses based on the definition of cases and controls because the phenotype 
definition was very diverse across the studies, and this could have been the source 
of the observed heterogeneity.
Table 2. Association analysis finger length pattern and OA*
No. of cases/no. total (%)
Type 1/2 Type 3 OR (95% CI) P
Combined RS-II and RS-III
Knee OA 465/3459 (13) 189/1205 (16) 1.01 (0.83-1.24) 0.901
Hip OA 152/3288 (4) 80/1180 (7) 1.25 (0.92-1.69) 0.149
Hand OA 643/3322 (19) 324/1167 (28) 1.64 (1.36-1.96) < 0.0001†
Stratified analysis
RS-II
Knee OA 258/1494 (17) 126/608 (21) 1.08 (0.83-1.40) 0.584
Hip OA 101/1498 (7) 60/611 (10) 1.21 (0.84-1.73) 0.300
Hand OA 455/1526 (30) 237/623 (38) 1.52 (1.22-1.91) < 0.001†
RS-III
Knee OA 207/1965 (11) 63/597 (11) 0.91 (0.66-1.25) 0.559
Hip OA 51/1890 (3) 20/569 (4) 1.34 (0.77-2.33) 0.309
Hand OA 188/1797 (11) 87/544 (16) 1.99 (1.45-2.72) < 0.0001†
*All analyses are adjusted for age, gender and body mass index. OA = osteoarthritis; OR = odds 
ratio; 95% CI = 95% confidence interval; RS-II = Rotterdam Study II; RS-III = Rotterdam Study III.
† Significant
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The first analysis included the studies with a clinical, symptomatic definition for 
the cases and/or controls. In addition, we included data from the Rotterdam Study 
examining symptomatic knee OA cases versus asymptomatic cases. This meta-
analysis showed a low heterogeneity (I2 = 43%) and a significant association with 
type 3 finger length pattern (OR 1.70, P= 7.0*10−8) (Figure 2A).
The second meta-analysis performed included the studies examining the asso-
ciation of type 3 finger length pattern with radiologic OA in the general population. 
This meta-analysis showed no evidence of an association between type 3 finger 
length pattern and radiologic OA (OR 0.99, P= 0.957) (Figure 2B).
Additionally, we performed meta-analyses on hip OA (summary effect OR 1.27, P= 
0.001 in the fixed-effects model) and hand OA (summary effect OR 1.37, P= 0.009 in 
the random-effects model [I2 = 68%]). However, there were only 3 studies (including 
our own) available for this analysis and the phenotype definition was diverse. Specifi-
cally, the 2 previous studies for hip OA had a clinical OA phenotype (including pain in 
their definition), while our study was based on a radiographic OA definition.
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Zhang et al. 2008 1.94 1.25 3.01 0.003
Ferraro et al. 2010 2.59 1.54 4.36 0.000
Haugen et al. 2011 0.93 0.61 1.42 0.736
Sigurjonsdottir et al. 2013 1.65 1.24 2.20 0.001
de Kruijf et al. (this study) 1.01 0.83 1.23 0.923
1.28 1.12 1.48 0.000
0.1 0.2 0.5 1 2 5 10
Favours A Favours B
Meta Analysis
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Figure 1. Forest plot meta-analysis of the association between type 3 finger length pattern and knee 
osteoarthritis (Included both clinical and radiological knee osteoarthritis). 95% CI = 95% confidence 
interval.
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Figure 2A. Forest plot meta-analysis of the association between type 3 finger length pattern and 
symptomatic knee osteoarthritis (Included only clinical or symptomatic knee osteoarthritis). 95% CI 
= 95% confidence interval.
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Association analysis of symptomatic OA and joint pain in the Rotterdam Study
First, we analyzed the association between type 3 finger length pattern and symp-
tomatic versus asymptomatic OA, but found no significant association for symp-
tomatic knee OA (OR 1.22, P= 0.352), symptomatic hip OA (OR 0.74, P= 0.410), or 
symptomatic hand OA (OR 1.35, P= 0.093). Next, we investigated the association 
between chronic joint pain, independent from the underlying cause, and type 3 
finger length pattern; the results are shown in Table 4. Type 3 finger length pattern 
was associated with joint pain (OR 1.18, P= 0.022). In the subsequent analysis for 
more severe pain cases (joint pain at > 2 sites), this effect became stronger, with an 
OR of 1.41 (P= 1.4*10−3).
Study name Statistics for each study Odds ratio and 95% CI
Odds Lower Upper 
ratio limit limit p-Value
Haugen et al. 2011 0.93 0.61 1.42 0.738
de Kruijf et al. (this study) 1.01 0.83 1.23 0.923
0.99 0.83 1.19 0.957
0.5 1 2
Favours A Favours B
Meta Analysis
Overall effect
(Fixed effects model, I2=0%)
Figure 2B. Forest plot meta-analysis of the association between type 3 finger length pattern and 
radiological knee osteoarthritis (Included only radiological knee osteoarthritis). 95% CI = 95% con-
fidence interval.
Table 4. Association analysis finger length pattern and chronic joint pain*
No. of cases/total no. (%)
OR (95% CI) PType 1/2 Type 3
Combined RS-II and RS-III
Chronic joint pain 1,463/3,297 (44) 511/1,104 (46) 1.18 (1.02-1.37) 0.022
>2 different sites 478/2,318 (21) 182/777 (23) 1.41 (1.14-1.74) < 0.001†
Stratified analysis
RS-II
Chronic joint pain 616/1,331 (46) 248/504 (49) 1.27 (1.02-1.58) 0.032†
>2 different sites 227/944 (24) 91/348 (26) 1.37 (1.01-1.86) 0.043†
RS-III
Chronic joint pain 847/1,966 (43) 263/600 (44) 1.12 (0.92-1.36) 0.247
>2 different sites 251/1,374 (18) 91/429 (21) 1.47 (1.10-1.98) 0.010†
*All analyses are adjusted for age, sex and body mass index. OR = odds ratio; 95% CI = 95% confi-
dence interval; RS-II = Rotterdam Study II; RS-III = Rotterdam Study III.
† Significant
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As described previously, the prevalence of type 3 finger length pattern can be 
overestimated by severe hand OA in the 2D, leading to misclassification. In a sensi-
tivity analysis, we excluded subjects with severe OA in the 2D because severe hand 
OA might be correlated with OA and pain at other sites of the body. The analysis 
showed similar ORs for joint pain anywhere in the body (OR 1.18, P= 0.033) and for 
joint pain at > 2 different sites of the body (OR 1.40, P= 3.63*10−3).
Discussion
In this large population-based cohort study, we found no evidence of an asso-
ciation between type 3 finger length pattern and radiographic knee or hip OA. A 
meta-analysis of these results with previous publications showed high heteroge-
neity, possibly caused by a mixture of radiographic and symptomatic definitions 
of cases and controls. When the meta-analysis was restricted to the symptomatic 
definition for knee OA, a highly significant association was found. For hip OA, the 
meta-analysis was also significant, but because of the limited data, especially for 
radiographic hip OA, we were not able to investigate the role of the difference 
between radiographic and symptomatic OA. In addition, we observed in the Rot-
terdam Study that a longer ring finger compared to the index finger was associated 
with having chronic joint pain. All of these associations were independent of well-
known risk factors of OA and pain, such as age, sex, and BMI.
Previously, 3 case-control studies [11,12,14] focused mainly on OA of the knee. 
The definition of the OA cases was heterogeneous, ranging from radiographic OA 
to severe clinically relevant OA or OA-related total knee replacement. More impor-
tantly, the controls were allowed to have neither radiographic OA nor joint pain at 
several sites of the body. In these settings, an association was found between type 
3 finger length pattern and knee OA. The study by Haugen et al. was a population-
based study that used a radiographic knee OA definition, while the controls were 
subjects who did not have radiographic knee OA. This was similar to our case 
definition, and the 2 population-based cohorts did not replicate the association 
between knee OA and type 3 finger length pattern [13]. This suggests that it was 
not the OA in these studies but the chronic pain that might explain the association 
found. Indeed, we found a consistent positive association of type 3 finger length 
pattern and chronic joint pain in the Rotterdam Study. The association became 
even stronger when we selected a more severe phenotype (chronic joint pain in 
> 2 sites), suggesting a robust association. These findings were not influenced by 
the presence of severe hand OA, which could have been a confounder in this as-
sociation.
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Keogh et al. previously examined the relationship between finger length pat-
tern and pain by studying experimental pain in 50 healthy adults [21]. The authors 
observed that women with type 3 finger length ratio were more sensitive to ex-
perimental pain. Although these results need further replication, these findings are 
consistent with our results.
A possible mechanism behind this association is the influence of embryogenic 
sex hormone exposure on brain development [15,22]. We speculate that higher 
androgen levels might influence the regulation and coping of pain stimuli by the 
brain, thereby increasing the susceptibility for developing chronic joint pain. A 
supposed mechanism for this phenomenon can be the effect of androgens on the 
setting of the hypothalamic–pituitary–adrenal stress axis [23].
We observed a highly significant association between type 3 finger length pat-
tern and OA of the hand. Additionally, the meta-analysis of the results from hand 
OA combined with the previous studies showed similar results. OA of the fingers 
can lead to shortening because of narrowing of the joint space due to cartilage 
breakdown, and can therefore confound the finger length pattern determination 
and lead to misclassification. We therefore performed a sensitivity analysis exclud-
ing all subjects with joint space narrowing in the 2D. This attenuated the association 
toward a smaller effect size (OR 1.43 for type 3 finger pattern), but the association 
remained highly significant. This association has been previously described by 
Haugen et al. [13]. When the authors excluded subjects with joint space narrowing 
in the index finger, the effect was attenuated to a lower effect size, but still had an 
OR of 1.35, similar to our results. This might suggest that a consistent association 
with hand OA was apparent in both of the population studies, even after adjust-
ment for severe hand OA. However, we cannot completely exclude some residual 
confounding.
Androgen levels are known to be involved in the development of the skeleton, 
which could explain the relationship with OA. For example, androgens have been 
shown to influence HOX gene expression during development of chondrocytes 
in the fingers [24]. This might not only result in differences in the development of 
finger length, but also a cartilage more susceptible to OA later in life.
In summary, we observed a consistent association between type 3 finger length 
pattern and radiographic hand OA, but found no evidence for an association with 
radiographic knee or hip OA. However, a meta-analysis suggested that symptom-
atic knee OA is significantly associated with type 3 finger length pattern. In addi-
tion, we found an association between type 3 finger length pattern and chronic 
joint pain. Future prospective studies are needed to explore the possibilities of 
type 3 finger length pattern as a noninvasive biomarker for chronic joint pain.
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Abstract
Background: Chronic pain is more prevalent in women than men, with increasing 
differences between sexes in advanced age. This could be caused by differences in 
sex hormone levels. We therefore studied the relation between sex hormones and 
the prevalence and incidence of chronic pain.
Methods: The association between sex hormone levels and chronic pain was ex-
amined in 9,717 participants aged 45 years and older from the Rotterdam Study, a 
population-based study. Chronic pain was defined as pain in the lower back, hands, 
knees and/or hips for at least three months. Sex hormone levels included estrogen, 
testosterone, androstenedione and 17-hydroxyprogesterone. Relations between 
hormones and prevalent and new onset chronic pain were analyzed using linear 
and logistic regression, stratified by gender.
Results: Women with androstenedione or estradiol levels in the lowest tertile had 
more chronic pain (odds ratio 1.20; 95% CI 1.03-1.39 and odds ratio 1.27; 95% CI 
1.10-1.48 respectively). Mean estradiol levels were lower among men with chronic 
pain (mean difference −3.88 pmol/L; P= 0.005). Lowest tertile 17-hydroxyprogester-
one in women was associated with 38% more new onset pain. All these associations 
were independent from age, BMI, health and lifestyle factors and osteoarthritis.
Conclusions: Lower sex hormones levels are associated with chronic musculoskele-
tal pain, independent from lifestyle and health related factors, in community dwell-
ing elderly women. These results suggest that sex hormones play a role in chronic 
pain and should be taken into account when a patient presents with chronic pain. 
Therefore, sex hormones may be a potential treatment target for these patients.
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Introduction
Chronic pain is sexually dimorphic, with women having a higher prevalence of 
chronic pain conditions, such as fibromyalgia and chronic widespread pain, when 
compared to men. [2, 17, 26]
The differences between women and men with respect to their risk for chronic 
pain are multifaceted and complex. Previous studies have suggested that sex hor-
mones play a role in the development of chronic pain and also in the sensitivity to 
painful stimuli. [6, 12, 22] Especially in women, the changes in sex hormones over 
time seem to influence their sensitivity for pain. For example, chronic pain disor-
ders such as musculoskeletal pain and fibromyalgia are increasing in prevalence 
after menopause and differences in pain sensitivity have been observed during the 
menstrual cycle.[1, 3, 20, 21]
Estrogen and testosterone are the two most frequently studied sex hormones in 
relation to pain. Testosterone is thought to be important during the development 
of the nervous system and is hypothesized to influence pain sensitivity later in life. 
In rats, higher testosterone levels are shown to increase pain sensitivity later in life.
[13]
Estrogen is thought to influence pain sensitivity and incidence of pain later in life. 
More or longer estrogen exposure during life has been found to be associated with 
a higher rate of migraine later in life [4], whereas lower current estrogen levels, like 
in postmenopausal women, has been linked to chronic musculoskeletal pain [7, 19]. 
However, no large studies have investigated the relationship between hormone 
levels in women and the occurrence of chronic pain in the general population. In 
men, testosterone is suggested to have a putative protective role against the de-
velopment of musculoskeletal pain [5], although a recent large population-based 
study in men was unable to find this relationship [25], and instead observed that 
elevated levels of gonadothropins were associated with chronic pain.
One of the major pathologies in elderly individuals causing chronic musculoskel-
etal pain is osteoarthritis. This disease is also known to be sexually dimorphic and 
its incidence rises as well after menopause [16].
To further elucidate the impact of sex hormonal aspects on chronic musculosk-
eletal pain, we investigated the association of levels of the main sex hormones, 
estrogen and testosterone, and its precursors, with the prevalence and incidence 
of chronic musculoskeletal pain adjusted for the main confounders.
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Methods
Study population
This study was embedded in the Rotterdam study, a large prospective population-
based cohort study which included men and women of 45 years and over. The 
design and rationale of this study are described in detail elsewhere [14].
In summary, the Rotterdam Study aims to investigate the determinants, incidence 
and progression of chronic disabling diseases in the elderly. The first cohort, Rot-
terdam Study I (RS-I) was initiated in 1989 including 7983 persons aged 55 years 
and older and was extended in 1999 with 3011 additional participants in Rotterdam 
Study II (RS-II). In 2005, Rotterdam Study III (RS-III) added another 3932 individuals 
aged 45 years and older. For all three inclusion cycles together, the participation 
rate at baseline was 72%.
All participants were examined in detail at baseline (N= 14,926) and follow-up 
visits every ±5-10 years [14]. In summary, a home interview was conducted and the 
subjects underwent an extensive set of examinations at the research center.
The Rotterdam Study has been approved by the medical ethics committee ac-
cording to the Population Study Act Rotterdam Study, executed by the Ministry of 
Health, Welfare and Sports of the Netherlands. A written informed consent was 
obtained from all participants.
Chronic musculoskeletal pain
During the home interview, participants were asked about current musculoskeletal 
pain in hands, hips, knees and lower back using a dichotomous variable (yes/no). If 
present, the duration of this pain was recorded. Chronic musculoskeletal pain was de-
fined as pain in the hands, hips, knees and/or lower back for more than three months.
To investigate whether sex hormone levels may be associated with the develop-
ment of chronic musculoskeletal pain, we studied the relation between hormone 
levels and new onset chronic pain. For this purpose, we selected the individuals 
without chronic pain at the moment of sex hormone measurement. New onset 
pain was defined as not having pain at this first visit and presence of chronic pain at 
the next follow up visit (5-10 years later). Controls in this analysis were participants 
without chronic pain at the first visit and without chronic pain at the follow up visit. 
A flow chart of the included individuals per cohort is provided in Figure 1.
Sex hormone measurements
Sample collection: Blood samples were collected in non-fasting individuals between 
8:30 and 16:00, for determination of steroid levels, at the third visit of RS-I (1997-1999, 
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3920 participants), the baseline visit of RS-II (2000-2001, 2750 participants) and the 
baseline visit of RS-III (2006-2008, 3465 participants).
Analytical determinations: Estradiol was measured using an electrochemilumi-
nescence immunoassay on a Cobas 8000 Modular Analyzer (Roche Diagnostics 
GmbH, Mannheim, Germany) (lower limit of detection of 18.4 pmol/L). Testoster-
one, androstenedione and 17-hydroxyprogesterone were measured simultaneously 
with a LC-MS/MS method using the CHS™ MSMS Steroids Kit (Perkin Elmer, Turku, 
Finland). The Steroids Kit uses a combined solvent extraction and protein precipi-
tation method with acetonitrile containing the deuterated internal standards 2H5-
testosterone, 2H5-androstenedione and 2H8-17α-hydroxyprogesterone. The internal 
standard underwent processing identical to the analytes. The chromatographic 
separation was performed on a Waters® (Milford, MA, USA) Acquity™ UPLC HSS 
T3 1.8 µm column (diameter 1 mm, length 10 cm) and in-line fi lter frit 0.2 µm with an 
acetonitrile/MeOH gradient. A Waters XEVO-TQ-S system equipped with an ESI 
source operating in the electrospray positive mode was used for quantitation. The 
lower limits of quantitation for testosterone, androstenedione and 17-hydroxypro-
gesterone were 0.07, 0.20 and 0.10 nmol/L, respectively. The intraassay coeffi cients 
of variation for testosterone, androstenedione and 17-hydroxyprogesterone were 
<5.7%, <7.4% and <6.1%, respectively.
Health and lifestyle factors
Alcohol consumption: The alcohol consumption use was investigated by interview 
data and defi ned by number of alcoholic beverages consumed per day. Six catego-
Total Population: n=14,926
RS-I 
n=7,983
RS-II 
n=3,011
RS-III 
n=3,932 Source population
Data available on chronic
pain and hormone levels
Population Cross-sectional analysis: n=9,811
RS-I 
n=3,738
RS-II 
n=2,631
RS-III 
n=3,442
No prevalent pain at 
baseline and follow-up 
data available
Population Longitudinal analysis: n=3,412
RS-I 
n=1,307
RS-II 
n=1,221
RS-III 
n=884
Figure 1. Flow chart of included individuals from the Rotterdam study
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ries were made for the analysis (no alcohol use, 1-2 beverages, 3-4 beverages, 5-6 
beverages, 7-9 beverages, >10 beverages).
Smoking: From the interview data we formed 3 categories for smoking to be 
used in the analysis (never smoked, ever smoked and current smoker).
Depression: For the definition of depression, we used the Center for Epidemio-
logical Studies Depression scale (CES-D). [18] This self-reporting scale of depres-
sive symptoms gives a score between 0-80. Depression was defined as a CES-D 
score of 16 or above.
Medication use: As a proxy for overall health, we used the amount of different 
medications used as derived from the interview data. Used medications were cat-
egorized using the Anatomical Therapeutic Chemical Classification System (ATC) 
(http://www.whocc.no/atc/structure_and_principles/). Two categories were made 
for medication use: <5 different medications and ≥5 different medications.
Osteoarthritis definition
Radiographs were scored for the presence of a total hip replacement and radio-
graphic osteoarthritis (ROA) of the hip, knee and hand according to the Kellgren 
and Lawrence (K/L) score [15]. Knee and hip ROA were defined as a K/L score≥2 
of one or both joints or a total joint replacement (TJR). Hand ROA was defined as 
presence of a K/L score ≥2 in 2 out of 3 hand joint groups (DIPs, PIPs, CMC1/TS) of 
one or both hands. The overall presence of osteoarthritis (OA) was then defined as 
having OA in the hip, knee or hand.
Statistical analysis
The distribution of the various hormone levels followed a normal distribution, ex-
cept for estradiol for which many subjects had undetectablelevels. A total of 1786 
women and 27 men had estradiol level below the detection limit. We therefore 
refrained from analyzing estradiol as a continuous variable in women. Associations 
between hormone levels and chronic musculoskeletal pain, were analyzed using 
multivariate regression models adjusted for age and Body Mass Index (BMI), health 
and lifestyle factors (alcohol use, smoking, depression, medication use) and years 
since menopause (women only).
The relation between the risk of chronic pain (both prevalent and new onset) 
and various hormone levels was then evaluated with a tertile-based analysis. The 
tertiles were defined in a sex-specific manner and all analyses were stratified for 
sex.
Logistic regression analysis was used to estimate the risk of chronic pain. Risks 
were calculated in the tertile based analyses, with the highest tertile of hormone 
level as the reference. All estimated risks for chronic pain were adjusted for age, 
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Body Mass Index (BMI), health and lifestyle factors (alcohol use, smoking, depres-
sion and medication use) and years since menopause (women only) and stratified 
for gender. In the analyses for new onset chronic pain, additional adjustment was 
done for follow-up time.
In further analyses, we studied the associations between hormone levels and 
specific locations of chronic joint pain: the knee, hip, lower back and the hand.
We used an additional model for all the association analyses between hormone 
levels and chronic musculoskeletal pain, with adjustment for the presence of OA.
SPSS version 21.0 (SPSS INC., Chicago, USA) was used for the analyses and a 
P <0.05 was considered to be statistically significant. Since the different analyses 
were performed in a sequel to elucidate the associations found, we did not adjust 
the significance level for multiple comparisons.
Results
In this study, a total of 9.811 participants of the Rotterdam Study were included 
with a mean age of 64.9 years. The population consisted of 5,545 women and 4,266 
men. The population characteristics are shown in Table 1. Chronic musculoskeletal 
pain, in accordance with the used definition, was present in 62% of the women 
compared to 45% of the men. For the individuals without pain at the moment 
of hormone measurement, 1558 developed chronic pain before the next follow-
up measurement (mean follow up time = 5.6 years ± 2.3). Mean hormone levels 
were higher in men compared to women. Since most of the women (89%) were 
postmenopausal, estradiol levels were low in a large amount of the women. For 
1786 women (32%), estradiol levels were below the detection level. We therefore 
only evaluated the association between estradiol levels and chronic pain in women 
using the tertile-based analysis, in which the women with undetectable levels were 
part of the lowest tertile. The distribution of the other hormones followed a skewed 
normal distribution.
Sex hormone levels and presence of chronic musculoskeletal pain
Table 2 shows that in a linear regression model, women with chronic pain had lower 
mean 17-hydroxyprogesterone (HP) levels as compared to women without pain 
(mean difference 0.06 mmol/L).
A minority of women (11%) were pre- or peri-menopausal, which could be of 
influence in this analysis. We therefore repeated the analysis excluding the pre- 
and peri-menopausal women. This did not influence the results significantly. For 
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men, a significantly lower estradiol level was found in individuals with chronic pain. 
No associations were found with the other 3 hormone levels.
The subjects were grouped into sex-specific tertiles for the hormone levels, the 
cutoff points for each of the hormone levels are given in table 3. We subsequently 
analyzed the hormone levels by taking the highest tertile as the reference (Table 
3). All analyses were adjusted for potential confounders, including age, BMI, health 
and lifestyle factors, and years since menopause (women only).
Table 1. Population characteristics
Total Females Males
N= Mean 
(SD) or 
percentage
N= Mean 
(SD) or 
percentage
N= Mean 
(SD) or 
percentage
Age 9811 64.9 (9.8) 5545 65.2 (10.1) 4266 64.4 (9.4)
BMI 9753 27.3 (4.3) 5505 27.5 (4.7) 4248 27.1 (3.7)
Alcohol (mean 
consumptions/day)
9234 1.1 (0.7) 5233 0.9 (0.6) 4001 1.3 (0.8)
Smoking (% present/
past)
9800 47.9/19.3 5538 38.4/18.9 4262 60.3/19.8
Depression (% positive 
CES-D)
1761/9382 18.8 1248/5297 23.6 513/4085 12.6
Medication use (% 5 of 
more medications)
1403/9533 14.7 869/5384 16.1 534/4149 12.9
Knee osteoarthritis 1390/8168 14.2 928/4561 20.3 462/3607 12.8
Hip osteoarthritis 633/8232 6.5 393/4613 8.5 240/3619 6.6
Hand osteoarthritis 1849/7957 18.8 1307/4459 29.3 542/3498 15.5
Estradiol (pmol/L) 9653 87.65 (141.3) 5473 75.13 (183.3) 4180 104.03 (40.6)
Testosterone (nmol/L) 9724 7.99 (9.0) 5495 0.95 (0.8) 4229 17.14 (6.0)
Androstenedione 
(nmol/L)
9660 2.92 (1.4) 5465 2.67 (1.4) 4195 3.25 (1.5)
17-hydroxyprogesterone 
(mmol/L)
9717 1.96 (1.5) 5493 1.18 (1.0) 4224 2.96 (1.3)
Prevalent chronic pain 5362/9811 54.7 3461/5545 62.4 1901/4266 44.6
new onset chronic pain 1558/3412 15.9 857/1637 52.4 701/1775 39.5
Knee pain 2568/9811 26.2 1763/5545 31.8 805/4266 18.9
Hip pain 1515/9811 15.4 1100/5545 19.8 415/4266 9.7
Back pain 3285/9811 33.5 2135/5545 38.5 1150/4266 27.0
Hand pain 2243/9811 22.9 1695/5545 30.6 548/4266 12.8
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We observed a consistent higher risk (20-27% higher risk) of chronic pain for the 
women having estradiol and androstenedione levels in the lowest tertile. For men, 
no significant associations between hormone levels and the presence of chronic 
pain was found (supplemental table 1).
We next investigated whether the associations between hormone levels and 
chronic pain in women could be explained by the presence of OA, as a common 
musculoskeletal pain disorder. In total, we had 7764 individuals with data on OA 
(for hip, hand and knee), data on hormone levels and data on chronic pain avail-
able. Table 3 shows that additional adjustment for the presence of osteoarthritis in 
‘multivariate 2’ did not affect the risk estimate significantly.
Sex hormone levels and chronic pain among the different joint sites
To further investigate whether sex hormone levels were consistently associated 
with pain at specific joint sites, the association analyses were repeated for pain in 
the knee, hand, hip and lower back separately, as shown in table 4 for women. In 
earlier analysis, we observed that women in the lowest tertile had an increase in the 
risk of chronic pain compared to the other two tertiles. We therefore show the odds 
ratios for the lowest tertile as compared to the highest tertile.
Table 2. Cross sectional analysis of the differences in sex steroid levels between chronic pain cases 
vs subjects without chronic pain
Women Men
Chronic pain vs 
no chronic pain
new onset 
chronic pain
Chronic pain vs 
no chronic pain
new onset 
chronic pain
N= 4781 N= 1526 N= 3687 N= 1387
MD (SE)
P-value
MD (SE)
P-value
MD (SE)
P-value
MD (SE)
P-value
Androstenedione −0.07 (0.04) 
0.93
−0.18 (0.07) 
0.01
−0.05 (0.05) 
0.26
−0.03 (0.08) 
0.67
17-Hydroxyproges-
terone
−0.06 (0.03) 
0.05
−0.14 (0.06) 
0.03
0.016 (0.044) 
0.717
−0.04 (0.07) 
0.56
Testosterone −0.03 (0.02) 
0.15
0.01 (0.04) 
0.96
0.25 (0.19) 
0.20
−0.03 (0.30) 
0.91
Estradiol* NA NA −3.88 (1.37) 
0.005
1.72 (2.02) 
0.40
MD: Mean Difference; SE: Standard Error. Age, BMI, health and lifestyle factors (alcohol use, smok-
ing, depression and medication use) and years since menopause adjusted univariate general linear 
models were used. *For Estradiol, women were not analyzed (NA) because 33% of the women had 
estradiol levels below detection limit, for men only individuals with values above the detection limit 
were included in the analysis (4179/4206 males). Hormone levels were in nmol/L for androstenedione 
and testosterone, in mmol/L for 17-hydroxyprogesterone and pmol/L for estradiol.
70 Chapter 3.2
Interestingly, although the trends were similar for all associations, knee and hip 
pain were especially associated with estradiol levels (OR 1.31; 95%CI 1.12-1.53 and 
OR 1.22; 95%CI 1.02-1.46 respectively). For lower back pain, only androstenedione 
level was also found to be associated (OR 1.18; 95%CI 1.01-1.37). Chronic hand 
pain was associated with androstenedione, testosterone as well as estradiol levels 
(OR 1.23; 95%CI 1.06-1.44, OR 1.19; 95%CI 1.02-1.39 and OR 1.22; 95%CI 1.05-1.43 
respectively).
Table 3. Cross sectional multivariate analyses of the relationship between hormone levels and risk 
for chronic pain in women
Multivariate 1
N= 4782
Multivariate 2
N= 4364
OR (95% CI)
P-value
OR (95% CI)
P-value
Androstenedione
1st tertile <1.97 1.20 (1.03-1.39) 
0.02
1.23 (1.05-1.44) 
0.01
2nd tertile 1.97-2.94 1.07 (0.92-1.23) 
0.40
1.11 (0.95-1.29) 
0.19
3th tertile >2.94 Reference Reference
17-hydroxyprogesterone
1st tertile <0.71 1.10 (0.95-1.28) 
0.22
1.15 (0.98-1.34) 
0.09
2nd tertile 0.71-1.16 1.03 (0.89-1.19) 
0.70
1.06 (0.91-1.23) 
0.47
3th tertile >1.16 Reference Reference
Testosterone
1st tertile <0.66 1.11 (0.96-1.29) 
0.17
1.11 (0.95-1.30) 
0.18
2nd tertile 0.66-1.00 1.02 (0.88-1.18) 
0.78
1.01 (0.87-1.18) 
0.86
3th tertile >1.00 Reference Reference
Estradiol
1st tertile <19.12 1.27 (1.10-1.48) 
0.002
1.32 (1.13-1.55) 
0.001
2nd tertile 19.12-51.75 1.25 (1.07-1.45) 
0.004
1.28 (1.09-1.50) 
0.003
3th tertile >51.75 Reference Reference
Results are from multivariate logistic regression analysis. OR denotes Odds Ratio, CI denotes Confi-
dence interval. Cutoff points for tertile are given in nmol/L for androstenedione and testosterone, in 
mmol/L for 17-hydroxyprogesterone and pmol/L for estradiol.
Multivariate 1: This analysis included adjustments for age, BMI, health and lifestyle factors (alcohol 
use, smoking, depression and medication use) and years since menopause for women.
Mutivariate 2: Multivariate analysis 1 and additional adjustment for presence of osteoarthritis.
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Consistent with earlier analysis for overall chronic pain risk in men (as shown in 
supplemental table 2), we did not observe consistent associations between hor-
mone levels and specific joint sites. Only androstenedione levels were significantly 
associated with chronic hand pain.
Sex hormone levels and new onset chronic musculoskeletal pain
We estimated the risk for future chronic pain in those individuals that had no chronic 
pain at the time of hormone measurement (n=3412). A total of 1558 individuals 
developed chronic pain between the first visit, when hormone measurement was 
performed, and the follow up visit 5-10 years after.
Table 4. Cross sectional multivariate analyses of the relationship between hormone levels and risk 
for chronic pain at specific sites in women
Chronic
knee pain
Chronic
hip pain
Chronic
low back pain
Chronic
hand pain
OR (95% CI)
p-value
OR (95% CI)
p-value
OR (95% CI)
p-value
OR (95% CI)
p-value
Androstenedione
Multivariate 1 1.13 (0.97-1.33)
0.11
1.14 (0.95-1.37)
0.16
1.18 (1.01-1.37) 
0.04
1.23 (1.06-1.44) 
0.01
Multivariate 2 1.10 (0.93-1.32) 
0.27
1.18 (0.96-1.44)
0.11
NA 1.23 (1.03-1.46) 
0.022
17-hydroxyprogesterone
Multivariate 1 1.10 (0.95-1.29) 
0.21
1.04 (0.87-1.24) 
0.67
1.11 (0.96-1.29) 
0.16
1.15 (0.99-1.34) 
0.07
Multivariate 2 1.13 (0.94-1.34)
0.18
1.08 (0.88-1.32)
0.45
NA 1.13 (0.95-1.34) 
0.18
Testosterone
Multivariate 1 1.02 (0.87-1.19)
0.81
1.19 (0.99-1.43)
 0.06
1.15 (0.99-1.34) 
0.06
1.19 (1.02-1.39) 
0.03
Multivariate 2 0.96 (0.81-1.14) 
0.63
1.12 (0.92-1.37) 
0.26
NA 1.18 (0.99-1.400) 
0.06
Estradiol
Multivariate 1 1.31 (1.12-1.53) 
0.001
1.22 (1.02-1.46)
0.03
1.15 (0.99-1.33) 
0.08
1.22 (1.05-1.43) 
0.01
Multivariate 2 1.37 (1.15-1.64)
4.82*10−4
1.26 (1.03-1.54)
0.02
NA 1.20 (1.01-1.44) 
0.04
Multivariate logistic regression was performed using tertiles for hormone levels. The odds ratio is for 
subjects in the lowest tertile, as compared with subjects in the highest tertiles. Odds ratios are given 
with 95% confidence limits between brackets.
Multivariate 1: This analysis included adjustments for age, BMI, health and lifestyle factors (alcohol 
use, smoking, depression and medication use) and years since menopause. N= 4782
Multivariate 2: Multivariate analysis 1 and additional adjustment for presence of site-specific osteo-
arthritis. N= 3968. These data were not available for low back.
72 Chapter 3.2
We observed that women with new onset chronic pain had lower androstene-
dione and 17-hydroxyprogesterone levels at baseline (Table 2, mean difference 
−0.18 nmol/L; P= 0.01 and mean difference −0.14 mmol/L; P= 0.03). No associa-
tions between baseline hormone levels and new onset chronic pain were found 
in men. We then tested whether the hormone levels were associated with the 
onset of chronic pain in the tertile-based analysis (Table 5). Consistent with the 
previous analysis, lower levels 17-hydroxyprogesterone was associated with higher 
incidence of chronic pain in women at follow up (OR 1.38 95%CI 1.06-1.80). Women 
Table 5. Longitudinal analysis of new onset chronic pain and the association with hormone levels
Women
N= 1527
Men
N= 1377
Odds ratio (95% CI)
P-value
Odds ratio (95% CI)
P-value
Androstenedione
1st tertile <1.97 1.17 (0.89-1.53) 
0.26
0.95 (0.73-1.25) 
0.72
2nd tertile 1.97-2.94 0.99 (0.77-1.29) 
0.96
1.07 (0.83-1.37) 
0.63
3th tertile >2.94 Reference Reference
17-hydroxyprogesterone
1st tertile <0.71 1.38 (1.06-1.80) 
0.02
0.97 (0.75-1.27) 
0.65
2nd tertile 0.71-1.16 1.18 (0.92-1.53) 
0.260
0.97 (0.76-1.25) 
0.82
3th tertile >1.16 Reference Reference
Testosterone
1st tertile <0.66 1.09 (0.83-1.42) 
0.54
0.98 (0.75-1.27) 
0.85
2nd tertile 0.66-1.00 1.05 (0.81-1.36)
0.73
0.98 (0.72-1.19)
0.56
3th tertile >1.00 Reference Reference
Estradiol
1st tertile <19.12 0.84 (0.69-1.09)
0.19
0.87 (0.68-1.13)
0.30
2nd tertile 19.12-51.75 0.91 (0.69-1.20)
0.50
1.02 (0.79-1.31)
0.91
3th tertile >51.75 Reference Reference
Results are from multivariate logistic regression analysis. OR denotes Odds Ratio, CI denotes Confi-
dence interval. Cutoff points for tertile are given in nmol/L for androstenedione and testosterone, in 
mmol/L for 17-hydroxyprogesterone and pmol/L for estradiol.
This analysis included adjustments for age, BMI, health and lifestyle factors (alcohol use, smoking, 
depression and medication use) and years since menopause for women.
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with 17-hydroxyprogesterone levels in the lowest tertile had a 38% increased risk of 
new onset chronic pain when compared to women in the highest tertile.
In men, we did not find a significant association between sex hormone levels 
and new onset chronic musculoskeletal pain. Additional analyses, adjusting for 
prevalent OA, did essentially not influence the risk estimates.
Discussion
In this large population based study cohort including more than 9,500 people 
aged 45 years and over, we observed that women with chronic pain had lower 
androstenedione, 17-hydroxyprogesterone and estradiol levels. In addition, we 
found that women with new onset chronic pain also had lower androstenedione 
or estradiol level at baseline. Women with androstenedione levels in the lowest 
tertile, had a 38% higher risk for new onset chronic musculoskeletal pain when 
compared to women with androstenedione levels in the highest tertile. All these 
associations were independent from possible confounders, such as age, years since 
menopause, BMI, health and lifestyle factors and osteoarthritis. In addition, we 
demonstrated that the trends of these associations were consistent among specific 
sites: for knee, hip, lower back and hand pain. Hand pain was associated with three 
of the four studied sex hormones in women. Lower levels of androstenedione, 
testosterone and estradiol resulted in higher risk for chronic hand pain.
Estradiol is thought to be pain modulating in a complex manner.[7] The mecha-
nisms for this modulating effect are thought to involve neuroanatomical and neuro-
chemical systems which regulate the nociceptive circuitry at spinal and supraspinal 
level. Estrogen exposure over time, but also current estrogen levels can sensitize 
the body for painful stimuli and therefore facilitating the development of chronic 
pain. The influence of estrogen levels on pain sensitivity is also shown by studies 
on pain sensitivity during the different phases of the menstrual cycle, during which 
estrogen and other sex hormones are known to fluctuate [1, 7, 12].
A large study in elderly men by Tajar et al found, for musculoskeletal pain, a 
significant association with gonadotrophins but not with steroid hormones [25]. 
This is in line with the results presented in this study, in which we did not find 
consistent associations between chronic musculoskeletal pain in men and the sex 
hormones studied. From our study, it can be noted that sex hormones are associ-
ated with chronic pain much more for women than for men. One possible explana-
tion may include the differences in pathophysiology of chronic pain between men 
and women. In women, hormones may play a larger role. The exact mechanisms 
behind these differences remain to be investigated. In a recent study, the sexual 
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dimorphism in pain sensitivity was attributed to involvement of adaptive immune 
cells in female mice. In this study, they demonstrated that T-cell infiltration is in-
volved in mechanical allodynia, only in female mice. In absence of these adaptive 
immune cells and in testosterone treated female mice, they observed a more male, 
glial-dependent pathway. [23] Therefore, we hypothesize that sex hormones are 
involved in this observed difference between males and females, since especially 
estrogen is known to enhance the immune system. [8]
Besides estradiol levels, we found androstenedione and 17-hydroxyprogester-
one to be significantly associated with chronic musculoskeletal pain in women. 
Androstenedione is an important precursor for other sex hormones. Since circu-
lating estradiol levels are low in postmenopausal women, the precursors might 
have a more important role in the mechanism of action. The precursors can be 
metabolized into active sex hormones in the peripheral tissues. [11] In support 
of this hypothesis, animal studies demonstrated aromatization of androgens into 
estrogen in the dorsal root ganglion in the spinal cord [10]. This might imply a 
mechanism in which estrogen regulates pain in a paracrine manner.
Our study has a number of strengths: It has a population-based and longitudinal 
design. In addition, to our knowledge, the sample size is larger than any other 
previous study. Moreover, the assessment of lifestyle and health confounders was 
done using validated instruments.
A number of issues should be noted when interpreting the results of this study. 
First, the population we used were 45 years and over, which means that most 
women in the study were postmenopausal and had very low estradiol levels. In 
addition, a large part of the analysis was done using a cross-sectional design, which 
prevented us to draw firm conclusions about causality of the findings. However, 
longitudinal analyses, showed similar effect sizes for new onset musculoskeletal 
pain in women. Probably since the included number of individuals in this analysis 
was much lower, statistical level of significance was less decisive as compared to 
the cross sectional design. The fact that the hormone levels were also associated 
with new onset chronic pain, suggests that the differences in hormone levels are 
preceding the pain, and not the other way around. Sex hormones are known to 
fluctuate during the day. In our study, blood samples were collected between 8:30 
and 16:00, which could have influenced our measurements. It is unlikely that this 
fluctuation influenced the associations found in this study, since the pain assess-
ment does not vary across the day and considering the large number of individuals 
included in this study. Pain severity scores were not available in this study, but could 
have improved the definition of chronic pain.
In women, we found consistent results of sex hormones being associated with 
prevalent and new onset pain in all different analyses. For men, there were also 
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some significant, but less consistent associations found. Considering the number 
of different tests performed, these findings in men could be subject to type I errors 
and should therefore be interpreted with caution.
We also performed analyses in which we adjusted the identified associations for 
the presence of osteoarthritis. The main reason for this was the fact that estrogen 
is thought to be involved in the development of osteoarthritis, the main cause of 
musculoskeletal pain in the elderly. [24] Our results suggest an independent asso-
ciation of androstenedione and estradiol, on the prevalence of chronic musculosk-
eletal pain, in women. As previously described, the role of estradiol and other sex 
hormones in the pathophysiology of osteoarthritis is not very clear, although the 
hormonal changes in postmenopausal women are often thought to be involved[9]. 
This study supports the limited influence of sex hormones on the pathophysiology.
In summary, lower sex hormones levels are associated with an increased risk for 
having and developing chronic musculoskeletal pain, independent from lifestyle 
and health related factors, in women. These results suggest that sex hormones 
may play a role in chronic pain and should be taken into account when a patient 
presents with chronic pain. Therefore, sex hormones may be a potential treatment 
target for these patients.
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Supplementary table 1. Cross sectional multivariate analyses of the relationship between hormone 
levels and risk for chronic pain in men
Multivariate 1
N= 3688
Multivariate 2
N= 3400
OR (95% CI)
P-value
OR (95% CI)
P-value
Androstenedione
1st tertile <1.97 1.08 (0.90-1.28) 
0.42
1.12 (0.93-1.34) 
0.23
2nd tertile 1.97-2.94 1.03 (0.88-1.22) 
0.69
1.07 (0.90-1.28)
0.42
3th tertile >2.94 Reference Reference
17-hydroxyprogesterone
1st tertile <0.71 0.97 (0.82-1.15) 
0.74
1.00 (0.84-1.19) 
0.98
2nd tertile 0.71-1.16 0.90 (0.76-1.06) 
0.19
0.93 (0.78-1.10)
0.38
3th tertile >1.16 Reference Reference
Testosterone
1st tertile <0.66 0.94 (0.79-1.11)
0.47
0.93 (0.78-1.12) 
0.45
2nd tertile 0.66-1.00 0.89 (0.73-1.01)
0.06
0.86 (0.72-1.02) 
0.07
3th tertile >1.00 Reference Reference
Estradiol
1st tertile <19.12 1.15 (0.98-1.38)
0.09
1.17 (0.99-1.39) 
0.07
2nd tertile 19.12-51.75 1.17 (0.99-1.35) 
0.06
1.20 (1.01-1.43)
0.04
3th tertile >51.75 Reference Reference
Results are from multivariate logistic regression analysis. OR denotes Odds Ratio, CI denotes Con-
fidence interval.
Multivariate 1: This analysis included adjustments for age, BMI, health and lifestyle factors (alcohol 
use, smoking, depression and medication use) and years since menopause
Mutivariate 2: Multivariate analysis 1 and additional adjustment for presence of osteoarthritis.
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upplementary table 2. Cross sectional analysis of hormone levels and prevalent chronic knee, hip, 
low back and hand pain in men
Chronic
knee pain
Chronic
hip pain
Chronic
low back pain
Chronic
hand pain
OR (95% CI)
p-value
OR (95% CI)
p-value
OR (95% CI)
p-value
OR (95% CI)
p-value
Androstenedione
Multivariate 1 1.11 (0.89-1.39) 
0.34
0.74 (0.55-1.01) 
0.06
1.07 (0.88-1.30) 
0.49
1.33 (1.03-1.72) 
0.03
Multivariate 2 1.20 (0.94-1.53) 
0.14
0.72 (0.51-1.00)
0.05
NA 1.40 (1.05-1.88) 
0.02
17-hydroxyprogesterone
Multivariate 1 1.08 (0.88-1.33) 
0.47
1.11 (0.83-1.49) 
0.47
1.00 (0.83-1.21) 
0.97
0.97 (0.76-1.25) 
0.83
Multivariate 2 1.19 (0.94-1.49) 
0.15
1.09 (0.79-1.49) 
0.59
NA 1.02 (0.77-1.35) 
0.89
Testosterone
Multivariate 1 0.96 (0.78-1.19) 
0.71
0.98 (0.74-1.31) 
0.91
0.95 (0.79-1.15) 
0.61
0.97 (0.76-1.24)
0.82
Multivariate 2 0.98 (0.78-1.24)
0.89
0.91 (0.67-1.24) 
0.55
NA 0.96 (0.73-1.26)
0.76
Estradiol
Multivariate 1 1.09 (0.89-1.34)
0.38
0.97 (0.73-1.28) 
0.82
1.17 (0.97-1.41) 
0.10
1.10 (0.87-1.39) 
0.44
Multivariate 2 1.09 (0.87-1.36)
0.48
0.85 (0.63-1.16) 
0.31
NA 1.05 (0.81-1.38) 
0.70
Multivariate logistic regression was performed using tertiles for hormone levels. The odds ratio is for 
subjects in the lowest tertile, as compared with subjects in the highest tertiles. Odds ratios are given 
with 95% confidence limits between brackets.
Multivariate 1: This analysis included adjustments for age, BMI, health and lifestyle factors (alcohol 
use, smoking, depression and medication use) and years since menopause. N= 3688.
Multivariate 2: Multivariate analysis 1 and additional adjustment for presence of site-specific osteo-
arthritis. N=3164. These data were not available for low back.
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Abstract
Background and purpose: Central sensitization in chronic pain involves structural 
brain changes that influence vulnerability to pain. Identifying brain regions involved 
in pain processing and sensitization can provide more insight into chronic pain. 
This study examines structural brain changes in chronic pain and experimental pain 
in a large population-based study.
Materials and methods: For 3892 participants in the Rotterdam study, global and 
regional MR imaging brain volumes were automatically segmented and quantified. 
Chronic joint pain was defined as pain for more than half of all days during the past 
6 weeks. Heat pain thresholds were measured in a subset of 1538 individuals. The 
association between the presence of chronic joint pain and global and lobar brain 
volumes was studied. Subsequently, literature was reviewed and the association 
of chronic pain and heat pain thresholds with 11 brain regions associated with 
musculoskeletal pain in previous publications was studied.
Results: Total gray matter volume was smaller in women with chronic pain (Beta 
0.066, P= 0.016). This effect was primarily driven by lower gray matter volume in 
the temporal lobe (Beta 0.086, P= 0.005), the frontal lobe (Beta 0.060, P= 0.039), 
and the hippocampus (Beta 0.099, P= 0.002). In addition, we observed that a lower 
heat pain threshold was associated with smaller volumes of the hippocampus (Beta 
0.017, P= 0.048), the thalamus (Beta 0.018, P= 0.009), and the anterior cingulate 
cortex (Beta 0.016, P= 0.037). In men, no significant associations were observed.
Conclusions: The primary identified brain areas, the temporal and frontal lobes and 
the hippocampus, indicated involvement of emotional processing. The volumetric 
differences found indicated a sex-specific neuroplasticity in chronic pain. These 
results emphasized sex-specific and multidisciplinary pain treatment.
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Introduction
Chronic musculoskeletal pain is very common in the general elderly population, 
with a prevalence up to 50%−60%. Experienced chronic joint pain does not always 
reflect the extent of objective pathology. [1-4] Central sensitization plays an impor-
tant role in the development of chronic joint pain. Chronic pain and central sensi-
tization result in higher vulnerability for developing chronic pain at multiple sites 
and higher sensitivity for painful stimuli. [5] Differences in pain processing may be 
expressed in functional and structural changes in the nervous system. MR imaging 
allows us to identify brain regions involved in this process of central sensitization, 
which can provide more insight into chronic pain.
Previous studies that examined structural brain alterations in chronic pain focused 
on a variety of pain phenotypes, such as migraine, back pain, osteoarthritis, and 
fibromyalgia. [6-15] Typically, the study size was small; the largest studies included 
approximately 100 subjects. The small sample sizes of these studies led to a mod-
est statistical power, thereby influencing the reproducibility of the results. [16] In 
addition, all previous reports had a case-control design, which selected individuals 
who were referred to the clinic as chronic pain cases. As a result, many different 
areas were shown to associate with a particular pain phenotype but only a few 
areas of the brain showed consistent associations. For example, the thalamus was 
found to be positively associated with chronic low back pain by Schmidt-Wilcke et 
al. [17] but negatively associated with chronic low back pain by Apkarian et al. [18] 
Regions that are part of the limbic system and signaling pathway were among the 
identified pain-associated brain areas. Furthermore, each different pain phenotype 
showed different patterns of structural brain changes, with some overlapping re-
gions, for example, the hippocampus. [7] Despite the possible identification of 
structural brain alterations in these selected clinical cases, it remains unclear which 
brain regions are morphologically altered in chronic pain in the general popula-
tion. Therefore, in this study, after review of the existing literature, we attempted 
to replicate previous identified regions to find brain structures robustly associated 
with musculoskeletal pain.
Individuals with chronic pain are shown to be more sensitive to experimental pain 
stimuli. Central sensitization can be detected by lower pain thresholds. [19-21] The 
stimulus response curve is shifted to the left, which results in lower pain thresh-
olds or higher reported pain intensity scores for a stimulus. The spread of central 
sensitization, manifested because general hyperalgesia is one of the fundamental 
processes in the development of chronic pain. [22-25] Lower pain thresholds, as 
part of central sensitization, might be associated with structural brain changes. 
Thus far, the relation between experimental pain and structural brain alterations 
86 Chapter 4.1
has only been studied in 1 study of 80 healthy individuals. [26] In addition, Semino-
wicz et al. [27] showed, in a rat model for long-term neuropathic pain, that thermal 
and mechanical hyperalgesia is associated with structural brain changes.
Given the high prevalence of chronic musculoskeletal pain in the elderly and 
the burden of chronic musculoskeletal pain on quality of life, more insight into the 
pathophysiology is necessary to understand chronic pain in the general population 
and improve treatment options. In this study, we examined, in a large population-
based cohort study, the association of chronic musculoskeletal pain and heat pain 
thresholds with MR imaging– based structural brain changes. We studied changes 
in global and lobar brain volumes and, in addition, specific brain regions previously 
reported to be associated with musculoskeletal pain phenotypes.
Materials and methods
Study Population: The Rotterdam Study
The Rotterdam Study is a large prospective population-based cohort study of 
persons aged 45 years and older. The study design and rationale are described 
elsewhere in detail. [28] In summary, the objective of the Rotterdam Study is to 
investigate the determinants, incidence, and progression of chronic disabling dis-
eases in the elderly. The first cohort, Rotterdam Study I consisted of 7983 persons 
aged ≥ 55 years and was initiated in 1989. This study population was extended in 
2000, which added 3011 participants in Rotterdam Study II and, in 2005, added 
another 3932 subjects aged ≥ 45 years in Rotterdam Study III. All the participants 
were examined in detail at baseline. In summary, a home interview was conducted, 
and the subjects had an extensive set of examinations at the research center.
The participants in the study as presented here were derived from the Rotterdam 
Scan Study, [29] an ongoing population-based cohort study that investigated brain 
changes on MR imaging, which is embedded in the Rotterdam Study. The Rot-
terdam Study has been approved by the medical ethics committee according to 
the Population Study Act Rotterdam Study executed by the Ministry of Health, 
Welfare and Sports of the Netherlands. Written informed consent was obtained 
from all the participants.
MR Imaging Acquisition and Processing
MR imaging scanning was performed on a 1.5T-scanner with an 8-channel head 
coil (GE Healthcare, Milwaukee, Wisconsin). An extensive description of the scan 
protocol is provided elsewhere. [29] In short, the protocol included a T1-weighted 
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sequence, a proton-attenuation weighted sequence, and a fluid-attenuated inver-
sion recovery sequence. [29]
Automated brain tissue classification based on a k-nearest-neighbor-classifier 
algorithm extended with white matter lesion segmentation [30,31] was used to 
quantify global and lobar brain volume, gray matter volume, white matter volume, 
and intracranial volume (in mL3). This method has been optimized and validated 
for the Rotterdam Scan Study and includes a standardized and validated image 
analysis workflow to enable objective, accurate, and reproducible extraction of 
brain volumes. [29] Segmentation and labeling of smaller specific brain regions 
was performed by FreeSurfer version 4.5 (http://surfer.nmr.mgh.harvard.edu/). [26] 
This procedure automatically assigns a neuroanatomic label to each voxel in an 
MR imaging volume based on probabilistic information obtained from a manually 
labeled training set. FreeSurfer was used with the default parameters, including 
skull-stripping and using the automatically generated brain mask.
Review of the Literature and Selection of Candidate Replication Regions
We systematically searched the literature by using the PubMed data base on July 
7, 2014, with search terms “structural and brain and MR imaging and chronic and 
pain.” In addition, we screened the references of included articles to extend the 
search. The review of literature identified 83 articles, of which 68 articles were 
excluded based on the following selection criteria: 1) the article represents original 
data, and 2) the trait of interest is musculoskeletal pain. Finally, 15 studies were 
included in the total review.
Assessment of Chronic Joint Pain
All the participants completed a pain homunculus to report chronic painful sites in 
the body. The pain homunculus showed a picture of the front and the back of the 
human body. The participants were asked the following question, “Did you have 
pain anywhere in your body, for at least half of the days, during the last six weeks?” 
Circles were drawn by the participant around the painful areas. The homunculi 
were scored by using a template that assigned 14 different joint pain regions (eg, 
neck, shoulders, elbows, hands, low back, hips, knees, feet). Chronic joint pain was 
defined as subjects having one or more painful sites. Furthermore, participants 
should have visited a medical physician at least once for this chronic joint pain. This 
information was derived from the questionnaire during the home interview.
In addition, because we used a more heterogenic pain phenotype compared 
with previous studies, we defined 3 chronic pain phenotypes to be able to compare 
our results better with previous literature. The phenotypes examined in the studies, 
also selected for the review, were fibromyalgia, chronic low back pain, and hip 
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osteoarthritis pain. Because we did not have data on fibromyalgia, we used chronic 
widespread pain as a proxy. Chronic widespread pain was defined as subjects hav-
ing pain in the left side of the body, in the right side of the body, above the waist, 
below the waist, and in the axial skeleton (by following the Fibromyalgia Criteria of 
the American College of Rheumatology). [32] Hip osteoarthritis pain was defined 
as a Kellgren-Lawrence score of ≥ 2 and chronic pain in the same hip. Controls in 
these analyses were individuals without chronic pain.
Heat Pain Threshold Measurement
For the measurement of heat pain threshold, we used a commercially available 
thermosensory analyzer, the TSA II (Medoc Advanced Medical Systems, Durham, 
North Carolina). The probe, with a surface of 2 cm by 2 cm was placed on the ventral 
site of the non-dominant forearm. The start temperature of the probe was 32°C. 
The temperature increased by 2°C per second, and the participant was asked to 
push a large quiz button when the temperature became painful. This measurement 
was repeated 5 times; the mean of the last 3 measurements was used. Because this 
was measured approximately 5 years after the brain MR imaging was acquired, we 
included only those individuals with a stable pain state. Individuals with chronic 
pain at both the time of brain MR imaging and chronic pain at the time of the heat 
pain threshold measurement were considered as cases, individuals without chronic 
pain at both time points were considered as controls.
Population for Analysis
A total of 4898 participants who were part of Rotterdam Study I, Rotterdam Study 
II, or Rotterdam Study III were invited to undergo an MR imaging. We excluded 
individuals who had dementia (n= 30) or had MR imaging contraindications (n= 
389). Of 4479 eligible persons, 4082 (91%) participated. Due to physical inability, 
imaging could not be performed in 44 individuals. Of 4038 persons with complete 
MR imaging examinations, 59 had to be excluded because of motion artifacts or 
susceptibility artifacts on their scans, which left 3979 persons with complete brain 
MR imaging. Pain data were not available for 87 of these persons, whereas data on 
the need for medical treatment for the pain medication was not available for 516 
individuals, which left 3376 persons for the analyses. For the association analysis 
with the heat pain threshold measurements, a subset of 839 individuals with a 
stable pain state as described above was used.
Statistical Analysis
Linear regression models were used to test the association between chronic 
musculoskeletal pain, heat pain thresholds, and brain volumes. We calculated z 
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scores (X – mean/SD) of the brain volumes to allow direct comparability between 
the various effect estimates for the analyses between pain and the different brain 
structures. Z score standardization is done in the common way by (brain volume – 
mean brain volume)/SD.
Because previous studies found differences on pain-associated regions between 
the sexes, we stratified for sex and adjusted for age, intracranial volume, and the 
presence of depression according to the self-reporting Center for Epidemiologic 
Studies Depression scale, defined by a score of > 16. SPSS version 21.0 (SPSS Sta-
tistics for Windows; IBM, Armonk, New York) was used for the association analysis. 
The null hypothesis tested was that there is no difference in brain volumes in the 
studied structures between individuals without chronic musculoskeletal and those 
with chronic musculoskeletal pain. The second hypothesis tested was that brain 
volumes of the studied structures are not associated with heat pain thresholds. A P 
value of < 0.05 was considered statistically significant.
Association Analysis with Chronic Musculoskeletal Pain and Heat Pain 
Threshold
First, we performed an association analysis without hypothesizing where to expect 
structural alterations in the brain in chronic joint pain. Therefore, we investigated 
the association of global volumes of gray and white matter with chronic joint pain. 
Next, we segmented the brain into the 4 main lobes (frontal, temporal, parietal, 
and occipital). Gray and white matter volumes in the different lobes were then 
studied for the association with chronic joint pain. Subsequently, we investigated 
the association of chronic joint pain with the volumes of the selected regions re-
ported in the literature (Table 1).
In the effort to replicate previous findings, we examined the association of 
chronic widespread pain as a proxy for fibromyalgia, chronic low back pain, and 
hip osteoarthritis pain with brain region volumes in our sample. In addition, we 
investigated the association of the brain region volumes with heat pain thresholds.
Results
Population characteristics for the 3892 persons with brain MR imaging and chronic 
pain information are shown in Table 2. The prevalence of chronic pain and depres-
sion was higher in women compared with men, and the total intracranial volume 
was smaller in women. Heat pain thresholds were higher in men compared with 
women (48.0°C vs 46.6°C).
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Table 1. Selected brain regions for analysis
Brain region Reference +/- N Chronic pain disorder
Thalamus Apkarian et al. 2004 [18] - 52 CLBP
Schmidt-Wilcke et al. 2006 [17] + 36 CLBP 
Schmidt-Wilcke et al. 2007 [40] - 42 Fibromyalgia 
Ivo et al. 2013 [9] - 28 CLBP 
S1 Rodriguez-Racke et al. 2009 [39] - 32 Hip OA
Seminowicz et al 2011 [41] - 34 CLBP 
Kong et al 2013 [36] + 36 CLBP 
Insular cortex Kuchinad et al. 2007 [37] - 20 Fibromyalgia
Rodriguez-Racke et al. 2009 [39] - 32 Hip OA 
Valet et al. 2009 [42] - 39 Pain syndrome (DSM IV) 
Robinson et al. 2011 [11] - 25 Fibromyalgia 
Seminowicz et al 2011 [41] - 34 CLBP 
Anterior cingulate 
cortex
Burgmer et al. 2009 [34] - 28 Fibromyalgia
Valet et al. 2009 [42] - 39 Pain syndrome (DSM IV) 
Rodriguez-Racke et al. 2009 [39] - 32 Hip OA 
Seminowicz et al 2011 [41] - 34 CLBP 
Jensen et al. 2013 [35] - 39 Fibromyalgia 
Midcingulate cortex Kuchinad et al. 2007 [37]
Buckalew et al. 2008 [33]
Wood et al. 2009 [43]
Robinson et al. 2011 [11]
Ivo et al. 2013 [9]
-
-
-
-
-
20
16
14
25
28
Fibromyalgia
CLBP
Fibromyalgia
Fibromyalgia
CLBP
Prefrontal cortex Apkarian et al. 2004 [18] - 52 CLBP
Dorsolateral Seminowicz et al 2011 [41] - 34 CLBP 
Ivo et al. 2013 [9] - 28 CLBP 
Prefrontal cortex Rodriguez-Racke et al. 2009 [39] - 32 Hip OA
Ventrolateral Burgmer et al. 2009 [34] - 28 Fibromyalgia 
Seminowicz et al 2011 [41] - 34 CLBP 
Posterior cingulate 
cortex
Kuchinad et al. 2007 [37] - 20 Fibromyalgia
Valet et al 2009 [42] - 39 Pain syndrome (DSM IV) 
Wood et al. 2009 [43] - 14 Fibromyalgia 
Robinson et al. 2011 [11] - 25 Fibromyalgia 
Orbitofrontal cortex Schmidt-Wilcke et al. 2007 [40] + 42 Fibromyalgia
Valet et al. 2009 [42] - 39 Pain syndrome (DSM IV) 
Rodriguez-Racke et al. 2009 [39] - 32 Hip OA 
Seminowicz et al 2011 [41] - 34 CLBP 
Hippocampus Lutz et al. 2008 [38] - 60 Fibromyalgia
Zimmerman et al. 2009 [14] - 20 Chronic pain 
Amygdala Burgmer et al. 2009 [34] - 28 Fibromyalgia
Rodriguez-Racke et al. 2009 [39] - 32 Hip OA 
Note: + indicates larger volume in chronic pain; - indicates smaller volume in chronic pain; CLBP, 
chronic low back pain; OA, oateoarthritis; DSM IV, Diagnostic and Statistical Manual of Mental Dis-
order, 4th edition.
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Chronic Joint Pain and Global and Lobar Brain Volumes
The associations between chronic musculoskeletal pain and global and lobar brain 
volumes are shown in Figure 1. No significant association between chronic mus-
culoskeletal pain and total brain volume was observed in the overall population. 
When we stratified according to sex, we observed a significant association with total 
gray matter in the women. Total gray matter was smaller in women with chronic pain 
(difference in Z score, Beta 0.066; P= 0.016). When we divided the brain into the 4 
main lobes, this lower gray matter volume was found to be primarily located in the 
temporal lobe (Beta 0.086, P= 0.005) and the frontal lobe (Beta 0.060, P= 0.039). In 
the men, we did not find differences in global brain volumes between participants 
with and those without chronic pain. Excluding participants with depression defined 
by a Center for Epidemiologic Studies Depression scale score of > 16 (81 men, 247 
women) in the sensitivity analysis did not alter these effects.
Chronic Joint Pain and Predefined Brain Regions
Next, we focused our analysis on volumes of specific brain regions that were previously 
reported in the literature as being associated with musculoskeletal pain phenotypes 
(Table 1). These regions were selected on the basis of a systematic review. In total, 
15 studies that assessed the relationship between brain structures and chronic pain 
were included in this review. [9,11,14,17,33-43] All brain regions previously reported 
to be significantly associated with chronic pain are shown in the supplemental table, 
together with the direction of the effect. We decided to include the brain regions that 
were reported to be associated with musculoskeletal pain at least twice. The 11 se-
lected regions are shown in Table 1, together with the sample size of each study, which 
were all fewer than 100 individuals. Segmentation of the 11 brain regions was done 
in 4898 individuals with the use of FreeSurfer software. We observed a significantly 
smaller hippocampal volume in women with chronic musculoskeletal pain (Beta 0.099, 
P= 0.002), whereas men showed a similar trend, though this did not reach significance 
(Figure 2). When data for men and women were analyzed together, a highly significant 
association was seen (Beta 0.092, P= 4.69*10−4).
Table 2. Baseline characteristics of the study population
Total (n=3376) Male (n=1525) Female (n=1851)
Mean age, years ± SD 60.3 ± 8.7 60.4 ± 8.7 60.1 ± 8.7
Chronic pain, no. (%) 1191 (35.3) 414 (27.1) 777 (42.0)
Mean intracranial volume, mL ± SD 1126 ± 119 1203 ± 102 1062 ± 91
Positive CESD, no. (%) 328 (8.5) 81 (4.6) 247 (11.7)
Mean heat pain threshold, °C ± SD (n=1538) 47.2 ± 3.2 48.0 ± 2.7 46.6 ± 3.4
Note: CESD indicates Center for Epidemiologic Studies Depression scale.
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We next studied specific pain subtypes to mimic earlier reports. We studied 
chronic widespread pain, chronic low back pain, and hip osteoarthritis pain sepa-
rately as determinants for brain region volumes. For the analyses of chronic wide-
spread pain and hip osteoarthritis pain, we observed similar effect directions for 
hippocampal volume but only for chronic low back pain was statistical significance 
reached (Beta 0.115, P= 0.033).
Among the subset with heat pain threshold measurements, we observed only in 
the women, a positive association between heat pain thresholds and hippocampal 
volume, thalamic volume, and the volume of the anterior cingulate cortex (Figure 
3), which indicated that lower pain sensitivity thresholds, which represent central 
sensitization, were indeed coinciding with smaller hippocampal, thalamic, and 
anterior cingulate cortex volumes.
          
Male         
    
Total Brain 
Volume     
    Beta 0.024     
    P 0.234     
        
         
Total Grey matter    Total White matter 
 0.036 Beta 0.016 
 P 0.276 P-value P 0.645 
      
       
Temporal Parietal Occipital Frontal Temporal Parietal Occipital Frontal 
0.027 -0.018 0.055 0.047 Beta 0.019 0.020 0.030 0.018 
P 0.496 P 0.615 P 0.200 P 0.165 P-value P 0.611 P 0.904 P 0.488 P 0.618 
      
                  
Female       
    
Total Brain 
Volume     
    Beta -0.017     
    P 0.322     
         
         
Total Grey matter    Total White matter 
-0.066 Beta  0.029 
P 0.016 P-value  P 0.296 
      
       
Temporal Parietal Occipital Frontal Temporal Parietal Occipital Frontal 
-0.086 -0.039 -0.049 -0.060 Beta 0.019 0.020 0.035 0.030 
P 0.005 P 0.207 P 0.150 P 0.039 P-value P 0.518 P 0.515 P 0.321 P 0.285 
         
      Figure 1. Chronic musculoskeletal pain and global brain volumes
Analyses adjusted for age, Intracranial Volume and Depression
Beta is the difference in standardized brain volume for individuals with chronic joint pain compared 
to those without chronic joint pain.
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Figure 2. Brain volumes in regions of the limbic system and signal processing in relation to chronic 
musculoskeletal pain in female (A) and male (B) subjects. Plots represent beta and standard error; 
Beta is the difference in standardized brain volume for individuals with chronic joint pain compared 
to those without chronic joint pain; Analyses were adjusted for age, intracranial volume and de-
pression. *P= 0.002. Thal indicates thalamus; Hippo, Hippocampus; Amyg, Amygdala; OFC, Orbi-
tofrontal cortex; vlPFC, ventrolateral prefrontal cortex; dlPFC, dorsolateral prefrontal cortex; PCC, 
posterior cingulate cortex; MCC, mid cingulate cortex; ACC, anterior cingulate cortex; Insula, insular 
cortex; S1, primary somatosensory cortex.
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Figure 3. Quantitative Sensory Testing (Heat pain threshold) and structural brain alterations in fe-
male (A) and male (B) subjects. Plots represent beta and standard error; Beta is the difference in 
standardized brain volume per degree of temperature (Celsius); Analyses were adjusted for age, 
intracranial volume and depression. *P < 0.05. Thal indicates thalamus; Hippo, Hippocampus; Amyg, 
Amygdala; OFC, Orbitofrontal cortex; vlPFC, ventrolateral prefrontal cortex; dlPFC, dorsolateral pre-
frontal cortex; PCC, posterior cingulate cortex; MCC, mid cingulate cortex; ACC, anterior cingulate 
cortex; Insula, insular cortex; S1, primary somatosensory cortex.
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Discussion
In this large population-based cohort of individuals with ages ≥ 45 years, we 
observed that chronic musculoskeletal pain was associated with a smaller global 
gray matter volume in the women. This smaller volume was primarily found in the 
temporal lobe, more specifically, in the hippocampus, part of the limbic system. In 
addition, again in the women, a lower heat pain threshold, which indicates higher 
(central) pain sensitivity, was associated with smaller volumes of the hippocampus, 
thalamus, and anterior cingulate cortex, regions that are involved in the limbic 
system and descending pain processing pathways. In the men, no significant as-
sociations between chronic joint pain or heat pain thresholds and brain volumes 
were observed.
To our knowledge, this is the first study that examined the association between 
chronic joint pain and structural brain changes in a population-based study. The 
number of studied patients was approximately 30 times larger than any previous 
study that examined the relationship between chronic pain and structural brain 
changes. Previous studies that examined structural brain alterations in pain 
consisted mostly of small and very specific clinical patient populations. [6-13,15] 
We used a hierarchical approach in studying brain structural differences. We first 
examined global brain tissue volumes and lobar volumes. Subsequently, we in-
vestigated those brain regions that were reported at least twice in the previous 
literature to be associated with chronic musculoskeletal pain. This strategy was 
chosen because previous studies showed inconsistent findings, which might be 
due to the different clinical pain phenotypes and low power that led to conflicting 
results, as highlighted previously. [16] Indeed, we were unable to replicate most of 
the previously implicated brain regions, which indicated that these brain regions 
are not consistently associated with chronic musculoskeletal pain.
The development of the brain is sex specific and influenced by sex hormones. It 
is shown that sex differences are also present with respect to pain processing. [44-
48] Therefore, we stratified our analyses according to sex. In women, gray matter 
in the temporal lobe and, especially, in the hippocampus was smaller in those with 
chronic pain. The hippocampus has previously been suggested as one of the al-
tered structures in the brain in several pain states. [6,7] In women, this involvement 
of the limbic system, therefore, could indicate a more emotional coping of pain.
Smaller volumes of the hippocampus, thalamus, and anterior cingulate cortex 
were also associated with lower heat pain thresholds in women in our study. The 
thalamus is important in the descending inhibitory signaling, which is known to be 
compromised in central sensitization in chronic pain, [5,7] which makes our findings 
more plausible. To our knowledge, this is the first study that examined the associa-
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tion between heat pain thresholds and brain structure volumes. A limitation of the 
analysis of heat pain threshold and brain volumes was that the 2 measurements 
were done during 2 different visits, with several years in between. To minimize this 
time bias, we examined only those participants who had chronic pain at both visits 
versus those who had no chronic pain at both visits.
In this study, we examined both the presence of chronic musculoskeletal pain 
and also heat pain sensitivity thresholds and their relationship to structural brain 
alterations. The presence of chronic musculoskeletal pain is a very subjective 
phenotype because it is determined by using questionnaires, and there is no test 
to measure pain. Heat pain thresholds are closely related to the sensitivity for 
developing chronic pain and for having chronic pain, which, therefore, makes it 
a more objective measure for chronic pain. The combined use of questionnaire 
data and heat pain thresholds to find associations with structural brain alterations, 
therefore, strengthens the results.
A possible disadvantage of population-based studies is the more heterogeneous 
pain phenotype compared with the selected clinical populations. However, this 
reflects the situation in the general population and shows that central sensitiza-
tion occurs not only in a selected patient population. In addition, chronic pain in 
community-dwelling subjects represents a huge problem, which affected 35.3% 
of our study population. However, its nature and cause is poorly understood, and 
often no apparent reason can be assigned to the chronic pain state. Studying pain 
in an unselected population without the selection bias of clinical reference could 
provide new insight in possible pathways involved in any chronic pain state.
The cross-sectional aspect of this study made us unable to speculate on the 
brain volume changes being a cause or an effect in the pathology of chronic pain. 
A previous study on structural brain changes in pain related to severe hip osteo-
arthritis showed normalization of these differences after hip replacement surgery, 
which indicates that the pain is causing structural brain changes, [39] but larger 
longitudinal studies are necessary for confirmation because sample size was small 
in this study (n= 10).
Depression coincides with chronic musculoskeletal pain, and, because both 
might affect the limbic system, [11] we adjusted the analysis for the presence of 
depression. In addition, excluding persons with depression from the model did not 
change the results, which indicated that our findings were not influenced by the 
presence of depression.
Because we started our study hypothesis-free and continued examining smaller 
regions, we performed a considerable amount of tests, which might have led to 
spurious findings. If we would have used a Bonferroni correction for the statistically 
significant P-value for the brain structures, then this would result in a P-value of 
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0.05/11 = 0.004; this is when assuming independency of the tests. Many results 
would still be considered statistically significant. However, not all of the tests were 
independent because the smaller regions were included in the larger lobes. There-
fore, deciding which exact P-value to use would have been challenging. In addition, 
the performed analyses were not hypothesis-free because we tried to replicate 
previous published results. Moreover, especially in the women, we showed very 
consistent and robust findings, with increasing effect sizes when we narrowed the 
examined regions.
Conclusions
In this large population-based study, we found that chronic musculoskeletal pain 
was associated with structural changes in parts of the limbic system in the brain. 
The hippocampus, especially, showed a very consistent and strong relationship 
with chronic joint pain and heat pain thresholds in women, which indicated a key 
role in the development of central sensitization and chronic pain. Structural altera-
tions in the brain in individuals with chronic pain support the presence of central 
sensitization. This process of central sensitization increases the risk for a longer 
period of chronic pain and increases the risk for developing chronic pain at other 
sites. [5] These results stress the importance of a multidisciplinary and sex-specific 
therapeutic approach to improve successful treatment.
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Supplemental table 1. Selected articles for review of previously found associations between brain 
region volumes and chronic pain phenotypes
Article Brain regions identified Direction +/-
Ivo et al. 2013 [9] Dorsolateral prefrontal cortex
Thalamus
Midcingulate cortex
-
-
-
Robinson et al. 2011 [11] Midcingulate cortex
Anterior cingulate cortex
Insular cortex
-
-
-
Zimmerman et al. 2009 [14] Hippocampus -
Apkarian et al. 2004 [18] Dorsolateral prefrontal cortex
Thalamus
-
-
Buckalew et al. 2008 [33] Posterior parietal cortex
Midcingulate cortex
-
-
Burgmer et al. 2009 [34] Prefrontal cortex
Amygdala
Anterior cingulate cortex
-
-
-
Jensen et al. 2013 [35] Anterior cingulate cortex -
Kong et al. 2013 [36] S1 +
Kuchinad et al. 2007 [37] Cingulate cortex
Insular cortex
Medial frontal cortex
Parahippocampal giri
-
-
-
-
Lutz et al. 2008 [38] Postcentral giri
Amygdala
Hippocampus
Superior frontal cortex
Anterior frontal cortex
Anterior cingulate cortex
-
-
-
-
-
-
Rodriguez-Raecke et al. 2009 [39] Anterior cingulate cortex
Insular cortex
Operculum
Dorsolateral prefrontal cortex
Amygdala
Brainstem
-
-
-
-
-
-
Schmidt-Wilcke et al. 2007 [40] Superior temporal girus
Thalamus
Orbitofrontal cortex
Cerebellum
Striatum
-
-
+
+
+
Seminowicz et al. 2011 [41] S1
Insular cortex
Anterior cingulate cortex
Dorsolateral prefrontal cortex
Ventrolateral prefrontal cortex
Orbitofrontal cortex
-
-
-
-
-
-
Valet et al. 2009 [42] Insular cortex
Anterior cingulate cortex
Posterior cingulate cortex
Orbitofrontal cortex
-
-
-
-
Wood et al. 2009 [43] Parahippocampal giri
Posterior cingulate cortex
Anterior cingulate cortex
-
-
-
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Abstract
Background: Increasing evidence relates chronic pain to grey matter alterations 
of the brain, but the role of white matter remains unclear, although it is known to 
facilitate signal transmission. Therefore, we investigated the association of chronic 
pain and white matter microstructure.
Methods: 3509 participants from the population-based Rotterdam Study (mean 
age 59.5 years) underwent chronic pain assessment and diffusion-MRI scanning. 
First, we studied the association of chronic pain with fractional anisotropy (FA) and 
mean diffusivity (MD) of global and lobar white matter. Second, we performed 
tract-specific analyses for 25 predefined white matter tracts, including axial diffusiv-
ity (AD) and radial diffusivity (RD). Finally, we investigated whether the identified 
tracts associated with perseverance of chronic pain.
Results: Chronic pain associated with lower global MD (beta −0.05, p-value 0.04), 
mainly driven by lower MD in the left frontal lobe (−0.05, p-value 0.05) and left 
temporal lobe (−0.07, p-value 0.01). Tract-specific analyses showed an association 
of chronic pain with diffusion-MRI parameters in the left medial lemniscus (FA: beta 
0.09, p-value 0.0002; MD: −0.07, p-value 0.01, RD: −0.09, p-value 0.002). Medial 
lemniscus FA was associated with chronic pain persistence after 5 years of follow-
up (beta 0.13; p-value 0.01).
Conclusions: Chronic pain is associated with lower MD in the left frontal and 
temporal lobe, and with higher FA, lower MD, and lower RD in the left medial lem-
niscus. These findings suggest increased wiring of the cerebral white matter, which 
may be lateralized. Left medial lemniscus FA related to persistence of chronic pain, 
indicating a potential prognostic value.
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Introduction
Chronic musculoskeletal pain is very common, with a prevalence of 40-60 percent, 
and increases with age[9]. In a chronic pain condition, central sensitization can 
cause a higher sensitivity for clinical and experimental pain [18, 31]. This mechanism 
of central sensitization is not yet fully understood, but structural and functional 
changes in the brain are thought to be involved. There is growing evidence for grey 
matter alterations in studies comparing chronic pain patients with healthy controls 
[1, 11, 20, 23]. We recently showed that grey matter alterations are also present in 
a population-based study of elderly community-dwelling individuals with chronic 
pain [6]. However, little research has been performed on the involvement of cere-
bral white matter in chronic musculoskeletal pain.
White matter and grey matter together facilitate signal transmission to and 
from the spinal cord and between brain regions. Therefore, studying the relation 
between chronic pain and white matter can bring us closer to understanding the 
brain involvement in chronic pain. Diffusion-magnetic resonance imaging (MRI) is 
an advanced MRI-technique to investigate the microstructure of cerebral white 
matter. The diffusion-MRI metrics fractional anisotropy (FA) and mean diffusivity 
(MD) are most commonly studied. FA correlates with white matter tract coherence 
and is influenced by factors such as the number of axons, their geometry and the 
myelinisation of axons. MD, the average rate of water diffusion per voxel, is sensi-
tive to cellularity, edema and necrosis [30]. In addition, axial and radial diffusivity 
may provide complementary information on mechanisms of change in white matter 
microstructure. Results of animal studies have indicated that decreased axonal dif-
fusivity is related to axonal injury and that increased radial diffusivity is associated 
with myelin breakdown [25].
Previous studies investigating the relation between chronic pain and white mat-
ter microstructure have focused on specific chronic pain disorders, such as irritable 
bowel syndrome, fibromyalgia, migraine and chronic pancreatitis[8, 10, 20, 26, 27], 
but the results have been inconsistent and lacked power to determine the common 
and specific white matter tracts involved in chronic pain.
In our study, a large prospective population-based cohort of individuals aged 45 
years and older, we investigated associations of chronic musculoskeletal pain and 
global, lobar and tract-specific diffusion-MRI parameters. Herewith, we aimed to 
identify robust and more generalizable associations and add to the knowledge of 
the pathophysiology of central sensitization in chronic musculoskeletal pain.
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Materials and Methods
Study population
The Rotterdam Study is a population-based cohort study among inhabitants of 
Ommoord, a suburb of Rotterdam, the Netherlands [13]. The original cohort (RS-I) 
consisted of 7983 participants, aged 55 years and older. In 2000 there was a first 
expansion of the cohort adding 3011 persons who had become 55 years of age or 
had moved into the district since the start of the study (RS-II), and in 2005 there was 
a second expansion with 3932 participants who had become 45 years of age or had 
moved into the district (RS-III).
The participants in the study as presented here were derived from the Rotterdam 
Scan Study, an ongoing population-based cohort study investigating brain changes 
on MRI, which is embedded in the Rotterdam Study since 2005 [14]. A total of 5430 
eligible participants were invited from all three Rotterdam Study cohorts. After 
excluding individuals who were diagnosed with dementia or had MRI contraindica-
tions (including claustrophobia) 4841 participated and underwent diffusion-MRI 
scanning of the brain. Among them, 53 scans were excluded due to incomplete 
acquisitions and 112 scans with artifacts hampering automated processing were 
excluded. We excluded 160 individuals with MRI- defined cortical infarcts. Of the 
4516 remaining participants with complete diffusion-MRI data, 3509 individuals 
also had pain data available, which constitutes the population for analysis in the 
present study.
The Rotterdam Scan Study has been approved by the medical ethics committee 
according to the Population Study Act Rotterdam Study, executed by the Ministry 
of Health, Welfare and Sports of the Netherlands. All participants gave written 
informed consent.
Assessment of chronic musculoskeletal pain
A pain homunculus was used to report chronic painful regions in the body. The 
pain homunculus showed a picture of the front and the back of the human body. 
Participants were asked the question: “Did you have pain anywhere in your body, 
for at least half of the days, during the last six weeks?” Participants indicated pain-
ful areas by drawing circles around those painful areas. Trained researchers scored 
the homunculi using a template, to assign 14 different joint pain regions (e.g. neck, 
shoulders, elbows, hands, low back, hips, knees and feet). Chronic musculoskeletal 
pain was defined as persons having one or more painful regions. The pain homun-
culus was part of the exam during all baseline and follow-up visits to the research 
center. Since the MRI took place during a separate visit, we used the homunculi 
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closest to the MRI exam. Mean time interval between interview and MRI visit was 
1.76 years (SD 1.43)
MRI acquisition and processing
Brain MRI was performed on a 1.5T MRI unit (General Electric Healthcare, Mil-
waukee, USA, software version 11x) dedicated to research project. The imaging 
protocol and sequence are described in more detail elsewhere [14]. In short, a 
T1-weighted sequence, a proton density-weighted sequence (PD), a T2-weighted 
fluid-attenuated inversion recovery (FLAIR) sequence, and a single shot, diffusion-
weighted spin echo echo-planar imaging (EPI) sequence were included in the 
structural imaging protocol. Maximum b-value was 1000 s/mm2 in 25 non-collinear 
directions; three volumes were acquired without diffusion weighting (b-value = 0 
s/mm2) [14].
A number of 1338 subjects were scanned with the phase and frequency encoding 
directions swapped for the diffusion acquisition due to a technical issue [5]. We 
treated this as a potential confounder, see statistical analysis. T1 and PD weighted 
scans were segmented into grey matter, white matter, cerebrospinal fluid (CSF) and 
background tissue, using an automated segmentation approach, based on a con-
ventional k-nearest-neighbor classifier [3, 28]. Supratentorial intracranial volume 
was estimated by summing total grey and white matter volumes, and CSF volume. 
White matter lesions were segmented using the tissue segmentation and the FLAIR 
image with an automated post-processing technique [3]. An automated multi-atlas 
segmentation with majority voting was performed to segment the frontal, parietal, 
occipital and temporal lobe.
Cortical infarcts were rated visually on FLAIR, proton-density-weighted and T1-
weighted sequences, and in case of involvement of grey matter, they were classi-
fied as cortical infarcts.
Diffusion post processing and tractography
All diffusion data were pre-processed using a standardized pipeline [4]. In short, 
MRI data were corrected for subject motion and eddy currents. A diffusion tensor 
model was estimated on the corrected data to compute FA and MD [4]. The dif-
fusion images were combined with the tissue segmentation to obtain global and 
lobar average diffusion-MRI measurements (FA, MD) inside the normal-appearing 
white matter (i.e. the white matter excluding white matter lesions). The corrected 
diffusion data was separately used for the diffusion tractography, described previ-
ously [5].
Inside 25 tracts, 11 of which were defined for left and right hemispheres separately, 
aggregated tract-specific white matter microstructural diffusion-MRI characteristics 
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(median FA, MD, radial, and axial diffusivity) were obtained and we standardized 
tract-specific diffusion-MRI measures (zero mean, unit SD). Tracts were categorized 
into brainstem tracts, projection tracts, association fiber tracts, limbic tracts and 
callosal tracts, based on anatomy [5].
Tract segmentations were used to obtain tract-specific volumes and, combined 
with the tissue segmentation, white matter lesion volumes. White matter lesion 
volumes were natural log transformed to accommodate their skewed distribution.
We could not fully incorporate the cerebellum in the field of view of the diffu-
sion scan. Therefore, for tractography alternative seed masks were selected until 
reasonable coverage was achieved to account for partial coverage of the medial 
lemniscus at the lower border of the scan. This was treated as a potential con-
founder in all models including the medial lemniscus (see statistical analysis).
Statistical analysis
Associations of chronic pain with diffusion-MRI parameters of white matter micro-
structure globally (FA, MD), per lobe (FA, MD), and tract specifically (FA, MD, axial 
and radial diffusivity) were evaluated using multiple linear regression models.
Mean differences in z-scores (95% CI) between chronic pain versus no pain 
groups were measured. Analyses were adjusted for age, sex, intracranial volume, 
white matter volume, and white matter lesion volume (using tract-specific volumes 
and white matter lesion volumes in the tract-specific analyses).
In all analyses, we treated the phase encoding direction of the diffusion scan as 
a potential confounder. In all tract specific analyses in which the medial lemniscus 
was studied we additionally adjusted for the variable position of the seed masks, 
as explained above.
Additional analyses were performed for significant findings. We additionally 
adjusted the analyses for the presence of depression. The presence of depression 
was determined using the self-reporting CES-D scale (Center for Epidemiologic 
Studies Depression). A score above 16 was considered positive for the presence of 
depression. Gender differences were explored by stratification of the analyses by 
gender. Since we also had information on chronic pain at follow up (approximately 
5 years later), we also performed a longitudinal analysis, to elucidate whether the 
whiter matter alterations could predict to perseverance of chronic pain over time. 
In this analysis, individuals with chronic pain on both visits were compared to the 
individuals whom had chronic pain on the first visit and did not have chronic pain 
anymore on the second visit. This analysis was executed for 2305 individuals of 
which 301 still had chronic pain.
For the tract-specific analysis, we corrected the p-value for multiple comparisons 
using Šidák correction, after estimating the number of independent tests, resulting 
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in a threshold for significance of 3.6*10−3 (at alpha level of 0.05). Analyses were 
carried out using SPSS 20.0.2 for Windows or R version 2.15.0.
Results
Population characteristics
Characteristics of the study population are described in Table 1. In total we com-
pared 1499 individuals with chronic musculoskeletal pain to 2010 individuals without 
pain. Persons with chronic pain were more often female (61% vs 50%) and the mean 
age was slightly higher (60 vs 59 years). The presence of depression was different 
between groups (respectively 4.9% and 13.1% for no chronic musculoskeletal pain 
and chronic pain). There was no significant difference between prevalence of pain 
in the left side of the body or the right side of the body (25% vs 24%).
Chronic pain and global and lobar diffusion-MRI measures
The association between chronic musculoskeletal pain and global and lobar dif-
fusion measures of white matter microstructure is shown in Table 2. We observed 
lower global MD in individuals with chronic musculoskeletal pain compared to 
those without chronic pain (mean difference in z-score −0.05, p-value 0.04). For 
the analysis of separate brain lobes, again a lower MD was found for presence of 
chronic musculoskeletal pain, in the left frontal lobe (mean difference in z-score 
−0.05, p-value 0.05) and in the left temporal lobe (mean difference in z-score −0.07, 
p-value 0.01). There was no association between chronic musculoskeletal pain and 
FA, neither on a global nor lobar level.
Table 1. Population characteristics
Total,
N=3509
No chronic pain,
n=2010
Chronic pain,
n=1499
Difference,
p-value
Age (years) 59.5 (8.2) 59.0 (8.1) 60.3 (8.4) 7.93*10−6
Female gender 55% 50% 61% 2.05*10−11
CESD positive** 8.4% 4.9% 13.1% 5.44*10−18
Intracranial volume (ml) 1128 (119) 1135 (119) 1117 (118) 4.21*10−6
White matter volume (ml) 412 (60) 415 (60) 408 (59) 1.77*10−4
White matter lesion volume (ml)* 4.48 (6.82) 3.49 (4.06) 3.85 (4.44) 0.06
Global mean FA 0.34 (0.01) 0.34 (0.01) 0.34 (0.01) 0.47
Global mean MD 0.73 (0.02) 0.73 (0.02) 0.74 (0.02) 0.39
Values represent means (SD) or percentages. *Values represent medians (IQR). **CESD positive is de-
fined as CESD score >16. Abbreviations: FA; fractional anisotropy, MD; mean diffusivity, 10−3 mm2/sec.
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Chronic pain and tract-specific diffusion-MRI measures
The complete results of the association analysis of chronic musculoskeletal pain and 
diffusion measures of all 25 white matter tracts are described in detail in Table 3.
A significant association of chronic musculoskeletal pain and tract-specific 
diffusion-MRI measures was found in the left medial lemniscus (Figure 1). FA in this 
tract was higher in individuals with chronic musculoskeletal pain (mean difference 
in z-score 0.09, p-value 2.0*10−4), MD and radial diffusivity were lower (mean dif-
ference in z-score −0.07, p-value 0.01, and −0.09, p-value 1.50*10−3 respectively). 
Additional adjustments for global FA or global MD did not change these results. 
None of the other white matter tracts showed a significant association between 
chronic musculoskeletal pain and white matter diffusion measures.
Additional analyses for the significant associations of white matter diffusion-
MRI and pain
Additional adjustment for depression for the association of global MD, left frontal 
lobe MD and left temporal lobe MD with chronic musculoskeletal pain, did not 
change the effect sizes and significance (beta −0.05; p-value 0.02, beta −0.06; 
p-value 0.05 and beta −0.06; p-value 0.02 respectively). For the MRI diffusion mea-
Table 2. Chronic musculoskeletal pain versus no pain and global diffusion-MRI measures
Fractional Anisotropy Mean Diffusivity
Global 0.01 (−0.05;0.06) 
0.31
−0.05 (−0.10;−0.003) 
0.04
Lobar
Frontal left 0.01 (−0.04;0.06) 
0.71
−0.05 (−0.11;−0.0002) 
0.05
Frontal right −0.03 (−0.08;0.03) 
0.39
−0.02 (−0.08;0.04) 
0.55
Temporal left 0.04 (−0.02;0.10) 
0.17
−0.07 (−0.12;0.01) 
0.01
Temporal right −0.03 (−0.09;0.04) 
0.43
−0.03 (−0.08;0.02) 
0.18
Parietal left 0.01 (−0.05;0.07) 
0.70
−0.04 (−0.09;−0.01) 
0.10
Parietal right 0.003 (−0.06;0.06) 
0.92
−0.04 (−0.09;0.01) 
0.13
Occipital left 0.03 (−0.04;0.09) 
0.40
−0.02 (−0.08;0.03) 
0.37
Occipital right −0.003 (−0.07;0.06) 
0.92
−0.05 (−0.11;0.01) 
0.14
Values represent the mean differences in z-scores (95% CI) and p-values between chronic pain vs no 
chronic pain. Linear regression adjusted for age, sex, intracranial volume, white matter volume and 
log-transformed white matter lesion volume. Mean diffusivity x 10−3 mm2/sec.
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sures of the left medial lemniscus, the only significantly associated white matter 
tract with chronic pain, the association also remained significant when additionally 
adjusting for the presence of depression (MD beta −0.09; p-value 0.004 and FA 
beta 0.09; p-value 1.0*10−3). A stratified analysis according to gender did not reveal 
gender differences in the associations (results not shown).
Longitudinal analyses; To further investigate whether changes in the white matter 
microstructural integrity predicted the perseverance of chronic pain, we examined 
the association of MRI diffusion measures of the left medial lemniscus between 
individuals who still have chronic pain approximately 5 years later and those indi-
viduals of whom the pain had disappeared. Fractional anisotropy of the left medial 
lemniscus was associated with persistence of chronic pain (beta 0.13; p-value 0.01). 
Mean diffusivity was not significantly associated with persistence of chronic mus-
culoskeletal pain, showing a similar effect as in the cross-sectional analysis (beta 
−0.043; p-value 0.446).
Figure 1. The left medial lemniscus, a white matter tract significantly associated with chronic muscu-
loskeletal pain, is shown in pink
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Discussion
In this study, we observed lower mean diffusivity of global normal-appearing ce-
rebral white matter in individuals with chronic musculoskeletal pain compared to 
individuals without pain. This association was mainly driven by lower MD in the left 
frontal and left temporal lobe. Additionally, in the tract-specific analysis, we found 
that chronic pain was associated with higher FA, a trend towards a lower MD, and 
lower radial diffusivity in the left medial lemniscus, but not in other tracts. Interest-
ingly, we found that this association is present in individuals that have persistent 
pain especially, indicating a potential prognostic value.
To the best of our knowledge, this is the largest study to investigate the as-
sociation between chronic musculoskeletal pain and diffusion-MRI measures of 
white matter microstructure globally, per lobe and tract-specifically. In comparison, 
the largest study up to now examining this relationship was a case-control study 
of 46 cases with 33 age-matched controls [19]. Another strength of this study is 
the population-based setting reducing selection bias, which might influence case 
control studies. This will increase the generalizability of the results to the general 
population with everyday pain. In addition, the fact that we examined an overall 
chronic musculoskeletal pain phenotype adds to the generalizability of the results 
to all sorts of chronic musculoskeletal pain instead of specific chronic pain states 
such as fibromyalgia or low back pain. Furthermore, diffusion-MRI measurements 
were performed with fully automated methods (observer-independent), that are 
publicly available [5].
Our study also has some limitations. A potential disadvantage is misclassification 
of the determinants, since pain questionnaires are subjective. Misclassification 
of individuals with or without chronic pain can occur in both ways. It is, however, 
not certain if misclassification will occur with greater frequency in one of the two 
groups or that this misclassification will be non-differential and thus will only dilute 
the results. In the tract-specific analyses we used median FA, MD and median axial 
and radial diffusivity, instead of the mean, since the median is more robust to varia-
tions in the tails of the measurement distributions. While effective to reduce the 
dimensionality of the analysis, this might have discarded spatial information that is 
retained in voxel-based techniques. An important limitation is that the cerebellum 
was not fully incorporated in the diffusion scan and the varying field of view makes 
conclusions on brain stem tracts less reliable.
In individuals with chronic pain, we found a lower global MD mainly driven by a 
lower MD in the left frontal and left temporal lobe. These findings point towards 
higher degree of microstructural integrity in individuals with chronic pain. The 
frontal and temporal lobe are part of the limbic system which plays an important 
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role in the emotional response to chronic pain [22]. More activity in these areas 
might have spurred further microstructural reinforcement and thereby explain 
these findings. In the tract-specific analysis, chronic musculoskeletal pain associ-
ated with higher FA and lower radial diffusivity in the medial lemniscus only. This is 
in contrast to a recent study [19] investigating tract-specific white matter involve-
ment in chronic musculoskeletal pain patients. This study found lower values of 
FA and higher values of radial diffusivity in several white matter structures; corpus 
callosum, cingulum, internal capsule and external capsule, uncinated fasciculus, 
superior longitudinal fasciculus and the cerebral peduncles containing the cortico-
spinal tracts in chronic low back pain patients compared to healthy controls. Our 
study differs from the study above at essential points. We used automated mea-
surements instead of region of interest-based measurements which might lead to 
more objective measurements. Furthermore, unlike earlier studies, we controlled 
our analyses for macrostructural white matter changes ((tract-specific) white matter 
volume and white matter lesion volume), to filter out real microstructural changes 
of the white matter.
Our findings of lower values of MD and higher values of FA in the medial lem-
niscus suggest a better white matter microstructural integrity of this white matter 
tract, in line with another study [16] that found denser white matter connections 
cerebellar in fibromyalgia patients compared to healthy controls. This study sug-
gests that in fibromyalgia patients, the medial prefrontal and orbitofrontal cortex 
loses connections with neighboring frontal regions and in contrast to this the 
cerebellum gains connections. Furthermore, denser white matter connections 
were related to greater evoked pain hyperalgesia and clinical pain interference. 
In chronic musculoskeletal pain, painful stimuli are continuously being transferred 
and processed. Chronic painful stimuli therefore possibly result in an increased tract 
density or increased ‘wiring’ of white matter tracts, since a previous study reported 
on remodeling of brain tissue after periods of neuronal activation [2], leading to 
(or coinciding with) central sensitization. In this phenomenon the central nervous 
system becomes more sensitive to painful stimuli in general and the descending 
inhibitory system is compromised. Dorsal column-medial lemniscal (DCML) system 
neurons are involved in conditioned pain modulation (the diffuse noxious inhibitory 
control-like effect). Neurons of the DCML system send out collateral branches that 
synapse with association neurons in the posterior horn of the spinal cord. Action 
potentials travelling through the lateral spinothalamic tract can be suppressed by 
action potentials that originate in neurons of the DCML system. Increased activity 
in the DCML tends to close the gate, reducing pain action potentials transmitted 
[24].
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In the stratified analyses for gender we did not find gender differences. Adjusting 
for gender is therefore sufficient in studying diffusion MRI measures and chronic 
musculoskeletal pain, to correct for differences in other determinants between 
genders, such as the higher presence of chronic pain in women.
We observed that chronic pain primarily associated with white matter microstruc-
tural integrity of the left hemisphere. It has been hypothesized that chronification 
of pain occurs more often on the left side of the brain, because the right cerebral 
hemisphere would be less efficient in processing painful stimuli [12, 21]. Existing 
literature is contradictory whether or not lateralization of chronic pain and sensiti-
zation in the brain exists [2, 17, 21, 29]. There was no clear difference between the 
prevalence of left of right-sided chronic pain. Therefore, the presented data can be 
interpreted as evidence for left sided lateralization of the chronic pain mechanism 
in the brain.
In the global and lobar analyses, we only found associations with MD but not 
with FA. In the tract specific analysis however, we found the strongest associations 
with FA. Increased wiring of tracts may lead to higher values of FA per voxel with 
concomitant decrease in MD. In complex regions with crossing fiber anatomy, FA 
may behave counter-intuitively and is less sensitive, as explained before [7, 15]. This 
might attenuate differences detected by FA in a global analysis, making MD more 
powerful to detect differences in a global analysis. Tract-specific analyses, however, 
may be less susceptible than global or lobar approaches to include large regions 
of crossing fibers in general and in particular in case of the medial lemniscus. 
Therefore, FA may be more sensitive to detect differences locally, than MD. Overall 
however, it should be noted that the different diffusion measures describe different 
aspects of white matter microstructure, which precludes one to one comparison in 
terms of sensitivity.
In conclusion, in a large population-based study of individuals of 45 years or 
older, we found indications for better wiring being present in the cerebral white 
matter in individuals with chronic musculoskeletal pain. This stronger wiring was 
mainly present lateralized in the left hemisphere in the frontal lobe, temporal lobe 
and medial lemniscus. This study adds to the existing knowledge of structural 
brain changes in chronic pain. The connections between cortical structures and the 
peripheral nervous system, as represented by the white matter, are also altered in 
chronic pain.
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Abstract
Objective: Chronic musculoskeletal pain is accompanied by central sensitization, 
which can be determined with quantitative sensory testing (QST). In this study, we 
aim to investigate whether central sensitization, as measured by thermal QST, is 
detectable in community-dwelling elderly individuals suffering from self-reported 
chronic pain and identify determinants influencing thermal QST measurement 
analyses and interpretation.
Methods: In 3,936 participants of the Rotterdam Study, cold and warmth sensitivity 
and heat pain thresholds were determined using the thermo-sensory analyzer TSA 
II (Medoc Advanced Medical Systems, Durham, NC, U.S.A.). Using Cox regression, 
associations were studied with chronic pain and potential determinants (body mass 
index [BMI], reaction speed, systolic and diastolic blood pressure, skin color, skin 
temperature, seasonal influence, depression, anxiety, atopic eczema, age at men-
arche, years since menopause, hormone replacement therapy (HRT) use during 
menopause, and reproductive lifespan).
Results: In addition to the effect of age and gender on thermal sensitivity, darker 
skin color and the presence of atopic eczema were associated with higher sensi-
tivity for heat pain. Cold sensitivity and warmth sensitivity thresholds were both 
influenced by BMI, reaction speed, skin temperature, season, depression, dark skin 
color, years since menopause, and reproductive lifespan. The presence of chronic 
pain was associated with 0.2 degrees lower heat pain threshold in all participants, 
and 0.3 degrees lower in individuals with chronic pain in more than 2 sites.
Conclusion: Higher sensitivity for heat pain, one feature of central sensitization, is 
present in community-dwelling elderly with chronic pain. Additional determinants 
should be considered when analyzing and interpreting QST measurements.
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Introduction
Quantitative sensory testing (QST) is a widely used method for assessing large and 
small nerve fiber function. It can be used to diagnose peripheral nervous system 
disorders but also diagnose and follow up sensitization of the central nervous 
system, as part of the pathophysiology of chronic pain. [1-5]
There are many different stimuli, which can be included in the protocol for 
quantitative sensory testing such as thermal, pressure, mechanical, electrical, and 
vibration stimuli. For the different stimuli, individual detection thresholds and pain 
thresholds can be determined. [6]
In previous articles, specific pain phenotypes originating from clinical study case 
groups have been studied, such as neuropathic pain, fibromyalgia, and osteoar-
thritis, and changes in QST measurements were observed. [1,3,5,7] The sample 
size of these studies was often modest. Efforts were made to define the reference 
thresholds for clinical use, but there is still limited information on thermal QST 
measurements in community-dwelling aging individuals. [6]
Age and gender were previously found to be associated with thermal QST mea-
surements, and interaction between age and gender for some of the QST measures 
was suggested. [8] However, there may be additional determinants to take into 
account when analyzing and interpreting these measurements. For example, the 
body mass index (BMI) is associated with a higher incidence of chronic pain [9-10] 
and could therefore be a confounder in studies examining stimuli that are applied 
to the skin, such as thermal stimuli thresholds. Additionally, in 2 recent papers by 
Olsen et al., the association between blood pressure and acute pain sensitivity has 
been studied. They found that hypoalgesia is more prevalent in individuals with 
higher blood pressure which was hypothesized to be linked through chronic pain-
related dysfunction in interacting cardiovascular–pain modulatory systems. [11,12]
As the QST measurements request the participants to push a “stop” button at a 
certain pain or sensitivity threshold, reaction speed may influence the results too, 
especially as the reaction time increases with age. When using thermal stimuli, it 
is plausible to take environmental temperature (seasons) or skin temperature into 
account.
Psychological factors have often been implicated to play a role in chronic pain, 
[13] and they might also have their influence on QST measurements, as mental 
state could influence performance on the test.
Another factor previously reported to be important in chronic pain is ethnicity or 
skin color; the prevalence of chronic pain and catastrophizing behavior has been 
reported to be higher in Afro-Americans compared to non-Hispanic whites. [14] 
Not only skin color but also skin conditions which compromise the skin barrier such 
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as atopic eczema might lead to altered results in QST. Additionally, as itch stimuli 
and pain stimuli travel via the same nerve fibers, continuous itch could also cause 
sensitization. [15,16]
It is known that postmenopausal women are more prone to develop chronic pain, 
[17] possible by lowered sex hormones, and this might be reflected in the QST 
measurements as well. Therefore, we examined the influence of several hormone 
exposure-related phenotypes: age at menarche, years since menopause, repro-
ductive lifespan, and hormone replacement therapy (HRT) use during menopause.
The aim of our study was to identify the determinants to be considered when 
interpreting thermal QST measurements, especially in the elderly population. In 
addition, we examined whether central sensitization is present and detectable in 
community-dwelling elderly individuals with chronic pain using a limited thermal 
QST protocol. Therefore, we studied the detection limits for cold and warmth 
stimuli and heat pain thresholds within the Rotterdam Study, a large prospective 
population-based study of individuals aged 45 years and over.
Methods
Study Population
The study population was embedded in the Rotterdam study, a large prospective 
population-based study of men and women of 45 years and older. The objective 
of the Rotterdam Study is to investigate determinants, incidence, and progres-
sion of chronic disabling disease in the elderly. The study design and rationale are 
described elsewhere in detail. [18] The first cohort, Rotterdam Study I (RS-I) started 
in 1989 with 7,983 participants. The study was extended in 1999 with another 3,011 
individuals in Rotterdam study II (RS-II). The third cohort, Rotterdam Study III (RS-III) 
started in 2006 adding 3,932 participants. All participants were examined in detail 
at baseline and follow-up visits approximately every 6 years. In summary, a home 
interview was conducted and an extensive set of examinations at the research 
center was conducted.
The Rotterdam Study has been approved by the Medical Ethics Committee of the 
Erasmus MC and by the Ministry of Health, Welfare and Sport of the Netherlands, 
implementing the “Wet Bevolkingsonderzoek: ERGO (Population Studies Act: Rot-
terdam Study).” All participants provided written informed consent to participate 
in the study and to obtain information from their treating physicians.
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Quantitative Sensory Testing
The quantitative sensory testing was conducted in a total of 4,039 participants. The 
measurements were performed between November 2010 and June 2014 during 
the fifth follow-up measurement of RS-I, the third follow-up measurement of RS-II, 
and the second follow-up measurement of RS-III.
We used a commercially available thermo-sensory analyzer, the TSA II (Medoc 
Advanced Medical Systems, Durham, NC, U.S.A.). The probe had a surface of 2 by 
2 cm and was placed on the inner site of the non-dominant forearm.
We measured 3 different thermal sensitivity thresholds: the cold sensitivity 
threshold, the warmth sensitivity threshold, and the heat pain threshold. For each 
measurement, the starting temperature of the probe was 32°C, while a minimum 
of zero degrees Celsius and a maximum of 50°C were set for safety reasons. After 
each measurement, the temperature was reset to 32°C before starting the next 
measurement. The participants were asked to push a large “red quiz button” when 
reaching the test threshold. All 3 threshold measurements were repeated 5 times 
in a row with 5-seconds in between the tests. For the analysis, the mean value of 
the last 3 measurements was used. First, the probe decreased in temperature with 
1 degree per second, to measure the cold sensitivity threshold. The participant 
was asked to push the button when feeling the sensation of a decrease in tem-
perature. Second, the probe increased in temperature, with 1 degree per second, 
to measure the warmth sensitivity threshold. The participant was asked to push 
the button when feeling the sensation of an increase in temperature. The third 
measurement was the heat pain threshold: During this measurement, the probe 
temperature increased with 1.5 degrees per second. The participant was asked to 
push the button when the warmth stimulus started to feel unpleasant or painful.
Excluded from the population for analyses were 30 individuals with preexistent 
peripheral of central nerve damage, including cerebral vascular accidents and 
paralysis in the medical history.
Chronic Musculoskeletal Pain
To identify individuals with chronic musculoskeletal pain, all participants completed 
a pain drawing. This drawing showed a drawing of the front and back of a hu-
man body, and the participant encircled the painful sites in their body where they 
experienced pain during at least half of the days during the last 6 weeks. In earlier 
analysis in this population, we observed that of all individuals indicating pain dur-
ing the last 6 weeks, more than 90% of the reported pain was present for more than 
3 months. Therefore, in this study, we considered the pain reported in the pain 
drawing as being chronic pain. The additional requirement for the individuals to 
have pain for at least half of the days adds a measure for clinical importance.
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The pain drawings were scored using a template with 14 different musculoskel-
etal joint regions (neck, lower back, 2 shoulders, 2 elbows, 2 hands, 2 hips, 2 knees, 
and 2 feet).
We examined 3 different pain phenotypes within this study. The first is whether 
the participant had pain anywhere in their body vs. participants without pain. The 
second phenotype is the number of different painful sites analyzed as a continuous 
variable: a score between 0 and 14. The third pain phenotype we defined studied 
a more severe pain phenotype: Cases were defined as participants having pain in 
more than 2 different sites of their body and controls having no pain. In this last 
analysis, we excluded individuals with pain at one or 2 sites.
Body Mass Index and Blood Pressure
Height and weight were measured with the subject in a standing position with 
indoor clothing without shoes.
Body mass index (BMI) was calculated using the commonly used formula: m/h2 
(m = weight in kg; h = height in m). Blood pressure was measured twice in sitting 
position with an automatic device. The mean values of systolic and diastolic blood 
pressure were used in the analysis.
Reaction Time
We measured reaction time in our study population using the computer program 
Reaction Time V4.03 (http://delphiforfun.org/programs/Reaction_times.htm). The 
participants were shown a big blue square on the screen of a computer and pushed 
a quiz button as fast as they could if the square appeared. This was repeated 7 
times, and the mean of the last 5 measurements was calculated as the reaction 
time.
Skin Temperature and Seasonal Influence
The skin temperature was measured using an infrared skin thermometer (Infrared 
clinical thermometer FTN, Medisana AG, Hilden, Germany). This measurement was 
performed at the same site of the QST measurement, the inner site of the non-
dominant forearm, and the temperature was recorded in degrees Celsius.
Using the date of the measurement, we defined in which season the measure-
ment took place. Seasons were defined astronomically; spring starting at March 
21, summer starting at July 21, autumn at September 21, and winter at January 21.
Psychological Factors: Depression and Anxiety
For the definition of depression, we used the Center for Epidemiological Studies 
Depression scale (CES-D). [19] This self-reporting scale of depressive symptoms 
QST and Chronic Pain in the General Population 129
5.1
gives a score between 0 and 80. Depression was defined as a CES-D score of 16 
or above.
We determined whether anxiety symptoms were present by a selection of ques-
tions from the Munich Composite International Diagnostic Interview. [20] Presence 
of anxiety symptoms was defined as ever having a sudden anxiety attack, unreason-
able fear in specific circumstances and/or unusual fear, anxiety or worrying during 
the last 4 weeks.
Dermatological Determinants: Skin Color and Atopic Eczema
Skin color was determined visually as described elsewhere. [21] During a full-body 
skin examination, the perceived skin color was graded by a trained physician into 
5 categories of darkness, reflecting the observed constitutive skin color assessed 
at sun unexposed body sites. The perceived skin color categories included the fol-
lowing: (1) very white, (2) white, (3) white to olive, (4) light brown, (5) brown to black.
The presence of atopic eczema was determined by trained physicians at the 
research center and defined by the previously described UK diagnostic criteria 
of atopic dermatitis. These guidelines comprise one major criterion (“An itchy 
skin condition”) plus 3 or more minor criteria (“history of involvement of the skin 
creases,” “a personal history of asthma or hay fever,” “a history of generally dry 
skin in the last year,” “visible flexural eczema,” and “onset under 2 years of age”). 
[22-24]
Reproductive Traits: Years Since Menopause, Reproductive Lifespan
Data on menopause, menarche, and HRT use during menopause were derived 
from the home interview. We calculated years since menopause and reproductive 
lifespan. Reproductive lifespan was calculated by subtracting age at menarche 
from age at natural menopause. In the studied population, there were no pre-
menopausal women included.
Statistical Analysis
Associations of the quantitative sensory measurements with the various determi-
nants were tested with Cox regression analyses. For safety reasons, the heat pain 
threshold measurement stopped at 50°C. However, approximately 15% of the par-
ticipants reached this temperature without pressing the button; this means that the 
actual heat pain threshold of these individuals was higher than 50°C. To solve this 
issue, a Cox regression model was fitted and the subjects who reached the maxi-
mum temperature were censored. For the analysis, we used the time to threshold 
in seconds as outcome, to be able to compare the increase of temperature in the 
warmth sensitivity threshold and heat pain threshold and the decrease in tempera-
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ture in the cold sensitivity threshold measurement. Beta therefore represents the 
adjusted mean differences to the measured threshold per unit for the continuous 
determinants and adjusted mean differences to the measured threshold for pres-
ence of the dichotomous determinants. We also studied the association between 
age and the variance of the QST measurements within subjects. All analyses were 
adjusted for age and gender, and P < 0.05 was considered statistically significant.
For the association analysis between the QST measurements and chronic pain, 
we additionally performed analysis stratified for gender and age categories (50 
to 59 years, 60 to 69 years, and 70 years and older). Also, we fitted a model with 
the newly found determinants as described above to study the influence of these 
determinants on the association of QST measurements and chronic pain.
Software package SPSS Version 21 (SPSS INC., Chicago, IL, U.S.A.) was used for 
all analyses.
Results
Population Characteristics
Within in Rotterdam study, quantitative sensory testing was conducted in a total of 
4,053 participants between November 2010 and June 2014. A total of 103 partici-
pants were excluded (47 because of not being alert or very tired, 26 had problems 
with understanding the test, and 30 participants had other reasons for a potential 
unreliable test results including, for example, neurodegenerative disease such as 
paralysis; 14 subjects were excluded because of technical difficulties) resulting in 
3,936 participants for the analysis. Population characteristics are shown in Table 1.
Mean age in this population is 66.0 years and 55.8% is female. Chronic pain is 
present in 45.4% of the individuals in the study and 12.9% have chronic pain in 
more than 2 sites of their body.
Figure 1 shows the distribution of the QST measures stratified for men and 
women. The warmth sensitivity measure showed a skewed normal distribution, 
the cold sensitivity measure distribution resembles half of a normal distribution. A 
considerable number of individuals did not reach their heat pain threshold before 
the measurement was stopped at 50°C for safety reasons, especially in men (24%).
Potential Determinants for QST Measurements
The results of the univariate association analysis of the QST measures with the 
various potential influential determinants are shown in Table 2. As expected, age 
and gender were strong determinants for each of the QST measures. All other 
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potential determinants were tested for their association with the 3 QST thresholds, 
while adjusting for age and gender.
We also investigated the influence of age on the QST measurements itself. To 
this end, we studied the difference in variance in all 3 measurements for the age 
Table 1. Population characteristics
N= Total, n=3,936
Age 3,936 66.0 (7.6)
Female gender 3,936 55.8%
BMI 3,933 27.6 (4.4)
Blood pressure
Systolic, mmHg 2,208 145 (22) 
Diastolic, mmHg 2,208 85 (11) 
Reaction Speed, s 3,828 0.37 (0.15)
Skin temperature, ˚C 3,936 31.7 (0.9)
Season measurement 3,936
Spring 953 24.2% 
Summer 623 15.8% 
Autumn 1,213 30.8% 
Winter 1,147 29.1% 
Depression, CESD > 15 3,773 17.4%
Anxiety 3,901 15.7%
Skin color 2,528
Very white 146 5.8% 
White 1,908 75.5% 
White to olive 380 15.0% 
Light brown 45 1.8% 
Brown to black 49 1.9% 
Atopic eczema (UK crit) 3,723 6.0%
Age at menarche, years 1,539 13.7 (6.0)
Years since Menopause 1,440 18.5 (9.7)
HRT use during menopause 1,540 9.3%
Reproductive Lifespan, years 1,422 35.6 (7.0)
Chronic pain 3,901 45.2%
Chronic painsites 3,901 1.0 (1.8)
>2 chronic painsites vs no pain 2,814 12.9%
Cold Sensitivity ˚C 3,936 28.8 (2.5)
Warmth Sensitivity ˚C 3,936 35.3 (2.0)
Heat Pain Threshold ˚C 3,936 47.5 (3.0)
Values represent means (and standard deviation) or percentages (%)
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categories 50 to 59 years, 60 to 69 years, and 70+ years of age (Table S1). As shown 
in Table 3, variance is increasing by age, for the heat and cold sensitivity threshold 
suggesting that these measurements are potentially less reliable in elderly subjects.
Cold Sensitivity Threshold
For cold sensitivity, the reaction speed was a strong determinant, independently 
associated from age and gender. A slower reaction speed was highly signifi cantly 
associated with a longer time to threshold (beta −0.014; P-value 9.82 × 10−14). A BMI 
above the mean of 27.6 was associated with a cold sensitivity threshold (CST) that 
was 0.12 degrees lower than subjects with a BMI lower than 27.6, which means that 
these individuals were less sensitive for cold stimuli. A lower skin temperature and 
environmental temperature (in winter) were both associated with a lower sensitivity 
for cold. In winter, the cold sensitivity threshold was approximately 0.14 degrees 
higher than in spring. Subjects with depression or anxiety symptoms were sig-
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nificantly less sensitive to cold stimuli (beta −0.096 and beta −0.091, respectively). 
Individuals with brown to black skin color were less sensitive to cold stimuli and felt 
the probe getting colder at 0.6 degrees lower temperature than individuals with 
white skin. A longer time since menopause in women was associated with a lower 
cold sensitivity and a longer reproductive lifespan increased the sensitivity to cold.
Table 2. Cox regression analysis of QST-measures and the studied potential influential determinants
Cold sensitivity Warmth sensitivity Heat pain threshold
Beta (SE) P-value Beta (SE) P-value Beta (SE) P-value
Age −0.021 (0.002) 2.42*10−24 −0.029 (0.002) 2.92*10−45 0.006 (0.002) 0.014
Female gender 0.036 (0.032) 0.260 0.253 (0.032) 5.48*10−15 0.573 (0.036) 3.01*10−57
BMI −0.014 (0.004) 1.64*10−4 −0.011 (0.004) 0.002 0.006 (0.004) 0.148
Blood pressure*
Systolic −0.007 (0.010) 0.490 0.023 (0.011) 0.037 0.003 (0.011) 0.812 
Diastolic −0.001 (0.018) 0.978 0.032 (0.019) 0.092 0.014 (0.020) 0.504 
Reaction Time −0.918 (0.123) 9.82*10−14 −0.642 (0.123) 1.86*10−7 0.117 (0.118) 0.322
Skin Temperature 0.114 (0.018) 2.52*10−10 −0.102 (0.018) 1.20*10−8 0.003 (0.020) 0.862
Season(ref=Spring)
Summer −0.008 (0.052) 0.880 −0.040 (0.052) 0.433 −0.013 (0.056) 0.818 
Autumn −0.010 (0.044) 0.818 −0.126 (0.044) 0.004 −0.037 (0.048) 0.442 
Winter −0.140 (0.044) 0.002 −0.136 (0.044) 0.002 −0.056 (0.048) 0.243 
Depression −0.096 (0.044) 0.028 −0.092 (0.044) 0.036 0.008 (0.047) 0.859
Anxiety −0.091 (0.045) 0.040 −0.070 (0.044) 0.117 0.036 (0.048) 0.457
Skin color (ref =White)
Very white −0.001 (0.087) 0.994 −0.050 (0.087) 0.561 0.047 (0.091) 0.604 
White to olive 0.038 (0.056) 0.496 0.087 (0.057) 0.125 −0.003 (0.061) 0.964 
Light brown −0.212 (0.152) 0.163 0.426 (0.151) 0.005 0.365 (0.158) 0.021 
Brown to black −0.631 (0.147) 1.66*10−5 0.329 (0.146) 0.024 0.620 (0.149) 3.22*10−5 
Atopic eczema −0.042 (0.070) 0.550 0.001 (0.070) 0.984 0.186 (0.073) 0.011
Age at menarche 0.003 (0.004) 0.491 −0.0005 (0.004) 0.911 −0.006 (0.005) 0.205
Yrs since Menopause −0.011 (0.005) 0.021 −0.011 (0.005) 0.020 −0.005 (0.005) 0.340
HRT use menopause 0.037 (0.090) 0.680 0.004 (0.090) 0.962 0.096 (0.094) 0.306
Reproductive Lifespan 0.010 (0.005) 0.023 0.010 (0.004) 0.030 0.005 (0.005) 0.245
Beta represents adjusted mean difference in time (s) to threshold per unit of the continuous deter-
minant or for the presence of the dichotomous determinant. Positive beta corresponds to shorter 
time to threshold and thus a higher sensitivity. SE: Standard error. Age analyses adjusted for gender 
and gender analyses adjusted for age. *Blood pressure: per 10 mmHg. All other analyses adjusted 
for age and gender.
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Warmth Sensitivity Threshold
Similar to the cold sensitivity, reaction speed was also a highly associated de-
terminant for warmth sensitivity thresholds (beta −0.642; P-value 1.86 × 10−7). In 
addition, a higher BMI was associated with a higher warmth sensitivity threshold 
(beta −0.011; P-value 0.002). A higher systolic blood pressure was associated with a 
lower sensitivity for heat (beta 0.023 per 10 mm Hg; P-value 0.037). Both skin color 
and environmental temperature were associated with warmth sensitivity; in winter, 
the warmth sensitivity threshold was 0.14 degrees higher than in spring, which was 
mainly driven by skin temperature. Depressive symptoms were associated with 
higher detection thresholds, corresponding to lower sensitivity (beta −0.092; P-
value 0.036).
Subjects with brown to black skin color were more sensitive to warmth stimuli 
than subjects with white skin color (beta 0.329; P-value 0.024). In women, the num-
ber of years since menopause was associated with a lower sensitivity for warmth 
stimuli (beta −0.011; P-value 0.020), and the length of the reproductive lifespan was 
associated with a higher sensitivity for warmth (beta 0.010; P-value 0.030).
Heat Pain Threshold
The mean heat pain thresholds (HPT) were 0.6 degrees lower in women than in 
men. Participants with brown to black skin experienced the warmth stimulus as 
being unpleasant or painful 0.6 degrees earlier than participants with white skin. 
Additionally, individuals with atopic eczema were more sensitive to heat pain. No 
associations were found for the other potential determinants. Given the large dif-
ferences in HPT measures between the sexes, we additionally stratified the analysis 
according to sex and found similar results.
Chronic Musculoskeletal Pain
We studied whether the presence of chronic musculoskeletal pain was associated 
with altered QST measures. As shown in Table 4, neither cold sensitivity nor warmth 
sensitivity threshold was associated with chronic pain (Table 4). However, the heat 
Table 3. Association of QST measurement variance and age categories, adjusted for gender
Age 
categories
Cold sensitivity threshold Warmth sensitivity threshold Heat pain threshold
Mean variance p-value Mean variance p-value Mean variance p-value
50-59 years
 n=941
0.800 Reference 0.585 Reference 3.089 Reference
60-69 years
 n=1936
1.075 0.016 0.636 0.550 3.080 0.958
70+ years
 n=1059
1.314 7.20*10−5 0.846 0.007 3.343 0.199
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pain threshold (HPT) was associated with the presence of chronic musculoskeletal 
pain (beta 0.108; P-value 0.002), representing a higher sensitivity for heat pain in 
subjects with chronic pain compared to subjects with no chronic pain. Moreover, a 
larger effect size was observed when the more severe phenotype of chronic pain 
in more than 2 sites in their body was tested (beta 0.195; P-value 2.43 × 10−4), 
corresponding to a 0.3 degrees lower HPT. In addition, the HPT was associated 
with the number of affected sites, indicating that this QST measure is related to the 
centralization and consequent spreading of chronic pain.
Stratification according to gender showed that the association of HPT with 
chronic pain was driven by women (beta 0.122; P-value 0.007 vs. beta 0.086; P-value 
0.136 in men). We further examined whether age was affecting this association 
and examined whether the difference in HPT between individuals with and without 
chronic pain changed at different ages. For the individuals aged 50 to 59 years, 
beta was 0.177 with a P-value of 0.016; for the 60 to 69 years of age group a beta of 
0.099, P-value 0.052; and for the oldest group aged 70 years and older, beta 0.049, 
P-value 0.471. These results suggest that central sensitization measured by HPT is 
less detectable in older subjects.
In a second model, we adjusted for the previously significantly associated deter-
minants skin color and atopic eczema, and we found an attenuation of the observed 
association between chronic pain and HPT by skin color. After adjustment, there 
was no significant association between HPT and the presence of chronic pain but a 
Table 4. Cox regression analysis for the relation between QST-measures and chronic pain
Beta (SE) P-value
Cold Sensitivity
 Chronic pain 0.007 (0.033) 0.839 
 Painsites 0.011 (0.009) 0.211 
 >2 painsites vs no pain 0.080 (0.050) 0.106 
Warmth Sensitivity
 Chronic pain −0.060 (0.033) 0.067 
 Painsites −0.002 (0.009) 0.866 
 >2 painsites vs no pain −0.022 (0.050) 0.660 
Heat Pain Threshold
 Chronic pain 0.108 (0.036) 0.002 
 Painsites 0.032 (0.009) 4.90*10−4 
 >2 painsites vs no pain 0.195 (0.053) 2.43*10−4 
Beta represents adjusted mean difference in time (s) to threshold per unit of the continuous deter-
minant or for the presence of the dichotomous determinant. Positive beta corresponds to shorter 
time to threshold and thus a higher sensitivity. SE: Standard error. All analyses adjusted for age and 
gender.
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trend remained (beta 0.069; P-value 0.116). However, in this last model, much less 
subjects were available for the analysis (n= 2,515) because of missing values for 
skin color.
Discussion
In this large prospective population-based study, we observed significant associa-
tions between chronic musculoskeletal pain and heat pain thresholds, indicating 
central sensitization is present in these community-dwelling individuals. Addition-
ally, we found several determinants to be independently associated with thermal 
stimuli thresholds which might be important to consider when analyzing and 
interpreting test results. For cold sensitivity detection thresholds, the identified 
determinants were age, BMI, reaction time, skin temperature, winter, anxiety, 
depression, skin color, years since menopause, and reproductive lifespan. The 
determinants for the warmth sensitivity detection include age, sex, BMI, reaction 
time, skin temperature, autumn and winter, depression, skin color and years since 
menopause, and reproductive lifespan. Heat pain thresholds were independently 
associated with age, sex, skin color, and atopic eczema.
To our knowledge, this is the first study to examine determinants of thermal QST 
measurements and the association with chronic musculoskeletal pain in such a 
large set of individuals aged 50 years and over. A recent article by Johansen et 
al. studied QST measures in a large set of elderly individuals, but focused their 
research on persistent postoperative pain. [25] As the prevalence of chronic pain 
is increasing with age, this is a very relevant population to study pain sensitivity. As 
sensitivity to, for example, thermal, stimuli are lower in older subjects, reference 
values as determined in younger and healthier subjects can influence the interpre-
tation of QST measurements. The reference values as previously determined could 
therefore be not very useful in an elderly population. We observed a considerable 
amount of the individuals in this study reaching the maximum threshold for the 
heat pain threshold (50°C), which was set because of safety reasons: 24% of men 
and 10% of women reached the threshold of 50°C. In addition, we found that in 
elderly subjects, the variance of the QST measures was also more pronounced, es-
pecially for cold sensitivity and warmth sensitivity thresholds, limiting the reliability 
of the results in these subjects. To our knowledge, this is the first study to show this 
limitation of the thermal QST in elderly subjects. This suggests that the heat pain 
threshold measurements might be difficult to interpret, especially in elderly men 
and other QST modalities might be more informative.
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In our study, we investigated the sensitivity to thermal stimuli using 3 modalities: 
the cold detection threshold, the warmth detection threshold, and the heat pain 
threshold. In particular, the heat pain thresholds were previously identified to be 
associated with central and peripheral sensitization in individuals having chronic 
pain. Descending inhibitory pathways are compromised in chronic pain states, 
which increase the sensitivity to painful stimuli. However, up to now, this has only 
been determined in chronic pain patients in the clinic compared to healthy controls. 
We identified that the HPT is increased in community-dwelling elderly individuals 
with self-reported chronic pain and we additionally showed that the HPT is related 
to the number of pain sites, indicating spreading of pain. This indicates that central 
sensitization is present in the general population and stresses the importance of 
good treatment for acute pain to limit the number of subjects who develop chronic 
pain.
We observed a consistent association between BMI and the temperature sen-
sitivity measurements. A higher BMI was associated with a higher prevalence of 
chronic pain, and potential mechanisms include higher levels of proinflammatory 
cytokines. These cytokines might also play a role in higher sensitivity for thermal 
stimuli, as they can sensitize the peripheral nerve endings. [26] Further research 
focusing on the influence of these proinflammatory cytokines on QST measures is 
necessary to elucidate this hypothesis.
Reaction speed decreases with age and greatly influences QST results. In par-
ticular, in an older population, the reaction speed should be taken into account 
for interpreting the results of the cold and the warmth detection threshold. We did 
not find an association between the reaction speed and the heat pain thresholds. 
During the heat pain threshold measurement, the subject feels the temperature 
rising until the moment it will become unpleasant or painful, so they can estimate 
how much longer they must wait until pushing the button. This anticipation could 
be the reason for reaction speed being less influential in this measurement. In 
addition, the duration of the heat pain threshold measurement is longer than the 
sensitivity threshold measurements, and therefore, reaction speed may influence 
the results less.
Very limited research has been performed on the influence of skin or environ-
mental temperature on QST measurements, although it is very plausible that the 
detection limits for cold and warmth are dependent on temperature of the skin 
and/or the environment. We were able to show that skin temperature is indeed 
associated with these detection limits and they should be used as covariates 
when analyzing these measurements. We also found an association between the 
winter season and the QST measurements, but this was primarily driven by skin 
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temperature. This means that environmental temperature influences the thermal 
QST measurements via the skin temperature.
The influence of psychological factors on pain and pain sensitivity, such as 
depression and anxiety, has been suggested before. [13] Depression and anxiety 
could lead to altered results of QST measurements. For example, anxiety could 
influence the test results: Participants may drop out early due to their fear of pain. 
To some extent, this effect was seen when the threshold was measured for the first 
time, as subjects tended to push the button earlier the first time compared to the 
rest of the measurements. We therefore measured each threshold 5 times and used 
the mean values of the last 3 measurements. We found marginally significant asso-
ciations between depression, anxiety, and the thermal detection thresholds, which 
were no longer significant in the multivariate analysis. We therefore conclude that 
these psychological factors had little influence on the measured thermal thresholds 
in this population.
QST measures and also the prevalence of chronic pain had previously been found 
to be associated with ethnicity. Skin color is one of the visible differences between 
ethnicities. Although differences in pain sensitivity are most likely multifactorial, 
local factors such as skin conditions could also be part of the mechanism. Not 
only the amount of melanocytes in the skin is different between skin colors, but 
also larger fibroblasts are observed in dark skin. A dark skin is known to be more 
sensitive to inflammation and injury, so it is plausible that the structural differences 
also cause a higher sensitivity to other external stimuli such as temperature and 
pain. [27-29]
We observed higher pain sensitivity in individuals with atopic eczema. Atopic 
eczema compromises the integrity of the skin barrier and therefore, nerve endings 
in the skin could be more sensitive to heat pain stimuli as we showed in our study. 
Additionally, it is known that neuronal processing of itch and pain is closely related. 
This might be explained by sensitization of the nervous system by itch, resulting is 
a higher sensitivity to experimental thermal pain stimuli, as described previously. 
[15,16]
In 2 recent publications by Olsen et al., [11,12] hypertension was found to be as-
sociated with hypoalgesia in a large population-based study. We tried to replicate 
these results by examining the relationship between systolic and diastolic blood 
pressure and thermal QST measurements and found only a marginal association 
between a higher systolic blood pressure and a higher sensitivity for warmth but 
not pain. Olsen et al. used the cold pressor test and pain ratings for assessing pain, 
and this study was therefore more focusing on the pain intensity and pain inhibitory 
system rather than detection thresholds like in our study. This might suggest that 
high blood pressure influences pain intensity but not detection.
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Postmenopausal women have more risk for developing chronic musculoskeletal 
pain, which can be due to hormonal changes and potential sensitization. After 
menopause, estrogen levels drop as ovarian production stops. In previous literature, 
estrogen levels were found not to be associated to thermal QST measurements 
although this was performed only in premenopausal women. [30] We found signifi-
cant association between years after menopause and reproductive lifespan with 
warmth detection limits and not with the other 2 QST measures, which suggest that 
there is only a limited influence of estrogen exposure on thermal QST measures in 
postmenopausal women. It remains to be determined whether estrogen levels in 
postmenopausal women directly influence pain sensitivity.
Limitations of our study include the limited amount of tested modalities of QST. 
Due to the extent of this study and the large amount of examinations performed, 
there was limited time available to examine more QST modalities.
In addition, because we used a general definition of chronic musculoskeletal 
pain, it is possible that some of the individuals had peripheral nerve changes due 
to their chronic pain syndrome, which could affect the QST measurement and the 
identified associations. However, this would be a very small amount compared to 
the total amount of individuals, and individuals with known peripheral nerve dam-
age were excluded.
In conclusion, we observed lower heat pain thresholds in individuals with chronic 
musculoskeletal pain, indicating that central sensitization is present in this preclini-
cal population. Additionally, we identified determinants that are important to be 
taken into consideration when analyzing and interpreting QST measurements.
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Abstract
Objectives: Hip and knee osteoarthritis (OA) are debilitating diseases that impair 
gait at severe stages. Although associations between OA and gait are established 
for normal walking, little is known on its relation with turning and tandem (heel-
to-toe) walking. Additionally, it is unknown how asymptomatic OA associates with 
gait, and whether associations differ by sex. We investigated how symptomatic 
and asymptomatic hip and knee OA associate with gait in community-dwelling 
individuals.
Methods: In 2385 participants of the population-based Rotterdam Study, gait was 
assessed by electronic walkway and summarised into seven gait domains. Hip and 
knee radiographs were graded for radiographic OA (ROA) using the Kellgren and 
Lawrence (K&L) score. Linear regressions were used to investigate associations 
between ROA and gait. Analyses were repeated including only participants with 
asymptomatic ROA, defined as a K&L-score of 2 without pain.
Results: In total, 154 participants (6.5%) had hip ROA and 493 (16.8%) knee ROA. 
We found no associations of knee ROA with gait. Hip ROA associated with Rhythm 
(0.27 SD [95%CI: 0.11; 0.43], p<0.001), Tandem (−0.25 SD [−0.42; −0.07], p=0.005), 
and Turning (−0.28 SD [−0.46; −0.10], p=0.003). Associations between hip ROA 
and gait differed significantly between men and women. Hip ROA associated with 
Tandem and Turning in men, while associating with Rhythm and Base of Support in 
women. Asymptomatic hip ROA associated with Rhythm and Tandem.
Conclusions: Hip ROA, but not knee ROA, associates with gait differences in normal 
walking, turning, and tandem walking in community-dwelling individuals. These as-
sociations differ between the sexes, and are even present for asymptomatic ROA.
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Introduction
Osteoarthritis (OA) is a debilitating disease that limits people in daily functioning, 
eventually leading to loss of independence. [1, 2] Prevalence of hip and knee OA is 
high in the elderly (7-30% in people aged ≥65 years) and expected to increase even 
more due to the aging population and increasing prevalence of obesity. [2-4] Both 
hip and knee OA are characterised by joint pain and stiffness, which may severely 
impair locomotion and gait. [5-9]
Gait is an important indicator of health and poor gait associates with higher fall 
risk and mortality. [10-14] Gait is a complex concept that can be assessed using 
many parameters. These parameters, as assessed by electronic walkways, can be 
summarised into seven independent gait domains that comprehensively describe 
gait. [15, 16]
Of these gait domains, previous studies found hip and knee OA to associate with 
Base of Support (larger step width), Pace (slower gait velocity), Phases (shorter sup-
port on both legs), Rhythm (higher cadence), and Variability (larger gait variability 
among steps). [5-9] Additionally, OA in only one leg (one-sided OA) was found to 
associate with larger gait asymmetry. [6-8]
Yet, previous studies included participants with mainly severe and symptomatic 
OA. [5-9] Little is known on associations of subclinical and asymptomatic OA with 
gait, which requires investigating a community-dwelling population. Early identifi-
cation of people with OA may allow for early, and hence expectedly more effective, 
intervention. [17] Another consideration is that previous studies only focused on 
associations of OA with gait in normal walking. [5-9] However, the ability to turn 
and walk tandem may deteriorate earlier with developing OA because of the com-
plex nature of these walking conditions. Additionally, although sex-differences in 
associations of knee OA with gait have been reported, it is unknown whether sex 
influences associations of hip OA with gait. [9]
We aimed to investigate associations of radiographic hip and knee OA with gait 
in normal walking, turning, and tandem walking, in a community-dwelling popula-
tion. Additionally, we investigated sex-differences in associations of OA with gait.
Methods
Setting
This study was embedded in the Rotterdam Study, a population-based cohort 
study from the Netherlands. [18] In 1990 and 2000, all inhabitants of Ommoord, a 
suburb of Rotterdam, aged 55 years and older were invited to participate. In 2006, 
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the cohort was extended by inviting all inhabitants of Ommoord aged 45 years and 
older. At baseline and every 3-4 years of follow-up, participants undergo a home 
interview and extensive medical examination at the research centre. From March 
2009 onwards, gait assessment was included in the study protocol. The current 
study includes all participants that completed gait assessment between March 
2009 and December 2011. This study was approved by the medical ethical commit-
tee of the Erasmus MC. All participants gave written informed consent.
Assessment of hip and knee OA
Weight-bearing anteroposterior radiographs of knee and hip were obtained as 
previously described. [19] Hip and knee OA were scored using the Kellgren and 
Lawrence (K&L) grading system. Radiographic OA (ROA) was defined as a K&L-
score of two or higher. [20]
In a sub-population, joint pain was identified with pain homunculi, showing a 
picture of the front and back of the human body. Participants were asked: “Did you 
have pain anywhere in your body, for at least half of the days, during the last six 
weeks?” If answered positively, participants had to mark painful areas with circles. 
Subsequently, a template was used to assign these areas to 14 different joint pain 
regions. For the current study, only pain in hip or knee was considered.
We considered a joint to have asymptomatic ROA when having a K&L-score of 2 
without pain.
Gait assessment
Details on our gait assessment protocol have been described elsewhere. [16] In 
short, gait was assessed using a 5.79 meter long electronic walkway (4.88 meter 
active area; GAITRite Platinum; CIR systems, Sparta, NJ, USA). Participants walked 
in three walking conditions: normal walk, turn, and tandem walk. In normal walk, 
participants walked at their usual pace over the walkway. This process was per-
formed eight times, of which the first recording was regarded as a practice walk 
and excluded from analyses. In turn, participants walked at their usual pace over 
the walkway, turned halfway, and returned. In tandem walk, participants walked 
heel-to-toe over a straight line present on the walkway.
Principal components analysis was used to summarise gait (means of both legs) 
into seven independent domains, as described previously: Base of Support, re-
flecting stride width and stride width variability; Pace, reflecting step length and 
velocity; Phases, reflecting double support time and single support phase (single 
support as a percentage of the gait cycle); Rhythm, reflecting cadence and single 
support time; Tandem, reflecting errors in tandem walking; Turning, reflecting turn-
ing time and turning step count; and Variability, reflecting step length variability 
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and step time variability. [16] To evaluate walking behaviour of a single leg, we 
used the highest correlating gait parameter from those domains that could be 
calculated for a single leg: step width variability for Base of Support, step length 
for Pace, single support phase for Phases, single support time for Rhythm, and step 
length variability for Variability. [16] We did not assess walking behaviour of a single 
leg for Tandem and Turning. Gait asymmetry was calculated as the value on gait 
parameters of the left leg minus the value on parameters of the right leg.
Study population
Between March 2009 and December 2011, 3242 persons were invited for gait 
assessment. Of these, 108 persons did not undergo gait assessment for the follow-
ing reasons: perceived physical inability (n=52), technical reasons (n=43), refusal 
(n=11), and other reasons (n=2). Of the remaining participants, we excluded 34 
participants for performing less than 16 steps in normal walks [21], 13 participants 
for use of walking aids, and one person for not following instructions.
Of 3086 participants with valid gait assessments, 2512 had radiographs avail-
able of both hips and/or both knees. Of these, 127 participants were excluded for 
having a total hip or knee replacement. Of 2385 included participants, 2292 had 
gradable radiographs available of both hips and 2361 of both knees.
Participants were used in four distinct analyses (see next section). In the first 
analysis on gait domains, 212 participants were excluded for missing the turn or 
tandem walk, resulting in 2087 participants included in analyses on hip ROA and 
2154 on knee ROA.
In analyses of one-sided hip ROA with gait asymmetry, gait of the osteoarthritic 
leg, and gait of the non-osteoarthritic leg, 49 participants were excluded for having 
hip ROA in both legs. Similarly, 182 participants were excluded in analyses of one-
sided knee ROA for having knee ROA in both legs. Hence, 2243 participants were 
included in analyses on one-sided hip ROA and 2179 in analyses on one-sided 
knee ROA.
Statistical analysis
We performed four distinct analyses to investigate associations of hip and knee 
ROA with gait.
First, we used gait domains to investigate associations between hip and knee 
ROA with gait in both legs.
Second, to analyse gait asymmetry, we recoded ROA of hip and knee as 1 if 
present in the left leg and −1 if present in the right leg. Participants without hip 
or knee ROA were coded as 0. Hence, positive associations between ROA and 
gait asymmetry imply that one-sided ROA relates to larger gait asymmetry with 
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higher values of gait parameters in the osteoarthritic leg. In contrast, negative as-
sociations imply larger gait asymmetry with higher values in gait parameters of the 
non-osteoarthritic leg.
Third, to analyse gait in the osteoarthritic leg of participants with one-sided hip 
or knee ROA, we used gait parameters of the ROA leg for participants with one-
sided ROA, and means of both legs for participants free of the respective ROA.
Fourth, in analyses of the non-osteoarthritic leg, we used gait parameters of the 
leg without ROA for participants with one-sided ROA, and means of both legs for 
participants without ROA.
Linear regression analyses were used to investigate associations of hip or knee 
ROA with gait domains, gait asymmetry, gait in the osteoarthritic leg, and gait in the 
non-osteoarthritic leg. Univariate ANOVAs were used to calculate mean z-scores 
of gait domains per K&L-score. All analyses were adjusted for age, sex, height, 
weight, and time interval between radiographic and gait assessment. Analyses on 
Tandem were additionally adjusted for mean step length and step count in the 
tandem walk.
Analyses were repeated after sex-stratification and with sex*ROA interaction 
terms included. To investigate whether associations were driven by gait velocity, all 
analyses were repeated while adjusting for gait velocity. [6, 7]
To investigate whether associations remained for asymptomatic ROA, analyses 
were repeated in the sub-population with pain data available, including only par-
ticipants without ROA or with asymptomatic ROA.
All statistical analyses were performed using IBM SPSS version 21.0.0.1 for Win-
dows.
Results
Participants had a mean age of 65.9 years (Standard deviation [SD] 8.9) and 53.6% 
were women (Table 1). Of 2385 participants, 512 (21.5%) had ROA. Of these, 112 
(4.7%) had ROA in hip only, 358 (15.0%) in knee only, and 42 (1.8%) in both hip and 
knee. Differences in prevalence of hip and knee ROA between men and women 
were non-significant.
Of 154 participants with hip ROA, 105 (68.2%) had one-sided hip ROA. Of 400 
participants with knee ROA, 218 (54.5%) had one-sided knee ROA.
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Table 1. Population characteristics.
Total (n = 2385) Men (n = 1106) Women (n = 1279)
Age, years 65.9 (8.9) 66.6 (9.2) 65.4 (8.6)
Height, cm 169.6 (9.2) 176.5 (6.6) 163.5 (6.4)
Weight, kg 78.7 (14.3) 85.7 (12.6) 72.6 (12.9)
ROAa, n 512 (21.5%) 227 (20.5%) 266 (20.8%)
Hip ROA, n 154 (6.5%) 74 (6.7%) 80 (6.3%)
One-sided hip ROA, n 105 (4.4%) 44 (4.0%) 61 (4.8%)
Knee ROA, n 400 (16.8%) 176 (15.9%) 224 (17.5%)
One-sided knee ROA, n 218 (9.1%) 102 (9.2%) 116 (9.1%)
Values are means (standard deviations) or numbers of participants (percentages).
a Radiographic hip or knee osteoarthritis.
Abbreviations: n, number of participants; cm, centimetres; kg, kilograms; ROA, radiographic osteo-
arthritis.
Associations of ROA with gait domains
Hip ROA associated with higher Rhythm (0.27 SD [95% confidence interval: 0.11; 
0.43], p<0.001), lower Tandem (−0.25 SD [−0.42; −0.07], p=0.005), and lower Turn-
ing (−0.28 SD [−0.46; −0.10], p=0.003) (Table 2).
In Figure 1, higher K&L-scores of the hip are shown to associate with lower Tan-
dem (p-trend=0.03) and Turning (p-trend=0.03), but higher Rhythm (p-trend<0.001). 
No significant p-trends were found across K&L scores for the other gait domains.
In sex-stratified analyses, hip ROA associated with lower Tandem (−0.32 SD 
[−0.55; −0.09], p=0.006) and Turning (−0.33 SD [−0.58; −0.09], p=0.008) in men, 
while associating with higher Base of Support (0.27 SD [0.04; 0.50], p=0.02) and 
Rhythm (0.30 SD [0.09; 0.52], p=0.005) in women (Table 3).
Knee ROA did not associate with any gait domain, but did demonstrate trends of 
an association with Tandem (−0.11 SD [−0.23; 0.01], p=0.08) and Turning (−0.11 SD 
[−0.23; 0.01], p=0.06) (Table 2).
In sex-stratified analyses, we found an association of knee ROA with Tandem 
(−0.23 SD [−0.40; −0.07], p=0.006) in women (Supplement 1). Additionally, we 
found this association to be significantly stronger (p=0.005) for women than men.
Adjustment for gait velocity did not change associations for hip or knee ROA.
Associations of one-sided ROA with gait
One-sided hip ROA associated with larger gait asymmetry, with shorter single sup-
port time and phase but larger step length in the osteoarthritic compared to the 
non-osteoarthritic leg (Table 4).
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Figure 1. Z-scores of gait domains across Kellgren and Lawrence scores. Dots are means adjusted 
for age, sex, height, weight, and time interval between radiographic and gait assessment. Error bars 
represent standard errors of the means.
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Additionally, one-sided hip ROA associated with shorter single support time and 
phase of the osteoarthritic leg and larger step length and step length variability of 
the non-osteoarthritic leg.
When stratifying for sex, all associations described above were present in women 
(Table 5). Additionally, one-sided hip ROA associated with larger step length vari-
ability of the osteoarthritic leg in women. In men, no associations were found for 
one-sided hip ROA.
We found significant sex-interactions, with associations of one-sided hip ROA 
with shorter single support phase of the osteoarthritic (p=0.004) and non-osteoar-
thritic leg (p=0.03) being stronger in women than men.
One-sided knee ROA did not associate with gait differences (Table 4). Similarly, 
we found no associations in sex-stratified analyses of one-sided knee ROA (Supple-
ment 2). Adjustment for gait velocity did not change associations for one-sided hip 
or knee ROA.
Associations of asymptomatic ROA with gait
Of 2385 participants, 1909 (80.0%) had pain data available, including 80 partici-
pants with hip ROA and 288 with knee ROA. Of these, 60 (75.0%) participants had 
asymptomatic hip ROA and 177 (61.5%) asymptomatic knee ROA.
After restriction to asymptomatic ROA, hip ROA remained significantly associ-
ated with Rhythm, Tandem, and single support time of the osteoarthritic leg in 
the overall population. In women, hip ROA remained significantly associated with 
Rhythm, larger gait asymmetry in single support time and phase, and single sup-
port time in both the osteoarthritic and non-osteoarthritic leg. No associations 
remained for asymptomatic knee ROA.
Discussion
Our study shows that hip ROA associates with gait in a community-dwelling 
population. We found this relation to remain when restricting to asymptomatic hip 
ROA. Hip ROA associated with gait differences in Rhythm, Tandem, and Turning. 
One-sided hip ROA was associated with larger gait asymmetry, and differences in 
gait parameters of both the osteoarthritic and non–osteoarthritic leg. Associations 
between hip ROA and gait were mainly driven by women. Knee ROA only associ-
ated with Tandem in women.
Strengths of our study include the population-based setting, assessment of gait 
in three walking conditions, radiographic classification of OA, investigation of sex-
differences, and restriction to participants with asymptomatic OA.
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Limitations of our study include the inability to assess gait mechanics, e.g. flexion 
angles and rotation moments. Additionally, the cross-sectional design precluded 
investigation of whether gait differences are a consequence of OA, or whether 
a deviant gait pattern increases the probability of developing (more severe) OA. 
Finally, gait was assessed at the research centre. Therefore, we may have missed 
people with severe OA that inhibited them to come to the research centre. Ad-
ditionally, people with OA that did visit the research centre may have refused 
gait assessment more often. Hence, our findings may only be generalizable to a 
relatively healthy population with less severe OA cases.
We found hip ROA to associate with gait differences in a community-dwelling 
population, even when restricting our osteoarthritic participants to those with 
asymptomatic hip ROA. Previous studies used clinic-based samples of patients 
with more advanced and severe hip OA. [6, 7] Our findings imply that hip OA may 
already impact gait at an early stage, in absence of pain symptoms. Interestingly, 
not only did hip ROA associate with gait differences in normal walking, but also in 
turning and tandem walking. This suggests that assessment of turning and tandem 
walking may provide additional information to identify people with early-stage hip 
OA. Previous research has already highlighted the importance of identifying OA 
at an early stage, to increase effectiveness of interventions to prevent or reduce 
its progress. [17] Our results suggest that gait assessment may aid in such an early 
identification of hip OA.
Similar to a previous study, we found hip ROA to associate with taking quicker 
steps (higher Rhythm). [6] In contrast to that study, we found no association of hip 
ROA with larger stride width (higher Base of Support) in the overall population, but 
only in women. Both taking quicker steps and larger stride width have been sug-
gested to be compensatory mechanisms to reduce pain. [6] However, our findings 
suggest that the quicker steps may instead result from a reduced motion range of 
the OA hip, because associations remained after restriction to participants with 
asymptomatic ROA. [6, 22] To the best of our knowledge, we are the first study to 
report that persons with hip ROA, especially men, have more difficulty in turning 
and tandem walking. These associations may be especially important, because 
problems in turning and tandem walking may reflect balance deficits that increase 
fall risk. [11, 23] Hence, decreased range of hip motion in participants with hip OA 
may increase fall risk and thus risk of fractures and other related morbidities.
Consistent with previous research, we found one-sided hip ROA to associate with 
larger gait asymmetry, with shorter single support time and phase but larger step 
length in the osteoarthritic compared to the non-osteoarthritic leg. [6] The asym-
metry in single support time and phase came from shorter single support on the 
osteoarthritic leg compared to normal, while asymmetry in step length came from 
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shorter step length of the non-osteoarthritic leg. These associations are presum-
ably compensatory mechanisms to avoid load on the osteoarthritic leg, which is 
supported by their attenuation after restriction to asymptomatic ROA. We found 
one-sided hip ROA to additionally associate with larger step length variability in the 
non-osteoarthritic leg. Larger step length variability of the non-osteoarthritic leg 
may reflect adaptations to unexpected limitation of movement or sudden onset of 
pain in the osteoarthritic leg. A previous study only found an association with step 
length variability in the osteoarthritic leg. [7] We found a similar association, but 
only in women. In general, larger gait variability suggests loss of gait control, and 
is clinically important through its strong association with the risk of falling. [12, 13]
We found associations of hip ROA with gait to be generally stronger in women 
than men. Only associations of hip ROA with Tandem and Turning were stronger 
in men. We found significant sex-interactions, with one-sided hip ROA associating 
stronger with single support phase of osteoarthritic and the non-osteoarthritic leg 
in women compared to men. These sex-differences suggest that women may either 
alter their gait pattern at an earlier stage of hip OA or change their gait pattern to 
a greater extent as an adaptive mechanism to reduce pain. Alternatively, a certain 
gait pattern, with higher prevalence in women (e.g. due to different anatomy of 
the pelvis), may lead to larger wear and tear of the hip joint, and thus to OA. 
Notwithstanding the mechanism, these findings suggest that, when using gait to 
identify hip OA, sex should be taken into account.
In contrast to most previous studies, we only found trends of associations for 
knee ROA with gait. [5, 6, 8, 9] This discrepancy may be explained by the relatively 
few participants with severe knee OA in our study. Possibly, knee OA only affects 
gait at more severe stages, or more power is needed to identify the subtle associa-
tions of subclinical knee OA with gait. Otherwise, restricted movement of the knee 
may be compensated by movement of the hip, while restricted movement of the 
hip may be harder to compensate, resulting in gait differences at an earlier stage.
Conclusions
In a community-dwelling population, hip OA associates with gait differences in 
normal walking, turning, and tandem walking. These associations were also found 
for asymptomatic hip OA, suggesting that gait patterns already change in absence 
of pain symptoms. One-sided hip OA associates with larger gait asymmetry and 
gait differences in both osteoarthritic and non-osteoarthritic leg. Associations of 
hip OA with gait are generally stronger in women than men. These findings sug-
gest that, especially in women, gait assessment could aid in early identification of 
persons with hip OA.
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 CHAPTER 6.2
Chronic joint pain in the lower 
body is associated with gait 
differences independent from 
radiographic osteoarthritis
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Abstract
Background: Gait is an important indicator of health. Chronic lower body pain may 
impair gait and lead to morbidity and mortality. We investigated the associations 
between lower body pain and gait in community-dwelling individuals, independent 
from osteoarthritis (OA).
Methods: This population based cohort study included 2304 Rotterdam Study 
participants who underwent electronic walkway gait assessment. Thirty different 
variables resulting from gait assessment were summarized into seven gait domains 
using principle components analysis: i.e. Rhythm, Variability, Phases, Pace, Tan-
dem, Turning, and Base of Support. Chronic lower body pain was assessed using 
pain drawings. OA was defined as a Kellgren & Lawrence score of 2 or higher on 
radiographs of the hip and/or knee. Linear regression analysis was used to study 
associations.
Results: Participants with chronic pain in the leg and hip, had lower Rhythm, Phases, 
and Pace, independent from OA. Additionally, we found unilateral pain to associate 
with larger gait asymmetry. No associations were found between chronic pain and 
the other gait domains, including gait variability. However, within individuals with 
hip pain, gait variability was higher in individuals with radiographic OA compared 
to those without OA.
Conclusions: This is the first population based study showing chronic lower body 
pain associates with gait differences independent from OA. Participants with pain 
were found to walk with slower and smaller steps, longer double support and more 
asymmetry. Proper care and treatment of chronic pain could be a way of reducing 
gait problems and thereby fall risk and associated mortality. In addition, gait as-
sessment may help identifying individuals with OA from those having pain due to 
other causes.
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Introduction
Chronic pain is very common in elderly people and affects daily functioning. 
Chronic lower body pain often causes decreased mobility and lower quality of life. 
Especially in older individuals, this decreased mobility is related to higher mortality 
[1-5].
Gait assessment, by electronic walkway, can provide accurate measurement of 
mobility. Gait is an accurate health indicator and strongly associates with falls and 
mortality [3,6-10].
Gait is highly complex and can be studied in many different ways, resulting in many 
different variables. As a consequence, the overlap across studies in variables used 
to study gait is limited. Ideally, gait is studied using as many variables as possible, 
but this would result in multiple testing as well as collinearity across variables. Over 
recent years, various studies have tried to solve this issue by principal components 
analysis (PCA) [10-13]. Using this method, the different studies investigating gait 
patterns will be better comparable since they use the same gait domain variables.
Previous studies on pain and gait parameters mainly focused on osteoarthritis 
(OA), the most common cause of lower body pain in elderly people [14-20]. The 
clinical definition of OA includes joint pain and joint damage on radiographs. 
However, joint damage does not necessarily result in joint pain. Similarly, not all 
individuals with chronic joint pain also have joint damage. It is therefore unclear 
whether previous observed gait differences in clinical OA case studies were due 
to OA or pain. Pain is the main reason for individuals to turn to their physician, but 
only part of the individuals coming to the general practitioner with joint pain also 
has OA. We therefore here study the relation between gait and chronic pain in 
the lower body. We additionally studied whether the observed differences in gait 
patterns were dependent on the presence of OA and whether individuals with OA 
could be identified with gait patterns among the individuals with pain. This study 
will add to the knowledge of gait in joint related complaints, since it is focused 
on the joint pain compared to the previous studies investigating joint damage. 
In addition, recognizing gait differences between OA-related and OA-unrelated 
pain might provide opportunities to distinguish people with OA from those having 
musculoskeletal pain due to other factors.
Additionally, better understanding of the relationship between lower body pain 
and gait may allow for new interventions to decrease pain and gait problems, and 
hence related morbidity and mortality. We studied associations of pain in the lower 
body with gait in a community dwelling population of middle-aged and elderly 
individuals.
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Methods
Study population
Between March 2009 and March 2012, 3651 persons were invited for gait assess-
ment. We excluded 163 individuals for physical inability to perform gait assessment, 
115 because of having hip or knee prosthesis and 27 due to technical problems. 
Thirty-four subjects were excluded because they completed less than 16 steps, 
reducing validity [22]. Furthermore, 12 participants refused gait assessment, 3 par-
ticipants used walking aids, one did not follow instructions and 2 were excluded 
for other reasons.
Of the remaining 3294 participants, 2304 had pain drawings data available, 
because pain drawings were temporarily removed from the study protocol. These 
2304 participants were used in the analysis.
Chronic joint pain assessment
Pain drawings were presented to participants to assess chronic joint pain. The pain 
drawing showed a picture of the front and the back of the human body. Participants 
were asked the following question: “Did you have pain anywhere in your body, for 
at least half of the days, during the last six weeks?”. Pain was recorded as ‘yes’ 
or ‘no’. Painful sites were marked by the participant. The drawings were scored 
using a template assigning 14 joint regions, including neck, shoulders, elbows, 
hands, low back, hips, knees and feet. For the current study, we used pain of the 
hips, knees, feet and low back. Leg pain was defined as hip, knee or foot pain. We 
created a summary score for pain in the lower body, in which we summed the pres-
ence of pain in the left leg, right leg and low back and divided this score by three.
Gait assessment
The full gait assessment protocol is published previously [13]. In short, gait was 
assessed using a 5.79 m long electronic walkway with pressure sensors (GAITRite 
Platinum; CIR systems, Sparta, NJ: 4.88 m active area; 120 Hz sampling rate), an 
accurate tool for gait assessment [23-25].
Participants followed a standardized gait protocol consisting of three walking 
conditions: normal walk, turning and tandem walk. In ‘normal walk’, participants 
walked eight times at their usual pace across the walkway. The first walk was 
considered a practice walk and was not used for gait parameter calculations. In 
‘turning’, participants walked across the walkway, turned halfway, and returned to 
their starting position. In ‘tandem walk’, participants walked heel-to-toe over a line, 
visible on the walkway.
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Principal components analysis summarized mean gait parameters of both legs into 
seven gait domains, as previously described: (1) Rhythm, reflecting cadence and single 
support time; (2) Variability, reflecting variability in step length and time; (3) Phases, 
reflecting double support time and single support time as a percentage of the total 
stride time; (4) Pace, reflecting step length and velocity; (5) Tandem, reflecting errors 
in tandem walking; (6) Turning, reflecting the number of steps and time needed to 
turn; and (7) Base of Support, reflecting stride width and stride width variability [13]. In 
the results, a lower value of the gait domains represents a worse gait.
From the principal component analysis, we can derive correlation estimates for 
every parameter for the amount of variance of gait explained by that particular vari-
able. To investigate walking behavior of one leg, we used the highest correlating 
gait parameters from the gait domains that could be computed for a single leg: 
single support time for Rhythm, step length variability for Variability, single support 
percentage for Phases, step length for Pace, and stride width variability for Base of 
Support. To study gait asymmetry, values on gait parameters of the right leg were 
subtracted from the values on gait parameters of the left leg.
Statistical analysis
We studied associations between lower body pain and gait domains by comparing 
gait patterns in people with pain to those without lower body pain.
Additionally, we investigated the effect of unilateral pain on gait asymmetry 
and effects in the painful or non-painful leg. Individuals with bilateral pain were 
excluded. We recoded pain in the left leg as 1, pain in the right leg as −1 and no 
pain as 0. Hence, a positive association indicates unilateral pain to result in larger 
asymmetry with higher values of gait parameters in the painful leg compared to 
the unpainful leg. To elucidate gait differences in the painful leg, we compared the 
painful leg of people having unilateral pain to the mean of both legs for individu-
als without pain. Similarly, to elucidate gait differences in the unpainful leg, we 
compared the unpainful leg of people with unilateral pain to the mean of both legs 
for individuals without pain.
We used linear regression analyses to investigate the associations of chronic 
pain in the lower body with the different gait domains, gait asymmetry, gait in the 
painful leg, and gait in the unpainful leg. All analyses were adjusted for age, sex, 
height, weight and time interval between pain and gait assessment. ‘Tandem walk’ 
analyses were additionally adjusted for mean step length and step count.
To investigate the influence of OA, we repeated the analysis on lower body pain 
and the gait domains, after excluding participants with radiographic OA in the 
hip or knee. Individuals in which OA was rated on radiographs as a Kellgren & 
Lawrence score of 2 or higher were used [26].
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Subsequently, we investigated whether gait is affected by OA in individuals with 
pain in hip and/or knee, by associating hip and knee OA with the seven gait domains 
within the individuals that have pain, representing symptomatic or clinical OA.
SPSS version 21.0 (SPSS INC., Chicago, USA) was used for all analysis.
Results
Population characteristics are described in Table 1. Mean age of the participants 
was 63.5 years and 54.8% were female. Pain in the lower body was present in 35.6% 
of the subjects, with pain in the lower back, hip, knee or foot being present in 
respectively 17.1%, 8.6%, 16.4% and 7.9% participants.
Associations between pain in the lower body and gait domains
The summary score of the number of painful body parts (right leg/left leg/low 
back) was associated with lower Rhythm (−0.19 SD; P= 0.005), Phases (−0.20 SD; 
P= 0.002) and Pace (−0.19 SD; P= 0.003), but higher Variability (0.16 SD; P= 0.046) 
(Table 2). We subsequently found that leg pain resulted in lower Rhythm (−0.11 
SD; P= 0.014), Phases (−0.15 SD; P < 0.001) and Pace (−0.10 SD; P= 0.018), while 
low back pain was only associated with lower Pace (0.10 SD; P= 0.034). Further 
investigation showed that the majority of the gait differences due to leg pain were 
driven by hip pain. Additionally, foot pain foot was associated with Phases (−0.14 
SD; P= 0.047), while knee pain was not associated with gait differences, despite 
larger power compared to hip and foot pain.
Table 1. Population characteristics
Characteristic Total (n = 2304)
Age [years] 63.5 (7.5)
Sex [females] 1262 (54.8)
Height [cm] 170.0 (9.2)
Weight [kg] 79.5 (14.7)
Body Mass Index 27.4 (4.1)
Pain in the lower body [n] 820 (35.6)
Pain lower back [n] 395 (17.1)
Pain Hip [n] 198 (8.6)
Pain Knee [n] 377 (16.4)
Pain Foot [n]
Summary score lower body pain [points]
183 (7.9)
0.18 (0.28)
Values are means (standard deviations) or numbers (percentages).
Abbreviations: cm = centimeters, kg = kilograms, n = number.
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Associations of unilateral pain with gait asymmetry
Unilateral leg pain associated with more gait asymmetry in step length, with larger 
step length in the painful leg compared to the unpainful leg (0.42 cm; P= 0.003) 
(Table 3). Additionally, unilateral leg pain associated with smaller step length and 
shorter single support percentage in both the painful and the unpainful leg com-
pared to participants without leg pain (−0.30 SD; P < 0.001 and −0.84 SD; P= 0.025) 
(Supplemental Table 1).
Unilateral hip pain associated with more asymmetry in step length and single 
support percentage, with larger step length (0.50 cm; P= 0.023) and shorter single 
support percentage (−0.24%; P= 0.045) in the painful leg compared to the unpainful 
leg (Table 3). Similar to unilateral leg pain, we found unilateral hip pain to associate 
with shorter single support percentage in the painful leg and smaller steps and 
shorter single support percentage in the unpainful leg, compared to participants 
without hip pain (Supplemental Table 1).
Unilateral foot pain was also associated with larger asymmetry in step length 
(0.56 SD; P= 0.010), with larger steps in the painful leg compared to the unpainful 
Table 3. Associations of unilateral pain in the leg, hip, knee and foot with gait asymmetry between 
both legs
Domain Rhythm Variability Phases Pace Base of 
Support
Gait 
parameter
Single Support 
Time (0.1 s)
Step length 
SD (cm)
Single Support 
Phase (%)
Step length 
(cm)
Stride width 
SD (cm)
Unilateral pain leg
Asymmetry −0.01
(−0.03; 0.00)
0.01
(−0.08; 0.11)
−0.13
(−0.28; 0.02)
0.42 **
(0.14; 0.70)
0.01
(−0.05; 0.07)
Unilateral pain hip
Asymmetry −0.02
(−0.05; 0.00)
−0.13
(−0.27; 0.02)
−0.24 *
(−0.47; −0.01)
0.50 *
(0.07; 0.94)
−0.05
(−0.15; 0.04)
Unilateral pain knee
Asymmetry −0.01
(−0.03; 0.01)
0.07
(−0.06; 0.19)
−0.09
(−0.29; 0.10)
0.05
(−0.31; 0.41)
0.02
(−0.06; 0.10)
Unilateral pain foot
Asymmetry −0.01
(−0.04; 0.02)
0.26 **
(0.09; 0.42)
−0.11
(−0.38; 0.16)
0.65 *
(0.15; 1.15)
0.01
(−0.10; 0.12)
Values represent differences in gait parameters (95% confidence interval) for presence of pain in the 
respective body part. Results in bold survived thresholds of nominal significance (*p < 0.05; **p < 
0.005). All analysis were adjusted for age, sex, height, weight, and time interval between pain and 
gait assessment. Leg: n = 2012; hip: n = 2231; knee: n=2103; foot: n = 2215.
Asymmetry: difference in gait asymmetry between painful and unpainful leg compared to asymmetry 
between both legs of people without pain.
Abbreviations: s = seconds, SD = standard deviation, cm = centimetres, n = number of participants.
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leg (Table 3). Furthermore, we found unilateral foot pain to associate with larger 
asymmetry in step length variability, with larger step length variability in the pain-
ful leg compared to the unpainful leg (0.26 cm; P= 0.003) (Table 3). We found no 
significant associations between unilateral knee pain and gait (Table 3 and Supple-
mental Table 1).
Role of OA in associations between pain in the lower body and gait
To study whether the observed associations between pain and gait were driven by 
OA, we excluded 582 participants with radiographic hip and/or knee osteoarthritis. 
Interestingly, the associations remained largely unchanged (Supplemental Table 
2), suggesting that associations of lower body pain with gait are at least not com-
pletely driven by hip and/or knee OA.
We next examined whether we could differentiate individuals with and without 
radiographic OA using gait pattern, within the subjects with hip or knee pain. In 
contrast to a higher variability when comparing hip pain versus no hip pain, we 
found painful hip OA to associate with lower Variability compared to pain without 
hip OA (−0.45 SD; P= 0.026). For painful knee OA, no significant associations with 
the gait domains were found (Table 4).
Discussion
In this study, we show that chronic lower body pain associates with gait differences 
in community-dwelling individuals. Lower body pain associated with Rhythm (taking 
slower steps), Pace (taking smaller steps), Variability (less variability among steps) 
Table 4. Relation between gait domains and OA in participants with pain in the hip or knee
Domain Rhythm Variability Phases Pace Tandema Turning Base of 
Support
OA hip 0.23
(−0.15; 
0.62)
−0.45 *
(−0.85; 
−0.05)
0.03
(−0.34; 
0.41)
−0.08
(−0.41; 
0.24)
−0.08
(−0.48; 
0.32)
−0.29
(−0.68; 
0.11)
0.00
(−0.41; 
0.41)
OA 
knee
0.15
(−0.07; 
0.37)
−0.01
(−0.24; 
0.22)
0.16
(−0.05; 
0.38)
0.12
(−0.07; 
0.30)
−0.12
(−0.35; 
0.11)
−0.06
(−0.28; 
0.17)
−0.07
(−0.30; 
0.16)
Values represent differences in z-scores of gait (95% confidence interval) for presence of osteoarthri-
tis in the respective body part. Osteoarthritis was scored as 1 = yes and 0 = no. Results in bold sur-
vived thresholds of nominal significance (*p < 0.05). All analyses were adjusted for age, sex, height, 
weight and the interval between OA and gait assessment. (n= 419, of which 25 with hip OA and 98 
with knee OA)
aAdditionally adjusted for the step count and step size within the tandem walk
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and Phases (longer double support time). These associations are mainly driven 
by leg pain, especially hip, and remained after exclusion of participants with OA. 
Furthermore, we found unilateral pain to associate with larger gait asymmetry and 
gait differences in both the painful and unpainful leg. For hip pain, gait variability 
was higher in individuals with radiographic OA compared to those without OA.
To our knowledge, we are the first large population-based study to investigate 
lower body pain in relation to gait. Few studies investigated the relation between 
pain and gait and focused on OA-related pain, the most common cause of joint 
pain in elderly. Hence, comparison of our findings with previous studies is limited. 
We found lower body pain to associate with slower and smaller steps with longer 
double support, which corresponds with previous studies investigating gait in knee 
OA [18-20]. In our study, these associations were especially driven by hip pain. Inter-
estingly, the associations remained after excluding participants with radiographic 
OA, suggesting they were independent. Hence, lower body pain may have clinical 
impact outside of OA, as longer double support is a risk factor for falling and gait 
speed (Rhythm, Phases, and Pace combined) strongly relates to mortality [3,10].
In addition, we found unilateral leg pain to associate with gait asymmetry and 
differences in gait of legs. Unilateral leg, hip and foot pain showed similar patterns 
of associations, such as larger step length asymmetry with larger step length in 
the painful compared to the unpainful leg. We found shorter single support time 
for the painful leg, which contrasts with a previous study in OA where they found 
a longer single support time for the affected leg, supporting independence of 
our findings from OA [15]. The observed lower single support percentage in both 
legs corresponds to a recent review on effects of OA on gait in osteoarthritic and 
non-osteoarthritic leg [27]. Most likely, these associations are the result compensa-
tory mechanisms to reduce load on the painful leg, by way of increasing its step 
length and increasing double support. Interestingly, we found unilateral foot pain 
to associate with larger asymmetry in step length variability, with larger step length 
variability in the painful leg. This association is especially important, because larger 
variability is considered a strong risk factor of falling [8-10].
Similar to a previous study, we found no associations of knee pain with gait [28]. 
Since directionality of associations was similar to hip and foot pain with smaller 
effect sizes, knee pain most likely has a less pronounced effect on gait and may 
therefore require more power to identify associations.
Joint pain is one of the hallmarks of OA, a common joint disease in older people 
that may have devastating consequences [29]. In a clinical setting, it is often diffi-
cult to distinguish OA-related pain from pain caused by other pathologies without 
radiographic examinations. In literature, both hip and knee OA strongly affect 
the gait pattern, suggesting a possible role for gait assessment in differentiating 
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OA-related pain from pain due to other causes [15,27]. Interestingly, we observed 
that individuals with hip OA pain have less variability between steps compared to 
individuals with hip pain due to other causes. This finding may indicate that gait 
assessment can aid in identifying OA in people with pain and might be helpful for 
the general practitioner. Before implementation of gait measurement into general 
practice, further research in patients presenting with hip pain in the general prac-
tice should be conducted. For example, additional value on top of other known 
physical tests, such as range of motion, should be explored.
Strengths of our study include the large population-based cohort design, en-
abling us to identify associations that may be generalizable to the general popula-
tion. Additionally, the gait assessment in different walking conditions, including 
turning and tandem walking, gives a comprehensive description of gait differences 
with chronic pain. Furthermore, because we did not focus on a single pathological 
origin of pain, we could provide information on the relations of general pain with 
the gait pattern. Radiographs were taken in all individuals, independent if they 
were suspected to have OA or not, so there were no suspected but undiagnosed 
subjects in the analysis concerning OA.
Limitations of our study include that gait was assessed at the research center, 
which may have prevented participants with severe gait problems from participating. 
Generalizability of our results may therefore be limited to a relatively healthy elderly 
population. Additionally, due to the cross-sectional study design, we are not able to 
identify the temporal relationship between pain in the lower body and gait. Although 
it is most likely that pain leads to gait differences, it is also possible that a deviant gait 
pattern causes joint pain. Hence, associations may be bidirectional, implicating that 
both interventions targeting pain may improve the gait pattern and interventions 
targeting gait may decrease pain. Future studies should further investigate this pos-
sible bi-directionality in the associations between lower body pain and gait.
In conclusion, in community-dwelling individuals, chronic lower body pain as-
sociates with gait differences, independent of OA. Individuals with pain in the 
lower body take slower and shorter steps with longer double support. Additionally, 
unilateral pain associates with larger gait asymmetry, and gait differences in both 
painful and unpainful leg. Our results further suggest that gait patterns might aid 
in distinguishing between OA and other pathology in people with musculoskeletal 
pain. Prospective analysis would be valuable to determine whether gait analysis is 
predictive for progression and/or pain.
Proper care and treatment of chronic pain could be a way of reducing gait 
problems and thereby fall risk and associated mortality. Future studies should in-
vestigate whether treatment of lower body pain aids in improving gait, and thereby 
reduces gait-related morbidity and mortality.
174 Chapter 6.2
References
1. Henderson, J.V., et al., Prevalence, causes, 
severity, impact, and management of 
chronic pain in Australian general practice 
patients. Pain Med, 2013. 14(9): p. 1346-61.
2. Reimers, C.D., G. Knapp, and A.K. Reimers, 
Does physical activity increase life expec-
tancy? A review of the literature. J Aging 
Res, 2012. 2012: p. 243958.
3. Studenski, S., et al., Gait speed and survival 
in older adults. JAMA, 2011. 305(1): p. 50-8.
4. Vagetti, G.C., et al., Association between 
physical activity and quality of life in the 
elderly: a systematic review, 2000-2012. Rev 
Bras Psiquiatr, 2014. 36(1): p. 76-88.
5. Hoeven, T.A., et al., Disability and not 
osteoarthritis predicts cardiovascular 
disease: a prospective population-based 
cohort study. Ann Rheum Dis, 2014.
6. Cesari, M., Role of gait speed in the assess-
ment of older patients. JAMA, 2011. 305(1): 
p. 93-4.
7. Cho, B.L., D. Scarpace, and N.B. Alexander, 
Tests of stepping as indicators of mobility, 
balance, and fall risk in balance-impaired 
older adults. J Am Geriatr Soc, 2004. 52(7): 
p. 1168-73.
8. Hausdorff, J.M., D.A. Rios, and H.K. 
Edelberg, Gait variability and fall risk in 
community-living older adults: a 1-year 
prospective study. Arch Phys Med Rehabil, 
2001. 82(8): p. 1050-6.
9. Maki, B.E., Gait changes in older adults: 
predictors of falls or indicators of fear. J Am 
Geriatr Soc, 1997. 45(3): p. 313-20.
10. Verghese, J., et al., Quantitative gait mark-
ers and incident fall risk in older adults. J 
Gerontol A Biol Sci Med Sci, 2009. 64(8): p. 
896-901.
11. Hollman, J.H., E.M. McDade, and R.C. 
Petersen, Normative spatiotemporal gait 
parameters in older adults. Gait Posture, 
2011. 34(1): p. 111-8.
12. Verghese, J., et al., Quantitative gait dys-
function and risk of cognitive decline and 
dementia. J Neurol Neurosurg Psychiatry, 
2007. 78(9): p. 929-35.
13. Verlinden, V.J., et al., Gait patterns in a 
community-dwelling population aged 50 
years and older. Gait Posture, 2013. 37(4): 
p. 500-5.
14. Al-Zahrani, K.S. and A.M. Bakheit, A study 
of the gait characteristics of patients with 
chronic osteoarthritis of the knee. Disabil 
Rehabil, 2002. 24(5): p. 275-80.
15. Bejek, Z., et al., The influence of walk-
ing speed on gait parameters in healthy 
people and in patients with osteoarthritis. 
Knee Surg Sports Traumatol Arthrosc, 
2006. 14(7): p. 612-22.
16. Kiss, R.M., Effect of walking speed and 
severity of hip osteoarthritis on gait vari-
ability. J Electromyogr Kinesiol, 2010. 20(6): 
p. 1044-51.
17. Kiss, R.M., Effect of severity of knee 
osteoarthritis on the variability of gait 
parameters. J Electromyogr Kinesiol, 2011. 
21(5): p. 695-703.
18. Debi, R., et al., Differences in gait patterns, 
pain, function and quality of life between 
males and females with knee osteoarthritis: 
a clinical trial. BMC Musculoskelet Disord, 
2009. 10: p. 127.
19. Elbaz, A., et al., Can single limb support 
objectively assess the functional severity 
of knee osteoarthritis? Knee, 2012. 19(1): p. 
32-5.
20. Nebel, M.B., et al., The relationship of self-
reported pain and functional impairment 
to gait mechanics in overweight and obese 
persons with knee osteoarthritis. Arch Phys 
Med Rehabil, 2009. 90(11): p. 1874-9.
21. Hofman, A., et al., The Rotterdam Study: 
2014 objectives and design update. Eur J 
Epidemiol, 2013. 28(11): p. 889-926.
22. Brach, J.S., et al., The reliability and validity 
of measures of gait variability in commu-
nity-dwelling older adults. Arch Phys Med 
Rehabil, 2008. 89(12): p. 2293-6.
Gait Differences in Chronic Joint Pain in the Lower Body 175
6.2
23. Bilney, B., M. Morris, and K. Webster, 
Concurrent related validity of the GAITRite 
walkway system for quantification of the 
spatial and temporal parameters of gait. 
Gait Posture, 2003. 17(1): p. 68-74.
24. Menz, H.B., et al., Reliability of the GAI-
TRite walkway system for the quantification 
of temporo-spatial parameters of gait in 
young and older people. Gait Posture, 
2004. 20(1): p. 20-5.
25. van Uden, C.J. and M.P. Besser, Test-retest 
reliability of temporal and spatial gait char-
acteristics measured with an instrumented 
walkway system (GAITRite). BMC Musculo-
skelet Disord, 2004. 5: p. 13.
26. Kellgren, J.H. and J.S. Lawrence, Radio-
logical assessment of osteo-arthrosis. Ann 
Rheum Dis, 1957. 16(4): p. 494-502.
27. Constantinou, M., et al., Spatial-temporal 
gait characteristics in individuals with 
hip osteoarthritis: a systematic literature 
review and meta-analysis. J Orthop Sports 
Phys Ther, 2014. 44(4): p. 291-B7.
28. Sugiura, H. and S. Demura, Effect of sub-
jective knee-joint pain on the laterality of 
knee extension strength and gait in elderly 
women. Arch Gerontol Geriatr, 2012. 54(2): 
p. 366-9.
29. Corti, M.C. and C. Rigon, Epidemiology 
of osteoarthritis: prevalence, risk factors 
and functional impact. Aging Clin Exp Res, 
2003. 15(5): p. 359-63.
176 Chapter 6.2
Su
p
p
le
m
en
ta
ry
 t
ab
le
 1
. A
ss
o
ci
at
io
ns
 o
f u
ni
la
te
ra
l p
ai
n 
in
 t
he
 le
g
, h
ip
, k
ne
e 
an
d
 fo
o
t 
w
ith
 g
ai
t 
in
 t
he
 p
ai
nf
ul
 a
nd
 u
np
ai
nf
ul
 le
g
.
D
o
m
ai
n
R
hy
th
m
V
ar
ia
b
ili
ty
P
ha
se
s
P
ac
e
B
as
e 
o
f 
Su
p
p
o
rt
G
ai
t 
p
ar
am
et
er
Si
ng
le
 S
up
p
o
rt
 T
im
e 
( s
)
St
ep
 le
ng
th
 S
D
 (c
m
)
Si
ng
le
 S
up
p
o
rt
 P
ha
se
 (%
)
St
ep
 le
ng
th
 (c
m
)
St
ri
d
e 
w
id
th
 S
D
 (c
m
)
U
ni
la
te
ra
l p
ai
n 
le
g
Pa
in
fu
l l
eg
0.
02
 (−
0.
02
; 0
.0
5)
0.
04
 (−
0.
05
; 0
.1
4)
−
0.
30
 *
* 
(−
0.
46
; −
0.
13
)
−
0.
84
 *
 (−
1.
58
; −
0.
11
)
0.
05
 (−
0.
05
; 0
.1
6)
U
np
ai
nf
ul
 le
g
0.
03
 (−
0.
01
; 0
.0
6)
0.
03
 (−
0.
06
; 0
.1
3)
−
0.
20
 *
 (−
0.
36
; −
0.
03
)
−
1.
28
 *
* 
(−
2.
02
; −
0.
54
)
0.
04
 (−
0.
06
; 0
.1
5)
U
ni
la
te
ra
l p
ai
n 
hi
p
Pa
in
fu
l h
ip
0.
01
 (−
0.
05
; 0
.0
7)
−
0.
06
 (−
0.
19
; 0
.0
8)
−
0.
57
 *
* 
(−
0.
81
; −
0.
32
)
−
0.
90
 (−
1.
98
; 0
.1
7)
−
0.
08
 (−
0.
23
; 0
.0
7)
U
np
ai
nf
ul
 h
ip
0.
03
 (−
0.
02
; 0
.0
9)
0.
07
 (−
0.
07
; 0
.2
1)
−
0.
35
 *
* 
(−
0.
60
; −
0.
11
)
−
1.
43
 *
 (−
2.
51
; −
0.
35
)
−
0.
03
 (−
0.
18
; 0
.1
2)
U
ni
la
te
ra
l p
ai
n 
kn
ee
Pa
in
fu
l k
ne
e
0.
02
 (−
0.
03
; 0
.0
7)
0.
10
 (−
0.
02
; 0
.2
2)
−
0.
09
 (−
0.
30
; 0
.1
2)
−
0.
31
 (−
1.
23
; 0
.6
0)
0.
05
 (−
0.
08
; 0
.1
8)
U
np
ai
nf
ul
 k
ne
e
0.
03
 (−
0.
02
; 0
.0
7)
0.
04
 (−
0.
07
; 0
.1
6)
−
0.
04
 (−
0.
25
; 0
.1
6)
−
0.
38
 (−
1.
30
; 0
.5
3)
0.
03
 (−
0.
10
; 0
.1
5)
U
ni
la
te
ra
l p
ai
n 
fo
o
t
Pa
in
fu
l f
o
o
t
−
0.
01
 (−
0.
08
; 0
.0
5)
0.
21
 *
 (0
.0
5;
 0
.3
6)
−
0.
30
 *
 (−
0.
58
; −
0.
02
)
−
1.
32
 *
 (−
2.
56
; −
0.
09
)
0.
08
 (−
0.
09
; 0
.2
5)
U
np
ai
nf
ul
 fo
o
t
0.
00
 (−
0.
07
; 0
.0
6)
−
0.
05
 (−
0.
20
; 0
.1
1)
−
0.
21
 (−
0.
49
; 0
.0
7)
−
1.
97
 *
* 
(−
3.
20
; −
0.
74
)
0.
07
 (−
0.
10
; 0
.2
4)
Va
lu
es
 re
p
re
se
nt
 d
iff
er
en
ce
s 
in
 g
ai
t p
ar
am
et
er
s 
(9
5%
 c
o
nfi
d
en
ce
 in
te
rv
al
) f
o
r p
re
se
nc
e 
o
f p
ai
n 
in
 th
e 
re
sp
ec
tiv
e 
b
o
d
y 
p
ar
t.
 R
es
ul
ts
 in
 b
o
ld
 s
ur
vi
ve
d
 th
re
sh
o
ld
s 
o
f n
o
m
in
al
 s
ig
ni
fic
an
ce
 (*
p
 <
 0
.0
5;
 *
*p
 <
 0
.0
05
). 
A
ll 
an
al
ys
es
 w
er
e 
ad
ju
st
ed
 fo
r 
ag
e,
 s
ex
, h
ei
g
ht
, w
ei
g
ht
, a
nd
 t
im
e 
in
te
rv
al
 b
et
w
ee
n 
p
ai
n 
an
d
 g
ai
t 
as
se
ss
m
en
t.
 
Le
g
: n
=
20
12
; H
ip
: n
 =
 2
23
1;
 K
ne
e:
 n
 =
 2
10
3;
 F
o
o
t:
 n
 =
 2
21
5.
Pa
in
fu
l l
eg
: D
iff
er
en
ce
 b
et
w
ee
n 
g
ai
t p
ar
am
et
er
s 
o
f p
ai
nf
ul
 le
g
 fo
r c
as
es
 (s
ub
je
ct
s 
w
ith
 u
ni
la
te
ra
l p
ai
n)
 a
nd
 m
ea
n 
g
ai
t p
ar
am
et
er
s 
fo
r c
o
nt
ro
ls
 (s
ub
je
ct
s 
w
ith
o
ut
 
p
ai
n)
U
np
ai
nf
ul
 le
g
: D
iff
er
en
ce
 b
et
w
ee
n 
g
ai
t p
ar
am
et
er
s 
o
f u
np
ai
nf
ul
 le
g
 fo
r c
as
es
 (s
ub
je
ct
s 
w
ith
 p
ai
n)
 a
nd
 m
ea
n 
g
ai
t p
ar
am
et
er
s 
fo
r c
o
nt
ro
ls
 (s
ub
je
ct
s 
w
ith
o
ut
 p
ai
n)
A
b
b
re
vi
at
io
ns
: s
 =
 s
ec
o
nd
s,
 S
D
 =
 s
ta
nd
ar
d
 d
ev
ia
tio
n,
 c
m
 =
 c
en
tim
et
re
s,
 n
 =
 n
um
b
er
 o
f p
ar
tic
ip
an
ts
.
Gait Differences in Chronic Joint Pain in the Lower Body 177
6.2
Su
p
p
le
m
en
ta
l t
ab
le
 2
. A
ss
o
ci
at
io
ns
 o
f p
ai
n 
in
 t
he
 lo
w
er
 b
o
d
y 
w
ith
 g
ai
t 
d
o
m
ai
ns
, w
ith
o
ut
 p
ar
tic
ip
an
ts
 w
ith
 o
st
eo
ar
th
rit
is
D
o
m
ai
n
R
hy
th
m
V
ar
ia
b
ili
ty
P
ha
se
s
P
ac
e
Ta
nd
em
a
Tu
rn
in
g
B
as
e 
o
f 
Su
p
p
o
rt
Su
m
m
ar
y 
sc
o
re
lo
w
er
 b
o
d
y 
p
ai
nb
−
0.
20
 *
(−
0.
36
; −
0.
04
)
0.
21
 *
(0
.0
2;
 0
.3
9)
−
0.
24
 *
*
(−
0.
40
; −
0.
08
)
−
0.
18
 *
(−
0.
33
; −
0.
03
)
0.
00
(−
0.
16
; 0
.1
6)
0.
02
(−
0.
16
; 0
.2
1)
0.
08
(−
0.
10
; 0
.2
6)
Pa
in
 lo
w
er
 b
ac
k
−
0.
06
(−
0.
17
; 0
.0
6)
0.
08
(−
0.
05
; 0
.2
1)
−
0.
03
(−
0.
14
; 0
.0
8)
−
0.
10
(−
0.
20
; 0
.0
1)
−
0.
04
(−
0.
16
; 0
.0
7)
0.
05
(−
0.
08
; 0
.1
8)
−
0.
04
(−
0.
17
; 0
.0
9)
Pa
in
 le
g
−
0.
11
 *
(−
0.
22
; 0
.0
0)
0.
10
(−
0.
02
; 0
.2
2)
−
0.
19
 *
*
(−
0.
29
; −
0.
09
)
−
0.
08
(−
0.
18
; 0
.0
2)
0.
00
(−
0.
11
; 0
.1
1)
0.
00
(−
0.
12
; 0
.1
2)
0.
05
(−
0.
06
; 0
.1
7)
Pa
in
 h
ip
−
0.
15
(−
0.
32
; 0
.0
1)
0.
03
(−
0.
16
; 0
.2
2)
−
0.
26
 *
*
(−
0.
42
; −
0.
10
)
−
0.
14
(−
0.
29
; 0
.0
2)
0.
06
(−
0.
10
; 0
.2
3)
0.
09
(−
0.
10
; 0
.2
8)
0.
14
(−
0.
05
; 0
.3
2)
Pa
in
 k
ne
e
−
0.
08
(−
0.
21
; 0
.0
5)
0.
05
(−
0.
10
; 0
.1
9)
−
0.
08
(−
0.
20
; 0
.0
5)
−
0.
07
(−
0.
19
; 0
.0
4)
0.
02
(−
0.
11
; 0
.1
5)
−
0.
03
(−
0.
17
; 0
.1
2)
0.
07
(−
0.
07
; 0
.2
1)
Pa
in
 fo
o
t
−
0.
03
(−
0.
20
; 0
.1
4)
0.
09
(−
0.
10
; 0
.2
8)
−
0.
13
(−
0.
29
; 0
.0
4)
−
0.
01
(−
0.
16
; 0
.1
5)
−
0.
12
(−
0.
29
; 0
.0
5)
−
0.
03
(−
0.
22
; 0
.1
6)
0.
07
(−
0.
12
; 0
.2
6)
Va
lu
es
 re
p
re
se
nt
 d
iff
er
en
ce
s 
in
 z
-s
co
re
s 
o
f g
ai
t (
95
%
 c
o
nfi
d
en
ce
 in
te
rv
al
) f
o
r p
ai
n 
in
 th
e 
re
sp
ec
tiv
e 
b
o
d
y 
p
ar
t.
 A
 lo
w
er
 v
al
ue
 o
f g
ai
t r
ep
re
se
nt
s 
w
o
rs
e 
g
ai
t.
 P
ai
n 
w
as
 s
co
re
d
 a
s 
1 
=
 y
es
 a
nd
 0
 =
 n
o
. R
es
ul
ts
 in
 b
o
ld
 s
ur
vi
ve
d
 t
hr
es
ho
ld
 o
f n
o
m
in
al
 s
ig
ni
fic
an
ce
 (*
p
 <
 0
.0
5;
 *
*p
 <
 0
.0
05
). 
A
ll 
an
al
ys
is
 w
er
e 
ad
ju
st
ed
 fo
r 
ag
e,
 s
ex
, 
he
ig
ht
, w
ei
g
ht
, a
nd
 t
im
e 
in
te
rv
al
 b
et
w
ee
n 
p
ai
n 
an
d
 g
ai
t 
as
se
ss
m
en
t.
 (n
=
15
57
)
a A
d
d
iti
o
na
lly
 a
d
ju
st
ed
 fo
r 
th
e 
st
ep
 c
o
un
t 
an
d
 s
te
p
 s
iz
e 
w
ith
in
 t
he
 t
an
d
em
 w
al
k
b
 P
ai
n 
lo
w
er
 b
o
d
y 
=
 (p
ai
n 
in
 lo
w
er
 b
ac
k 
+
 p
ai
n 
le
ft
 le
g
 +
 p
ai
n 
rig
ht
 le
g
) /
 3
.

 CHAPTER 7
General discussion

General Discussion 181
7
Chronic musculoskeletal pain is not just a symptom but a complex disease in its 
own right, with individual and environmental factors playing important roles in 
the pathophysiology. The overall objective of this thesis was to unravel disease 
determinants of chronic musculoskeletal pain.
We identified some potential new genetic and environmental risk factors for 
chronic musculoskeletal pain. We explored structural and functional alterations in 
the nervous system in chronic musculoskeletal pain and identified the impact of 
osteoarthritis and chronic lower body pain on mobility. In the general discussion, 
some general issues concerning chronic pain research and possible new directions 
for further research will be debated.
Definition of chronic pain
Objective versus subjective pain measurement
A very challenging but interesting and important issue in chronic pain research is 
the definition of chronic pain.
Pain is defined by the IASP as “an unpleasant sensory and emotional experience 
associated with actual or potential tissue damage, or described in terms of such 
damage. Pain is always subjective. Each individual learns the application of the 
word through experiences related to injury in early life. Biologists recognize that 
those stimuli which cause pain, are liable to damaged tissue. Accordingly, pain is 
that experience we associate with actual or potential tissue damage. It is unques-
tionably a sensation in a part or parts of the body, but it is also always unpleas-
ant and therefore also an emotional experience” [1]. The emotions involved are 
influenced by many individual and environmental factors. The subjective character 
of pain makes it more difficult to form a consensus on the definition. Therefore, a 
pure objective measure to quantify the pain experienced per individual does not 
exist. On the other hand, there are concrete endpoints linked to chronic pain that 
can be measured. Some of the measures that could potentially be used are thermal 
sensitivity thresholds and alterations in the structure of the brain. In this thesis, 
these measures are studied in more detail in a population-based study.
Thermal sensitivity, especially heat pain threshold, is increased in chronic pain. 
This is described in more detail in chapter 5 in this thesis. These thresholds can be 
used to more objectively measure pain sensitivity. With the measurement of these 
thresholds, control on the stimulus is applied, but the experience of these thresh-
olds remains a subjective experience of the tested individual. In this thesis, we 
show that these thresholds are associated with several factors that are influenced 
by environmental exposure, such as BMI, skin color and psychological factors such 
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as depression. Additionally, we found a strong indication that pain sensitivity is also 
heritable for a significant part. This is described in chapter 2. The findings in this 
thesis stress again the multifactorial complexity of not only chronic pain but also 
the potential objective measures underlying chronic pain and pain sensitivity.
In chapter 4, we describe a study in which we show structural differences in the 
brain in individuals with chronic musculoskeletal pain. A lower volume of grey mat-
ter was found in the temporal and frontal lobe and the hippocampus, which are 
part of the limbic system. This strengthens the consensus that emotional process-
ing is a substantial component in the pathogenesis of chronic pain.
Other objective measures, which might be relevant to study in relation to chronic 
pain, could be the measurement of central sensitization or conditioned pain modu-
lation e.g. diffuse noxious inhibitory control (DNIC). With these measurements, 
sensitization and neuronal plasticity of the nervous system and the descending 
inhibitory tracts, which are thought to be affected in chronic pain, can be studied 
more objectively. The descending inhibitory tracts are important in normal pain 
processing but can also be influenced by strong emotions to block pain.
However, subjective measurement of pain and chronic pain might reflect the 
burden of the disease in a better way. The influence of experienced pain on the 
quality of life is the major reason for the existence of pain medicine and research. 
Subjective pain experience account for the sickness absence and a higher health 
care consumption.
Since there are many factors influencing the chronification of pain, and some of 
them may still be unknown (Figure 1), a combination of objective and subjective 
measures would therefore better comprehend all aspects of chronic pain.
Duration to chronification of pain
Several definitions are used for the term chronic pain. Most of them are time de-
pendent, e.g. Pain existing for more than three months or six months. A definition 
which gives more right to the term chronic pain is “pain that persists beyond the 
normal time of healing”, which sometimes may be less than a month and in other 
cases more than six months[2]. Every injury has a different prognosis and for some 
conditions, especially degenerative diseases like osteoarthritis, healing may not 
occur at all. Therefore, a generalized definition of chronic pain being present if 
the pain exceeds three months of duration, as defined by the IASP, may not be 
sufficient to properly identify individuals with chronic pain.
In the studies presented in this thesis focusing on chronic musculoskeletal pain, 
we mostly used the definition ‘pain anywhere in the body for more than half of the 
days in the last six weeks’ which was recorded using a pain drawing. In this pain 
drawing, a drawing of a human body was shown in which the participant could 
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indicate the painful areas if present. We also collected questionnaire data on joint 
pain, in which the participants were asked if they had pain in a specific joint and for 
how long. Both definitions have their strengths and weaknesses.
With the pain drawings, pain in the last six weeks can be assessed, which ac-
cording to the IASP definition is not yet to be called chronic pain. However, we 
observed that over 95% of the individuals experiencing knee or hip pain on a daily 
basis for the last six weeks also experience this pain for longer than 3 months 
(based on specific questionnaire data).
In our studies, multiple results indicated that central sensitization, as part of the 
pathophysiology of chronic pain, is present in the general elderly population using 
the pain drawing data. Heat pain thresholds were significantly lower in individuals 
with chronic pain according to the pain drawing and also, structural brain MRI dif-
ferences were found using the same data. Chronification of pain might therefore 
be defined as the moment at which central sensitization is present, which may be 
earlier than 3 months. If we can develop reliable objective measures to identify this 
Figure 1. The multifactorial aspects of the development of chronic pain. Pain starts with tissue dam-
age. When acute pain is not relieved by normal healing, chronification can occur. The course from 
acute to chronic pain is influenced by many different factors.
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central sensitization, we will be able to make a better definition for chronic pain 
then to just look at duration, which will also improve the studies on chronic pain.
Although the questionnaire data is able to identify the individuals with pain 
longer than 3 months, the pain drawing includes the question if the pain is present 
for more than half of the days, which gives an idea on the burden of the disease.
Chronic pain can therefore be dissected in a number of different components. 
One of them is the duration of pain, while an objective measure, such as central 
sensitization, and a measure for severity or burden of the disease are other compo-
nents that should be taken into consideration.
Sex differences in chronic pain and pain sensitivity
Chronic musculoskeletal pain and pain sensitivity are known to be sexually di-
morphic. As described in this thesis, we found additional evidence in our studies 
for this phenomenon. The most notable observation was that the majority of the 
associations found were sex specific and mostly observed in women.
There are a few hypotheses on why the associations found in this thesis were 
mainly found in women. In a recent study, it was shown that pain sensitization is 
regulated by different immune cells in male and female mice, indicating different 
pathways for chronification of pain between sexes [3]. In addition, the difference in 
hormonal exposure during development and during life may be of great influence. 
As we showed in chapter 3.1, testosterone exposure during development influ-
ences the development of chronic pain later in life. Additionally, in chapter 3.2, we 
show that lower sex hormone levels are associated with an increased prevalence of 
chronic pain, especially in women.
Since pain is for a part subjective and psychological aspects such as coping and 
emotional behavior are different between sexes, these might play a role in the 
differences in reporting chronic pain between men and women. This might add 
another challenge in studying these differences in chronic pain and pain sensitivity.
Studying chronic pain in the general population
In this thesis, chronic pain was studied in the Rotterdam Study, a population based 
study of individuals aged 45 years and older. Within this population almost half 
of all individuals experience chronic pain, of which half is caused by osteoarthri-
tis. Most pain research worldwide is performed within very specific chronic pain 
syndromes, such as migraine or complex regional pain syndrome. Although these 
General Discussion 185
7
studies are capable of investigating determinants associated with those chronic 
pain syndromes, they lack the ability of generalizing their conclusions to commu-
nity dwelling individuals without those clearly defined pain phenotypes. Only 23% 
of all individuals with chronic pain ever visit a pain specialist and for approximately 
15% who do visit a medical professional no specific diagnosis can be made [4]. 
Thus, by studying only the patients in specialized pain clinics, many individuals who 
suffer from chronic pain on a daily basis, are not included. Therefore, a population 
based study using a more heterogeneous pain phenotype may lead to new insights 
into the pathophysiology of chronic pain. Since the prevalence of chronic pain 
increases with age, a community dwelling study population of individuals of 45 
years and over is highly relevant for daily practice.
The use of the Rotterdam study for pain research also caused some limitations. 
Since pain research is not the primary aim of the Rotterdam study and many other 
research questions are being studied, time and resources are limited to extensively 
measure all individuals with respect to their pain phenotype. This means choices 
had to be made, which questions to ask and which tests to perform. For example, 
quantitative sensory testing has a lot of different modalities, but the choice was 
made to only incorporate thermal stimuli in the research protocol. Thermal QST 
measurements are relatively easy and quick to perform and are commonly used 
in other studies, also in other population based studies. Another limitation is that 
the statistical methods in such a large study with thousands of people are different 
from the methods used in smaller studies. For example, in the study of structural 
brain alterations, voxel based techniques are computationally very challenging in 
such a large study population. In small sample sizes, this method has been used 
many times successfully but is prone to spurious findings due to multiple testing. 
In the study presented in this thesis, a volume segmentation method was used, 
which is more common in large imaging studies and follows a clear hypothesis-
driven approach. This deviating approach makes our study different from other 
clinical studies published before. One of the major advantages of our study is the 
more generalizable results when compared to very specific clinical studies. But 
therefore, it also introduces more heterogeneity into the study population which 
could prevent us from finding some of the associations.
Genetics of pain sensitivity
The proportion of genetic influence on pain and pain sensitivity has been under 
debate. In previous studies, the heritability of chronic pain and pain sensitivity has 
been estimated in classical twin studies. A recent review showed that large dif-
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ferences between heritability estimates can be found depending on the clinical 
phenotype [5], ranging from a heritability of around 50% for migraine to around 
25% for irritable bowel syndrome. Heritability of experimental pain sensitivity has 
been studied scarcely, with only 3 previous study reports. All three reports studied 
twins and used various experimental designs, with relative modest sample sizes 
[6-8]. Consequently, heritability estimates fluctuated from 0 to 60%. In this thesis, 
the genetics of one of the experimental pain modalities, the heat pain threshold, 
is investigated further, using a heritability calculation, a candidate gene approach 
and a genome wide association study (GWAS).
Heritability of heat pain threshold
In this population based study of individuals of 45 years and older, we found a 
heritability estimate of 19% for heat pain threshold. But once we stratified our 
population for the presence of chronic pain, the heritability for heat pain threshold 
was non-significant in participants with chronic pain and 32% in participants with-
out chronic pain. We also found a significant difference of heritability estimates 
between women and men (35% vs 9%).
Chronic pain is known to influence the heat pain threshold, as we have also 
demonstrated in chapter 5 in this thesis. Up to now, genetic studies on heat pain 
threshold and other quantitative sensory measurements did not take the presence 
of chronic pain into account. Since there is this large influence on the heritability 
estimate, genetic analysis for quantitative sensory testing should be stratified by or 
at least adjusted for the presence of chronic pain.
We found that within a population of men aged 45 years and older, the heat pain 
threshold is not easily measured in all subjects. In our study sample, almost 20% 
of all men reached the maximum threshold of 50 degrees Celsius for the heat pain 
threshold. As a consequence, part of the variability of the measurement is lost, 
which results in lower power to measure heritability in this part of the population. 
Another explanation for the low heritability estimate for heat pain threshold in 
men could be that this threshold in men is influenced by other factors, for example 
psychological, emotional factors or stronger descending inhibitory tracts.
The findings in this heritability analysis indicates that in individuals without chronic 
pain, 32% of the variance in the heat pain threshold measurements is explained 
by genetic variance of common SNPs. Since only part of the genetic variance is 
included in these common SNPs, the true heritability is likely to be even larger.
To estimate the heritability of the heat pain threshold, defined as the proportion 
of phenotypic variance due to only additive genetic effects within a population, we 
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used the restricted maximum likelihood (REML) method. This method is able to 
quantify heritability estimates attributable to all investigated variants in genome 
wide association studies and is implemented in the Genome-wide Complex Trait 
Analysis (GCTA) package [9]. There are several ways to estimate heritability, includ-
ing twin studies, pedigree analysis, etc. Heritability estimated from pedigree data 
is not the same as measuring the proportion of phenotypic variation explained 
by all SNPs in the population (which was used in this thesis) because the former 
includes the contribution of all causal variants, whereas the latter only includes the 
contribution of causal variants that are in linkage disequilibrium (LD) with geno-
typed common SNPs [9, 10]. This means that the true heritability estimate of heat 
pain threshold will probably be higher, since GCTA is only able to detect a part of 
the heritability. Yet, the GCTA method has been successfully applied for identifying 
the amount of ‘missing’ heritability in population based studies for other complex 
traits such as height [11]. In complex traits, it is unlikely that one or a few genetic 
variants account for the full phenotypic variance seen in the population. The heri-
tability estimate, as determined by this GCTA method, takes into account that the 
combination of variants in the genetic material makes up for the susceptibility for 
the studied disease or condition.
Genome wide association studies
In our search of finding the genes underlying the phenotypical differences in heat 
pain thresholds in the general population, we performed genome wide association 
studies (GWAS). One genome wide significant hit was found, a deletion on chro-
mosome 1 in the PAPPA2 gene. This gene encodes for a protein which is thought to 
regulate IGF, which is implicated to play a role in nociceptive sensitivity of primary 
afferent neurons.
In addition, we found a total of six other suggestive signals. Replication in inde-
pendent cohorts and additional functional testing are needed to demonstrate the 
true signals and causal associations.
Although we have performed the GWAS in the largest population sample with 
heat pain thresholds available at this moment (n= 3,795), we probably are still un-
derpowered to find all potential genetic signals. Chronic pain is a complex disease, 
with many genetic and non-genetic factors playing a role. In the search for genetic 
variations in other complex traits, such as BMI or cognition, large collaborations 
with a population sample of more than 50,000 individuals were needed to find 
more genetic variation associated with the trait. [12, 13]
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Systematic review of genetic variants previously described
Most other studies investigating the genetic background of pain sensitivity, fo-
cused on selected candidate genes previously described with pain and studied 
polymorphisms in those genes in modestly sized pain patient populations [14-26].
In a better powered setting, we studied six such candidate genes previously 
described to be associated with pain sensitivity measures (COMT, DRD3, OPRK, 
OPRM1, SLA6A4 and HTR1A) and did not replicate the previous findings. Since 
we used a population based study instead of specific patient populations, it is 
still possible that the previous associations are true for the studied phenotypes. 
Therefore, the genes previously described to be associated with pain sensitivity are 
probably not the causal genes and the search for genes influencing pain sensitivity 
is a long way from completed.
Suggestions for further research
Based on the findings in this thesis and the general issues raised in this chapter, 
several suggestions for further research can be provided.
Stratification according to sex
Across the chapters in this thesis and also in other literature, the sex differences in 
occurrence of chronic pain and pain sensitivity are clearly present. There are many 
factors different between the sexes influencing the sensitivity and susceptibility 
to pain, such as the hormonal influences, anatomy and physiology of the nervous 
system and also the psychological factors such as coping behavior and catastroph-
izing. Future epidemiological as well as genetic research should therefore stratify 
according to sex in order to find more robust and personalized risk factors for 
chronic pain.
Experimental pain sensitivity
In the Rotterdam study, only responses to thermal stimuli were measured in or-
der to study experimental pain sensitivity. We chose this measure because it is 
easily measured and noninvasive. This makes it appropriate for the use in a large 
population based study, such as the Rotterdam Study. Yet, there are several other 
experimental pain modalities, such as mechanical pressure, weighted pinprick and 
electrical stimuli.
As demonstrated in Figure 2, A-delta fibers and C fibers are both responsible 
for the transport of noxious stimuli. A-delta fibers are mostly sensitive to mechani-
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cal noxious stimuli and in a lesser extend to thermal noxious stimuli. In a state of 
sensitization, like in a chronic pain state, these A-delta fibers become more sensi-
tive for thermal stimuli as well. In a population based setting, many individuals 
are not sensitized, which could be an explanation for the large number of men in 
which we were not able to adequately measure the heat pain threshold. Studying 
other modalities of experimental pain stimuli, like mechanical pressure or electrical 
stimulation, may therefore be more fruitful in this population.
An interesting other objective measure for altered pain sensitivity could be 
conditioned pain modulation, e.g. diffuse noxious inhibitory control (DNIC). By 
studying the difference between the pain tolerance threshold before and after 
exposure to a second noxious stimulus (such as ice water), the function of the de-
scending inhibitory tracts, which are thought to be affected in chronic pain, can be 
measured. Research up to now suggest DNIC is associated with chronic pain but 
the relevance to selection and efficacy of pain treatment is not yet elucidated. [27]
Quantitative sensory testing can be very useful in the general population to 
study chronic pain and pain sensitivity pathways. In chronic pain patients, it can 
also be very useful to determine progress during treatment. For the diagnosis of 
chronic pain, central sensitization or neural plasticity in an individual patient in a 
clinical setting, QST is less useful at this moment, since reliable normal values are 
not available for all subpopulations, such as the elderly. Normal values are different 
for each individual and are influenced by many known but also unknown factors. 
Figure 2. Activation of nociceptive nerve fibers. Detection of a noxious stimulus occurs at the pe-
ripheral terminals of primary afferent neurons and leads to generation of action potentials that prop-
agate along the axon to the central terminals. Aβ fibers respond only to non-noxious stimuli, Aδ 
fibers respond to noxious mechanical stimuli and subnoxious thermal stimuli, and C fibers respond 
only to noxious mechanical, heat, and chemical stimuli. Adapted from Stahl, S.M., 2008, Essential 
Pharmacology Online.
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If all individuals included in large QST databanks would be analyzed for cluster-
ing, we potentially could define subgroups and identify different phenotypes. It is 
hypothesized that fulfilling the criteria of a single phenotype will help, in future, to 
personalize the choice of therapy and improve individual effects of treatment of 
chronic pain.
Genetics of chronic pain and pain sensitivity
As described in the first part of this chapter, defining the phenotype of chronic 
pain and pain sensitivity is challenging and this may in part be the reason that the 
genetic influence remains largely uncertain. The heritability estimates of several 
pain phenotypes surely suggest a genetic influence, but the GWAS results suggest 
a complex genetic architecture with many genetic variants with a small effect. The 
identification of the involved genes therefore requires larger sample sizes and col-
laborative networks to better understand the genetics of chronic pain. As shown in 
Figure 1, there are many different factors influencing the development of chronic 
pain, which should be incorporated in the pain definition to create a more robust 
phenotype.
Incorporation of pain severity scores might be an interesting addition to better 
define chronic pain compared to the focus on duration of pain, since it adds a 
measure of burden. In addition, studying individuals with joint damage with and 
without joint pain may further elucidate the genetic factors influencing if someone 
is susceptible for developing joint pain. Efforts in our study have not been success-
ful in this respect, mainly because of the lack of power for this analysis. Although 
the Rotterdam study is considerably large, collaboration efforts will be needed with 
improved phenotyping to further genetic pain research.
Other genetic methodological approaches could also provide more insight in 
the genetic architecture of pain. For example, sequencing for rare alleles or gene-
environment interactions.
Furthermore, the identified new genetic loci associated with chronic pain, espe-
cially PAPPA2, should be further investigated. Functional research has the potential 
to demonstrate true causal pathways and may lead to not only better understand-
ing of chronic pain but also new drug targets.
General Discussion 191
7
References
1. Loeser, J.D. and R.D. Treede, The Kyoto 
protocol of IASP Basic Pain Terminology. 
Pain, 2008. 137(3): p. 473-7.
2. Classification of chronic pain. Descriptions 
of chronic pain syndromes and definitions 
of pain terms. Prepared by the Interna-
tional Association for the Study of Pain, 
Subcommittee on Taxonomy. Pain Suppl, 
1986. 3: p. S1-226.
3. Sorge, R.E., et al., Different immune cells 
mediate mechanical pain hypersensitivity 
in male and female mice. Nat Neurosci, 
2015. 18(8): p. 1081-3.
4. Breivik, H., et al., Survey of chronic pain in 
Europe: prevalence, impact on daily life, 
and treatment. Eur J Pain, 2006. 10(4): p. 
287-333.
5. Nielsen, C.S., G.P. Knudsen, and O.A. 
Steingrimsdottir, Twin studies of pain. Clin 
Genet, 2012. 82(4): p. 331-40.
6. Angst, M.S., et al., Pain sensitivity and 
opioid analgesia: a pharmacogenomic twin 
study. Pain, 2012. 153(7): p. 1397-409.
7. Nielsen, C.S., et al., Individual differences 
in pain sensitivity: genetic and environ-
mental contributions. Pain, 2008. 136(1-2): 
p. 21-9.
8. Norbury, T.A., et al., Heritability of re-
sponses to painful stimuli in women: a 
classical twin study. Brain, 2007. 130(Pt 11): 
p. 3041-9.
9. Yang, J., et al., GCTA: a tool for genome-
wide complex trait analysis. Am J Hum 
Genet, 2011. 88(1): p. 76-82.
10. Yang, J., et al., Genome-wide complex trait 
analysis (GCTA): methods, data analyses, 
and interpretations. Methods Mol Biol, 
2013. 1019: p. 215-36.
11. Yang, J., et al., Genetic variance estima-
tion with imputed variants finds negligible 
missing heritability for human height and 
body mass index. Nat Genet, 2015. 47(10): 
p. 1114-20.
12. Davies, G., et al., Genetic contributions 
to variation in general cognitive function: 
a meta-analysis of genome-wide asso-
ciation studies in the CHARGE consortium 
(N=53949). Mol Psychiatry, 2015. 20(2): p. 
183-92.
13. Locke, A.E., et al., Genetic studies of 
body mass index yield new insights for 
obesity biology. Nature, 2015. 518(7538): p. 
197-206.
14. Bruehl, S., O.Y. Chung, and J.W. Burns, The 
mu opioid receptor A118G gene polymor-
phism moderates effects of trait anger-out 
on acute pain sensitivity. Pain, 2008. 139(2): 
p. 406-15.
15. Diatchenko, L., et al., Catechol-O-
methyltransferase gene polymorphisms 
are associated with multiple pain-evoking 
stimuli. Pain, 2006. 125(3): p. 216-24.
16. Fernandez-de-las-Penas, C., et al., Genetic 
contribution of catechol-O-methyltransfer-
ase polymorphism (Val158Met) in children 
with chronic tension-type headache. Pedi-
atr Res, 2011. 70(4): p. 395-9.
17. Fernandez-de-las-Penas, C., et al., 
Catechol-O-methyltransferase genotype 
(Val158met) modulates cancer-related 
fatigue and pain sensitivity in breast cancer 
survivors. Breast Cancer Res Treat, 2012. 
133(2): p. 405-12.
18. Fillingim, R.B., et al., The A118G single 
nucleotide polymorphism of the mu-opioid 
receptor gene (OPRM1) is associated with 
pressure pain sensitivity in humans. J Pain, 
2005. 6(3): p. 159-67.
19. Hooten, W.M., et al., Associations between 
serotonin transporter gene polymorphisms 
and heat pain perception in adults with 
chronic pain. BMC Med Genet, 2013. 14: p. 
78.
20. Huang, C.J., et al., Association between hu-
man opioid receptor genes polymorphisms 
and pressure pain sensitivity in females*. 
Anaesthesia, 2008. 63(12): p. 1288-95.
21. Jensen, K.B., et al., Increased sensitivity 
192 Chapter 7
to thermal pain following a single opiate 
dose is influenced by the COMT val(158)
met polymorphism. PLoS One, 2009. 4(6): 
p. e6016.
22. Lindstedt, F., et al., Serotonin-1A receptor 
polymorphism (rs6295) associated with 
thermal pain perception. PLoS One, 2012. 
7(8): p. e43221.
23. Lindstedt, F., et al., Perception of thermal 
pain and the thermal grill illusion is associ-
ated with polymorphisms in the serotonin 
transporter gene. PLoS One, 2011. 6(3): p. 
e17752.
24. Martinez-Jauand, M., et al., Pain sensitivity 
in fibromyalgia is associated with catechol-
O-methyltransferase (COMT) gene. Eur J 
Pain, 2013. 17(1): p. 16-27.
25. Potvin, S., et al., DRD3 Ser9Gly polymor-
phism is related to thermal pain perception 
and modulation in chronic widespread pain 
patients and healthy controls. J Pain, 2009. 
10(9): p. 969-75.
26. Sato, H., et al., Gender, variation in opioid 
receptor genes and sensitivity to experi-
mental pain. Mol Pain, 2013. 9: p. 20.
27 Yarnitsky, D, Conditioned pain modulation 
(the diffuse noxious inhibitory control-like 
effect): its relevance for acute and chronic 
pain states. Current Opinion in Anesthesi-
ology, 2010, 23.5: 611-615.


 CHAPTER 8
Summary/Samenvatting

Summary 197
8
Summary
Chronic musculoskeletal pain is a common disabling condition with a great impact 
on daily functioning. In the Netherlands, 19% of all individuals aged 21 years and 
older experience chronic pain and in elderly this is more than half. This means 
that more than 2 million Dutch people experience pain on a daily basis, which is a 
higher prevalence than most common diseases like diabetes and coronary heart 
disease.
Chronic pain and pain sensitivity are complex traits with a variety of potential de-
terminants. The development of chronic pain and an increased sensitivity to stimuli, 
caused by sensitization of the nervous system is an unintended consequence after 
tissue damage. In this scenario, the pain is prolonged or more severe compared to 
what might be expected during a normal healing process.
A wide variety of risk factors have been described for the development of chronic 
pain and pain sensitivity. The overall objective of this thesis was to identify and 
characterize causal and consequential determinants of chronic musculoskeletal 
pain and pain sensitivity in the general population.
First, in Chapter 2, the results of the study on the genetic background of heat 
pain sensitivity are presented. In 3795 individuals, the heritability for heat pain 
threshold was estimated to be 19%, and within individuals without chronic pain 
even 32%. Chronic pain influences the heat pain threshold substantially, as part of 
the pathophysiology of chronic pain via sensitization of the central nervous system.
Genetic polymorphisms previously found to be associated with pain sensitivity 
were not replicated in this study. In the search for potential new genetic markers, 
using a genome-wide association study, 6 suggestive signals were found and one 
genome-wide significant locus in the PAPPA2 gene, which is thought to be a local 
regulator of insulin-like growth factor (IGF) bioavailability. IGF is implicated to play 
a role in the nociceptive (pain) sensitivity of primary afferent neurons.
In Chapter 3, hormonal influences on the development of chronic pain are 
described. Type 3 finger length pattern (longer 4th digit compared to the 2nd digit) 
is influenced by a higher prenatal androgen exposure. The results in Chapter 3.1 
show that this finger length pattern is associated with joint pain at multiple sites 
with an odds ratio of 1.41. In addition, the association of osteoarthritis, as one of 
the major causes of joint pain in the elderly population, with type 3 finger length 
pattern was studied in a meta-analysis with previously published data. Type 3 finger 
length pattern showed to be associated with hand osteoarthritis and symptomatic 
knee osteoarthritis.
Since chronic pain is more prevalent in women, the relation between sex 
hormones and the occurrence and incidence of chronic musculoskeletal pain is 
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described in Chapter 3.2. Within 9,717 participants aged 45 years and older, the 
association between sex hormones (estradiol, testosterone, androstenedione and 
17-hydroxyprogesterone) and chronic pain was studied. Women with estradiol or 
androstenedione levels in the lowest tertile had a higher prevalence of chronic 
pain, independent from age, BMI, health and lifestyle factors or the presence of 
osteoarthritis. The lowest tertile of 17-hydroxyprogesterone in women was associ-
ated with 38% more incident chronic pain.
What happens to the brain in chronic pain is studied using MR imaging in more 
than 3,500 individuals in Chapter 4. First, the results of structural alterations in the 
brain in chronic pain are discussed in Chapter 4.1. Global and regional brain vol-
umes were automatically segmented and quantified. The total grey matter volume 
was smaller in women with chronic pain. This effect was primarily driven by smaller 
grey matter volume in the temporal lobe, the frontal lobe and the hippocampus. 
The identified volumetric differences in the specific brain areas, suggest gender-
specific neuroplasticity in chronic pain and involvement of emotional processing.
The role of brain white matter microstructure in chronic pain is investigated in 
Chapter 4.2. Using diffusion MR imaging of the brain, the association of chronic 
pain and the microstructure (fractional anisotropy and mean, axial and radial dif-
fusivity) of global, lobar and tract specific white matter was studied. The results 
presented suggest increased wiring of the cerebral white matter, especially in the 
left frontal and temporal lobe. In addition, increased wiring was also found in the 
left medial lemniscus in chronic pain and also in persistent chronic pain, indicating 
a potential prognostic value.
Central sensitization is part of the pathophysiology of chronic pain and can 
be determined with quantitative sensory testing. In Chapter 5, the thermal QST 
modality is studied. Higher sensitivity for heat pain, one feature of central sensitiza-
tion, was found to be present in community dwelling elderly with chronic pain.
Furthermore, determinants which can influence the measurement, analyses 
and interpretation of the thermal QST were identified. Based on experience and 
previous literature, the determinants studied were body mass index (BMI), reaction 
speed, systolic and diastolic blood pressure, skin color, skin temperature, seasonal 
influence, depression, anxiety, atopic eczema, age at menarche, years since meno-
pause, hormone replacement therapy use during menopause and reproductive 
lifespan. In addition to the effect of age and gender on thermal sensitivity, darker 
skin color and the presence of atopic eczema were associated with a higher sen-
sitivity for heat pain. Cold sensitivity and warmth sensitivity thresholds were both 
influenced by BMI, reaction speed, skin temperature, season, depression, dark skin 
color, years since menopause and reproductive lifespan. These additional determi-
nants should be considered when analysing and interpreting QST measurements.
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Chronic pain and osteoarthritis (OA) is associated with disability and decreased 
mobility. Therefore, the study on chronic pain and osteoarthritis and their influence 
on gait is presented in Chapter 6. Gait is an important indicator of health and 
impaired gait is related to increased morbidity and mortality.
In Chapter 6.1, the results are shown of the study on how hip and knee OA 
are related to gait in community dwelling individuals. Hip OA, but not knee OA, 
associates with gait differences in normal walking, turning, and tandem walking. 
Hip OA is associated with a higher rhythm (cadence) in normal walking and with 
making more mistakes in tandem walk and with making more steps during turning.
To further investigate whether the observed changes in gait in OA differ from 
changes in gait due to other causes, the association of lower body pain and gait 
parameters is further elucidated in Chapter 6.2. The results show that pain in the 
leg and hip, independent from OA, is associated with a lower rhythm (cadence) 
which is in contrast with the higher rhythm found in hip OA. In addition, individuals 
with chronic lower body pain were more likely to walk with smaller steps, with a 
longer double support and with more asymmetry. Gait assessment may help to 
differentiate individuals with OA from those having pain due to other causes.
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Samenvatting
Chronische gewrichtspijn is een veelvoorkomende invaliderende aandoening met 
een grote impact op het dagelijks functioneren. In Nederland heeft 19% van alle 
individuen boven de 21 jaar chronische pijn en voor ouderen is dit meer dan de 
helft. Dat zijn meer dan 2 miljoen Nederlanders die dagelijks pijn ervaren, wat 
betekent dat het meer voorkomt dan veelvoorkomende ziektes zoals diabetes en 
hart- en vaatziekten.
Chronische pijn en een verhoogde pijngevoeligheid zijn complexe aandoenin-
gen met een groot aantal aan mogelijke oorzakelijke factoren. Het ontstaan van 
chronische pijn en een verhoogde pijngevoeligheid door zogenaamde sensitisatie 
van het zenuwstelsel is een ongewenst gevolg na weefselschade. Hierdoor houdt 
de pijn langer aan en is heftiger van aard dan wat verwacht mag worden tijdens 
een normaal helingsproces.
Een grote aantal risicofactoren zijn beschreven voor de ontwikkeling van chroni-
sche pijn en een verhoogde pijngevoeligheid. Het doel van dit proefschrift is het 
identificeren en karakteriseren van oorzakelijke factoren en gevolgen van chroni-
sche gewrichtspijn en een verhoogde pijngevoeligheid in de algemene populatie.
Allereerst, in Hoofdstuk 2, worden de resultaten van de studie naar de geneti-
sche achtergrond van pijngevoeligheid gepresenteerd. In 3795 individuen, werd 
de erfelijkheid van de hittepijndrempel geschat op 19% en in alleen de personen 
zonder chronische pijn was dit zelfs 32%. Chronische pijn beïnvloedde de hitte-
pijndrempel substantieel, als onderdeel van het ziektemechanisme van chronische 
pijn, door een verhoogde gevoeligheid van het centrale zenuwstelsel.
Eerder in de literatuur beschreven associaties tussen pijngevoeligheid en varia-
ties in het DNA werden ook in deze populatie onderzocht, maar deze associaties 
werden niet teruggevonden. Middels een ‘genoom-wijde’ associatie studie is er 
gezocht naar mogelijke nieuwe genetische markers voor de hittepijndrempel, 
waarbij er 6 suggestieve signalen en 1 genoom-wijd significante locus in het PAP-
PA2 gen werden gevonden. Dit gen wordt gezien als een lokale regulator van de 
biologische activiteit van insulin-like growth factor (IGF). IGF speelt onder andere 
een rol in de gevoeligheid van de zenuwen die de pijnprikkel van de receptor naar 
het ruggenmerg vervoert.
In Hoofdstuk 3, wordt de invloed van hormonen op de ontwikkeling van chro-
nische pijn beschreven. Het type 3 vingerlengtepatroon (een langere ringvinger 
ten opzichte van de wijsvinger) wordt onder andere veroorzaakt door blootstelling 
aan geslachtshormoon tijdens de ontwikkeling in de baarmoeder. De resultaten 
in Hoofdstuk 3.1 laten zien dat personen met dit type vingerlengtepatroon, 41% 
vaker pijn ervaren in meerdere gewrichten. Ook is de associatie van artrose, als een 
202 Chapter 8
van de meest voorkomende oorzaken van gewrichtspijn in de oudere populatie, 
met type 3 vingerlengtepatroon onderzocht. Type 3 vingerlengtepatroon was 
geassocieerd met artrose van de handen en symptomatische artrose van de knie.
Aangezien chronische pijn meer voorkomt bij vrouwen, is in Hoofdstuk 3.2 
bestudeerd wat de relatie is tussen geslachtshormonen en de prevalentie en 
incidentie van chronische gewrichtspijn. In 9717 deelnemers van 45 jaar en ouder, 
is de associatie tussen geslachtshormonen (estradiol, testosteron, androsteendion 
en 17-hydroxyprogesteron) en chronische pijn onderzocht. Vrouwen met estradiol 
of androsteendion hoeveelheden in het bloed in het laagste tertiel hadden vaker 
chronische pijn, onafhankelijk van leeftijd, BMI, gezondheids- en leefstijlfactoren 
of de aanwezigheid van artrose. Het laagste tertiel van 17-hydroxyprogesteron bij 
vrouwen was geassocieerd met 38% meer incidente chronische pijn.
Wat er gebeurd in het brein bij chronische pijn is bestudeerd middels MRI in meer 
dat 3500 individuen in Hoofdstuk 4. Als eerste zijn de resultaten van structurele 
veranderingen in het brein in chronische pijn bediscussieerd in Hoofdstuk 4.1. De 
totale hoeveelheid grijze stof was kleiner in vrouwen met chronische pijn. Dit was 
met name gedreven door een kleinere hoeveelheid grijze stof in de temporaal-
kwab, de frontaalkwab en de hippocampus. De resultaten uit dit hoofdstuk sug-
gereren dat er bij chronische pijn sprake is van geslacht specifieke veranderingen 
in het brein en dat emotionele verwerking hierbij betrokken is.
De rol van microstructuur van witte stof in het brein in chronische pijn is bestu-
deerd in Hoofdstuk 4.2. Middels diffusie MRI van het brein, werd de associatie van 
chronische pijn met maten voor microstructurele integriteit van de witte stof be-
studeerd. De gepresenteerde resultaten suggereren een versterkte bedrading van 
de witte stof in het brein, met name in de linker frontaalkwab en temporaalkwab.
Daarnaast zijn de tekenen van versterkte bedrading in de linker mediale lem-
niscus niet alleen bij de aanwezigheid van chronische pijn gevonden maar ook bij 
langer aanhoudende chronische pijn, wat kan wijzen op een mogelijke prognosti-
sche waarde.
Centrale sensitisatie is deel van de pathofysiologie van chronische pijn en kan 
bepaald worden middels kwantitatieve sensorische testen (QST). In Hoofdstuk 5, 
is de thermale QST-modaliteit onderzocht. Een hogere gevoeligheid voor hittepijn, 
een van de kenmerken van centrale sensitisatie, is aangetroffen bij ouderen met 
chronische pijn in de algemene populatie.
Bovendien zijn er factoren geïdentificeerd welke de meting, analyse en inter-
pretatie van de thermale QST kunnen beïnvloeden. Gebaseerd op ervaringen en 
voorgaande literatuur, bestonden de bestudeerde factoren uit BMI, reactietijd, 
systolische en diastolische bloeddruk, huidskleur, temperatuur van de huid, 
seizoensinvloeden, depressie, angst, atopisch eczeem, leeftijd waarop de eerste 
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menstruatie plaatsvond, aantal jaren na de menopauze, hormoonvervangende 
therapie tijdens de menopauze en de duur van de reproductieve levensfase.
Naast het effect van leeftijd en geslacht op hittepijn gevoeligheid, was een 
donkere huidskleur en de aanwezigheid van atopisch eczeem geassocieerd met 
een hogere gevoeligheid voor hittepijn. Koude en warmte gevoeligheid werd 
beïnvloed door BMI, reactietijd, temperatuur van de huid, seizoen, depressie, een 
donkere huidskleur, aantal jaren sinds de menopauze en de duur van de repro-
ductieve levensfase. Deze additionele factoren moeten in acht worden genomen 
worden bij de analyse en interpretatie van QST-metingen.
Chronische pijn en artrose zijn geassocieerd met invaliditeit en een verlaagde 
mobiliteit. Daarom zijn in Hoofdstuk 6 de resultaten gepresenteerd van de studie 
naar chronische pijn, artrose en de invloed daarvan op het looppatroon. Het loop-
patroon is een belangrijke indicator voor gezondheid en een slechter looppatroon 
is geassocieerd aan een verhoogde morbiditeit en mortaliteit.
In Hoofdstuk 6.1 is onderzocht hoe heup en knie artrose gerelateerd zijn aan 
het looppatroon in oudere individuen in de algemene populatie. Heup artrose 
is geassocieerd met looppatroon veranderingen tijdens het normale lopen, het 
omdraaien en tijdens het ‘voetje voor voetje’ (tandem) lopen. Heup artrose is 
geassocieerd met een hoger ritme (cadans) tijdens het normale lopen en met het 
maken van meer fouten tijdens het tandem lopen en het nemen van meer stappen 
tijdens het omdraaien.
Om verder te onderzoeken of de geobserveerde veranderingen in het looppa-
troon bij artrose verschilt van de veranderingen in het looppatroon bij pijn door 
andere oorzaken, is de associatie van pijn in het onderlichaam en het looppatroon 
verder belicht in Hoofdstuk 6.2. De resultaten laten zien dat pijn in het been en de 
heup, onafhankelijk van artrose, geassocieerd is met een lager ritme (cadans). Dit 
is in contrast met het hogere ritme dat bij heup artrose werd gevonden. Daarnaast 
liepen individuen met chronische pijn in het onderlichaam vaker met kleinere 
stappen, stonden langer op twee benen en was er meer asymmetrie tussen de 
twee benen. Looppatroonanalyse kan daarom helpen om te differentiëren tussen 
artrose en pijn door andere oorzaken.
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